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Appendix A 
Search strategies for existing guidelines and results of guidelines identified for each database or website 
DATABASE 
 
NGC (US) G-I-N  (SCOTLAND) CMA INFOBASE (CANADA) 
Date  
 
24.03.2016 24.03.2016 25.03.2016 
Search strategy  Search under ―guideline database‖. 
 Key terms used: 
1) Oral cancer (262)  
2) Mouth cancer (54) 
3) Head and neck cancer (82) 
4) (Oral or mouth) and (carcinoma or 
neoplasm or nodule or mass or 
tumour) (292) 
5) (Head and neck) and (carcinoma or 
neoplasm or nodule or mass or 
tumour) (64) 
 Search under ―International Guideline 
Library‖, then limit to articles published in 
English. 
 Key terms used: 
1) Oral cancer  (11)  
2) Mouth cancer (8) 
3) Head and neck cancer (24) 
4) (Oral or mouth) and (carcinoma or 
neoplasm or nodule or mass or tumour) 
(188) 
5) (Head and neck) and (carcinoma or 
neoplasm or nodule or mass or tumour) 
(103) 
 
 Search under CMA Infobase Clinical 
Practice Guidelines Database (CPGs). 
 Key terms used: 
1) Oral cancer  (0) 
2) Mouth cancer (0) 
3) Head and neck cancer (3) 
4) (Oral or mouth) and (carcinoma or 
neoplasm or nodule or mass or tumour) 
(0) 
5) (Head and neck) and (carcinoma or 
neoplasm or nodule or mass or tumour) 
(0) 
 
Number of guidelines 
identified. 
n=754 n=334 n=3 
Number of guidelines 
excluded after 
title/abstract reviewed 
n= 749 
 
 
 
n= 324 
 
 
n=3 
 
 
Reasons to exclude  Not oral cancer guidelines (n=735). 
 Specific procedure guidelines (n=8). 
 Beyond scope of clinical area of interest 
(n=6). 
 Not oral cancer guidelines (n=316). 
 Specific procedure guidelines (n=2).  
 Beyond scope of clinical area of interest (n=4). 
 Under development (n=2). 
 
 Specific procedure guidelines (n=3). 
Number of guidelines 
included for detail 
review 
n=5  
(4 duplicate guidelines) 
 
n=10 
(5 duplicate guidelines) 
 
n=0 
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DATABASE 
 
SAGE (US) GAC (CANADA) ICSI (US) 
Date  
 
25.03.2016 17.02.2016 17.02.2016 
Search strategy  Search for ―Guideline Resource Centre‖, 
followed by ―Disease type‖ and then 
―Head and Neck‖. 
 
 Search for ―GAC endorsed guidelines‖. 
 
 Search for ―Guidelines A to Z‖. 
 
Number of guidelines 
identified 
 
n=108 n=109 n=39 
Number of guidelines 
excluded after 
title/abstract reviewed 
 
n=97 
 
 
n=109 
 
 
n=39 
 
 
Reason to exclude  Not oral cancer guidelines (n=83). 
 Specific procedure guidelines (n=11). 
 Beyond scope of clinical area of interest 
(n=3). 
 
 Not oral cancer guidelines (n= 109). 
 
 Not oral cancer guidelines (n=39). 
 
Number of guidelines 
included for detail 
review 
 
 
n=11 n=0 n=0 
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DATABASE 
 
NZGG (NZ) SIGN (SCOTLAND) ASCO (US) 
Date  
 
17.02.2016 17.02.2016 23.2.2016 
Search strategy  Search under publication section, then 
―Guides and standard‖ followed by 
―Diseases and conditions‖ and ―Cancer‖. 
 
 
 Search for guidelines‖, followed by ―published 
guidelines by topic‖ and ―cancer‖. 
 
 Search for ―Guidelines‖, followed by 
―Practice Guidelines‖ and ―Head and Neck 
Cancer‖. 
Number of 
guidelines identified 
 
n=23 n=24 n=1 
Number of 
guidelines excluded 
after title/abstract 
reviewed 
n=23 
 
 
n=23 
 
 
 
 
n=1 
 
 
Reason to exclude  Not oral cancer guidelines (n=22). 
 Provisional Document (n=1). 
 
 Not oral cancer guidelines (n=23) 
 
 
 Not oral cancer guideline (n= 1) 
 
 
Number of 
guidelines included 
for detail review 
 
 
n=0 
 
 
n=1 n=0 
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DATABASE 
 
NCI (US) ASTRO (US) BAHNO (UK) 
Date  
 
23.2.2016 24.2.2016 24.2.2016 
Search strategy  Search for ―publications‖. 
 
 
 Search for ―Clinical practice guidelines‖ 
followed by ―Head and Neck Cancer‖. 
 The guideline for the management of head and 
neck cancer is currently under development. 
 
 
 
 Search for ―Publication‖ followed by 
―Multidisciplinary Management Guidelines 
for Head and Neck Cancer‖. 
 
Number of 
guidelines identified 
 
n=0 n=0 n=1 
Number of 
guidelines excluded 
after title/abstract 
reviewed 
n=0 
 
 
n=0 
 
 
n=0 
 
Reason to exclude NA NA NA 
Number of 
guidelines included 
for detail review 
 
 
n=0 n=0 n=1 
NA: Not applicable 
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DATABASE 
 
ESMO (UK) CCO (CANADA) NCCN (US) 
Date  
 
24.2.2016 26.03.2016 24.2.2016 
Search strategy  Under Guideline Resource Centre, search 
for ―Clinical Practice Guidelines‖, then 
―Head and Necks‖. 
 
 Search for ―evidence-based guidelines‖. 
 Key terms used: 
1) Oral cancer (0) 
2) Mouth cancer (0) 
3) Head and neck cancer (6) 
4) (Oral or mouth) and (carcinoma or 
neoplasm or nodule or mass or tumour) (0) 
5) (Head and neck) and (carcinoma or 
neoplasm or nodule or mass or tumour) (0) 
 
 
 
 Search for ―NCCN Clinical practice 
guidelines‖ followed by ―NCCN Guidelines 
for the treatment of cancer by site‖ and 
―Head and Neck Cancers‖. 
 
Number of 
guidelines identified 
 
n=2 n=6 n=1 
Number of 
guidelines excluded 
after title/abstract 
reviewed 
n=1 
 
 
 
n=5 
 
 
n=0 
 
Reason to exclude  Not oral cancer guideline (n=1) 
 
 Not oral cancer guidelines (n= 5) 
 
NA 
Number of 
guidelines included 
for detail review 
 
 
n=1 n=1 n=1 
NA: Not applicable 
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DATABASE 
 
ESTRO (UK) FDA (US) SOR (FRANCE) 
Date  
 
24.2.2016 22.2.2016 22.2.2016 
Search strategy  Search for ―guideline*‖. 
 
 Search for ―guideline*‖:  
 
 Website in French 
Number of 
guidelines identified 
 
n=4 n=10  
Number of 
guidelines excluded 
after title/abstract 
reviewed 
n=4 
 
 
n=10 
 
 
 
 
 
Reason to exclude  Not oral cancer guidelines (n=4)  Not oral cancer guidelines (n=10) 
 
 
Number of 
guidelines included 
for detail review 
 
 
n=0 n=0  
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DATABASE 
 
RNAO (CANADA) AQM NIH (MARYLAND) 
Date  
 
30.3.2016 23.2.2016 24.2.2016 
Search strategy  Search for ―best practice guidelines‖> 
guidelines. 
 Key terms used: 
1) Oral cancer (3) 
2) Mouth cancer (1) 
3) Head and neck cancer (8) 
4) (Oral or mouth) and (carcinoma or 
neoplasm or nodule or mass or tumour) 
(0) 
5) (Head and neck) and (carcinoma or 
neoplasm or nodule or mass or tumour) 
(0) 
 
 Website in German  Search for ―NIH Guide‖: 
 
Number of 
guidelines identified 
 
n=12  n=3 
Number of 
guidelines excluded 
after title/abstract 
reviewed 
n=12 
 
 
 
 
 n=3 
 
 
Reason to exclude  Not oral cancer guidelines (10) 
 Specific procedure guidelines (n=2) 
 
  Not oral cancer guidelines (n=3) 
Number of 
guidelines included 
for detail review 
 
n=0  n=0 
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DATABASE 
 
AHRQ(US) NHMRC (AUSTRALIA) NICE (UK) 
Date  
 
24.2.2016 26.3.2016 17.02.2016 
Search strategy  The database of guidelines available from 
the National Guideline Clearinghouse. 
 
 The National Guideline Clearinghouse™ 
(NGC), an AHRQ initiative, is a publicly 
available database of evidence-based 
clinical practice guidelines and related 
documents 
 Search for ―Guidelines and Publications‖, 
followed by‖ Clinical Practice Guidelines 
Portal‖. 
 Key terms used: 
1) Oral cancer (1) 
2) Mouth cancer (0) 
3) Head and neck cancer (2) 
4) (Oral or mouth) and (carcinoma or 
neoplasm or nodule or mass or tumour) 
(0). 
5) (Head and neck) and (carcinoma or 
neoplasm or nodule or mass or tumour) 
(0). 
 
 Search under NICE Guidance, followed by 
―conditions and diseases‖ and ―cancer‖. 
 
Number of 
guidelines identified 
 
 n=3 n=1 
Number of 
guidelines excluded 
after title/abstract 
reviewed 
 n=2 
 
 
n=0 
 
Reason to exclude   Specific procedure guidelines (n=2)  
 
NA 
Number of 
guidelines included 
for detail review 
 
 
 n=1 n=1 
NA: Not applicable. 
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DATABASE 
 
TRIP DATABASE (UK) CRD (UK) 
Date  
 
26.3.2016 26.3.2016 
Search strategy TRIP DATABASE search engine> search Trip Database 
1. (title:ORAL CANCER) Filters: Guidelines (8)  
2. (title:MOUTH CANCER) Filters: Guidelines (0)  
3. (title:head and neck cancer) Filters: Guidelines (37) 
4. (Oral or mouth) and (carcinoma or neoplasm or nodule or mass 
or tumour) Filters Guidelines (3) 
5. (Head and neck) and (carcinoma or neoplasm or nodule or mass 
or tumour) Filters Guidelines (551) 
CRD search engine > CRD Database 
1) ((oral or mouth) AND (cancer)) and (Full publication record:ZDT) IN HTA 
FROM 2000 TO 2016 (71) 
2) ((head and neck) AND (cancer)) and (Full publication record:ZDT) IN HTA 
FROM 2000 TO 2016 (53). 
3) ((oral or mouth) AND (Carcinoma or neoplasm or nodule or mass or 
tumour)) and (Full publication record:ZDT) IN HTA FROM 2000 TO 2016 
(41) 
4) ((head and neck) AND (Carcinoma or neoplasm or nodule or mass or 
tumour)) and (Full publication record:ZDT) IN HTA FROM 2000 TO 2016 
(31) 
5) ((oral or mouth) AND (cancer) AND (guideline*or practice guideline*or 
practice guidelines or clinical practice guideline or clinical practice 
guidelines or best practice or recommendation or consensus statement or 
consensus or standard)) and (Full publication record:ZDT) IN HTA FROM 
2000 TO 2016 (9) 
6) ((head and neck) AND (cancer) AND (guideline*or practice guideline*or 
practice guidelines or clinical practice guideline or clinical practice 
guidelines or best practice or recommendation or consensus statement or 
consensus or standard)) and (Full publication record:ZDT) IN HTA FROM 
2000 TO 2016 (11) 
7) ((oral or mouth) AND (carcinoma or neoplasm or nodule or mass or tumour) 
AND (guideline*or practice guideline*or practice guidelines or clinical 
practice guideline or clinical practice guidelines or best practice or 
recommendation or consensus statement or consensus or standard)) and (Full 
publication record:ZDT) IN HTA FROM 2000 TO 2016 (3)  
8) ((head and neck) AND (carcinoma or neoplasm or nodule or mass or tumour) 
AND (guideline*or practice guideline*or practice guidelines or clinical 
practice guideline or clinical practice guidelines or best practice or 
recommendation or consensus statement or consensus or standard)) and (Full 
publication record:ZDT) IN HTA FROM 2000 TO 2016 (5). 
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DATABASE TRIP DATABASE (UK) CRD (UK) 
Number of 
guidelines identified 
 
n= 599 n= 224 
Number of 
guidelines excluded 
after title/abstract 
reviewed 
n= 585 
 
 
n= 219 
 
 
Reason to exclude  Not guideline (n=1) - Vision paper 
 Not oral cancer guideline (n=530) 
 Specific procedure guidelines (n=52) 
 Beyond scope of clinical area of  interest (n=2) 
 
 Not oral cancer guideline (n=144) 
 Specific procedure guidelines (n=55) 
 Beyond scope of clinical area of interest (n=20) 
Number of 
guidelines included 
for detail review 
 
 
n=14 
(5 duplicate guidelines) 
n=5 
(2 duplicate guidelines) 
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DATABASE COCHRANE LIBRARY (UK) 
 
MEDLINE 
Date  
 
26.3.2016 26.3. 2016 
Search strategy 1) "oral cancer":ti,ab,kw Publication Year from 2000 to 2016, in 
Technology Assessments (Word variations have been searched) 
(11). 
2) ―mouth cancer‖:ti,ab,kw Publication Year from 2000 to 2016, in 
Technology Assessments (Word variations have been searched) 
(11). 
3) ―head and neck cancer‖:ti,ab,kw Publication Year from 2000 to 
2016, in Technology Assessments (Word variations have been 
searched) (28). 
4) (Oral or mouth) and (carcinoma or neoplasm or nodule or mass or 
tumour):ti,ab,kw Publication Year from 2000 to 2016, in 
Technology Assessments (Word variations have been searched) 
(25). 
5) head and neck) and (carcinoma or neoplasm or nodule or mass or 
tumour):ti,ab,kw Publication Year from 2000 to 2016, in 
Technology Assessments (Word variations have been searched) 
(44). 
6) (oral or mouth) and (cancer or carcinoma or neoplasm or nodule or 
mass or tumour) and (guideline*or practice guideline*or practice 
guidelines or clinical practice guideline or clinical practice 
guidelines or best practice or recommendation or consensus 
statement or consensus or standard):ti,ab,kw Publication Year from 
2000 to 2016, in Technology Assessments (Word variations have 
been searched) (3). 
7) (head and neck) and (cancer or carcinoma or neoplasm or nodule or 
mass or tumour) and (guideline*or practice guideline*or practice 
guidelines or clinical practice guideline or clinical practice 
guidelines or best practice or recommendation or consensus 
statement or consensus or standard):ti,ab,kw Publication Year from 
2000 to 2016, in Technology Assessments (Word variations have 
been searched) (6). 
 
 
PUBMED search engine 
 
1) (oral cancer AND Guideline[ptyp] AND ( "2000/01/01"[PDat] : 
"2016/12/31"[PDat] ) AND Humans[Mesh]) Filters: Guideline; 
Consensus Development Conference, NIH; Consensus Development 
Conference; Publication date from 2000/01/01 to 2016/12/31; Humans 
(94). 
2) (mouth cancer AND Guideline[ptyp] AND ( "2000/01/01"[PDat] : 
"2016/12/31"[PDat] ) AND Humans[Mesh]) Filters: Guideline; 
Consensus Development Conference, NIH; Consensus Development 
Conference; Publication date from 2000/01/01 to 2016/12/31; Humans 
(34). 
3) ((head and neck cancer AND Guideline [ptyp] AND                         
("2000/01/01"[PDat] : "2016/12/31"[PDat] ) AND Humans[Mesh]) 
Filters: Guideline; Consensus Development Conference, NIH; Consensus 
Development Conference; Publication date from 2000/01/01 to 
2016/12/31; Humans (222). 
4) ((oral[Title]) OR mouth[Title]) AND (carcinoma or neoplasm or nodule 
or mass or tumour) Filters: Guideline; Consensus Development 
Conference, NIH; Consensus Development Conference; Publication date 
from 2000/01/01 to 2016/12/31; Humans (44). 
5) ((head[Title] AND neck[Title])) AND (carcinoma or neoplasm or nodule 
or mass or tumour) Filters: Guideline; Consensus Development 
Conference, NIH; Consensus Development Conference; Publication date 
from 2000/01/01 to 2016/12/31; Humans (45). 
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DATABASE COCHRANE LIBRARY (UK) 
 
MEDLINE 
Number of 
guidelines identified 
 
n=128 n=438 
Number of 
guidelines excluded 
after title/abstract 
reviewed 
n= 119 
 
 
n=411 
 
 
Reason to exclude  Not oral cancer guideline (n=30) 
 Specific procedure guidelines (n=57) 
 Beyond scope of clinical area (n=32) 
 Not oral cancer guideline (n=362) 
 Specific procedure guidelines (n=32) 
 Beyond scope of clinical area (n=5) 
 Another language (n=12) 
 
Number of 
guidelines included 
for detail review 
 
 
n=9 
(6 duplicate guidelines) 
n=27 
(15 duplicate guidelines) 
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DATABASE 
 
EMBASE YAHOO GOOGLE 
Date  
 
26.3.2016 24.2.2016 4.3.2016 
Search strategy UM library databases> Embase. 
 
Key terms used 
 
1. Oral or mouth:ti (1,458, 020) 
2. Head AND neck:ti (47,525). 
3. Cancer:ti OR carcinoma:ti OR neoplasm:ti OR  nodule:ti OR mass:ti 
OR tumour:ti (1,637,157) 
4. Guideline*:ti OR 'practice guideline*':ti OR 'practice  
        guidelines':ti OR 'clinical practice guideline':ti OR   
       'best practice':ti OR 'recommendation':ti OR  
       'consensus statement':ti OR 'consensus':ti OR  
       'standard':ti (140,221) 
5. #1 AND #3 AND #4 AND [article]/lim AND [humans]/lim AND 
[english]/lim AND [embase]/lim AND [2000-2016]/py (62) 
6. #2 AND #3 AND #4 AND [article]/lim AND [humans]/lim AND 
[english]/lim AND [embase]/lim AND [2000-2016]/py (272) 
 
(oral or mouth) or (head and neck) 
and (cancer or carcinoma or 
neoplasm or nodule or mass or 
tumour) and (guideline*or practice 
guideline*or practice guidelines or 
clinical practice guideline or 
clinical practice guidelines or best 
practice or recommendation or 
consensus statement or consensus 
or standard (224,000). 
 
(oral or mouth) or (head and 
neck) and (cancer or carcinoma or 
neoplasm or nodule or mass or 
tumour) and (guideline*or 
practice guideline*or practice 
guidelines or clinical practice 
guideline or clinical practice 
guidelines or best practice or 
recommendation or consensus 
statement or consensus or 
standard (305,000). 
 
Number of guidelines 
identified 
 
n=334 
 
 
n=15 
 
n=16 
 
Number of guidelines 
excluded after 
title/abstract reviewed 
n=329 
 
 
n=0 n=0 
Reason to exclude  Not oral cancer/ not guideline (n=317) 
 Specific procedure guidelines (n=11) 
 Beyond scope of clinical area (n=1) 
 
  
Number of guidelines 
included for detail 
review 
n=5 n=15 n=16 
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Appendix B 
Characteristics of the selected guidelines for full-text review 
No Organizations Guidelines Title Country Publication 
year 
Status Identified Clinical Area Reason to exclude 
Prevention  Diagnosis Treatment Follow-
up care 
1. National 
Comprehensive 
Cancer Network 
NCCN Clinical 
Practice Guidelines in 
Oncology (NCCN 
Guidelines) Head and 
Neck Cancer. Version 
1.2015  
The 
United 
States of 
America 
 
2015 
 
Updated for 
version 
2.2014 
 
√ √ √ √  
2.  National 
Comprehensive 
Cancer Network 
NCCN Guidelines® 
Insights Head and 
Neck Cancers, 
Version 1.2015. 
Featured Updates to 
the NCCN Guidelines  
 
The 
United 
States of 
America 
 
2015 
 
Not a 
guideline. 
 
    The document could not consider 
as a guideline. 
(This is an article that highlights 
the recent updates of the NCCN 
Clinical Practice Guidelines in 
Oncology (NCCN Guidelines) 
Head and Neck Cancers, Version 
1.2015). 
3. The 
Saskatchewan 
Cancer Agency 
Provincial Oral Cavity 
Cancer Treatment 
Guidelines 
  
Canada 2015 New  √ √ √  
4. Victoria 
Government 
Optimal care pathway 
for people with head 
and neck cancers  
 
Australia 2015 New  √ √ √  
5. Belgian Health 
Care 
Knowledge 
Centre 
 
 
 
 
Oral cavity cancer: 
diagnosis, treatment, 
and follow-up  
 
 
 
 
Belgium 2014 New  √ √ √  
 Excluded guideline 
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No Organizations Guidelines Title Country 
 
Publication 
year 
Status Identified Clinical Area Reason to exclude 
Preventive Diagnosis Treatment Follow-
up care 
6. Alberta Health 
Services 
 
Clinical Practice 
Guidelines HN-002. 
Oral cavity cancer  
Canada 2014 New 
 
 
 
 √ √ √  
7. National 
Health Services 
The Management of 
Head & Neck Cancer 
Pathway of Care. 
United 
Kingdom 
2014 Not a 
guideline 
    The document could not consider 
as a guideline. 
 (Pathway of care produced by 
the organisation was based on 
another guideline: Improving 
Outcomes in Head and Neck 
Cancers – The Manual (National 
Institute for Clinical Excellence, 
2004)). 
 
8. National 
Comprehensive 
Cancer 
Network 
NCCN Clinical 
Practice Guidelines in 
Oncology. Head and 
Neck Cancers. Version 
2.2014 
The 
United 
States of 
America 
 
2014 
 
Updated for 
version 
2.2013 
 √ √ √ The guideline had been replaced 
by a more recent version (The 
NCCN Clinical Practice 
Guidelines in Oncology (NCCN 
Guidelines). Head and Neck 
Cancers Version 1.2015). 
 
9. Fagan et al., 
Division of 
Otolaryngology 
University of 
Cape Town 
 
Management  
principles/ guidelines 
for head and neck 
cancer in developing 
countries 
 
South 
Africa 
2014 New √ √ √ √  
10. National 
Comprehensive 
Cancer 
Network 
NCCN Guidelines® 
Insights Head and 
Neck Cancers, Version 
2.2013. Featured 
Updates to the NCCN 
Guidelines  
 
The 
United 
States of 
America 
 
2015 
 
Not a 
guideline. 
    The document could not consider 
as a guideline. This is an article 
that highlights the recent updates 
of the NCCN Clinical Practice 
Guidelines in Oncology (NCCN 
Guidelines). Head and Neck 
Cancers Version 2.2013. 
 
Excluded guidelines.  
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No Organizations Guideline Title Country 
 
Publication 
year 
Status Identified Clinical Area Reason to exclude 
Prevention  Diagnosis Treatment Follow- 
up care 
11. National 
Imaging 
Associates, 
Magellan 
Clinical guidelines 
HEAD AND NECK 
CANCER  
The 
United 
States of 
America 
 
2014 New   √ 
(Radiation 
therapy) 
 
 
 
 
Specific procedure guideline. 
Only outline methods for 
delivering radiation therapy to the 
head and neck area. 
12. South Australia 
Cancer Service 
 
South Australian 
Head and Neck 
Cancer Pathway  
 
Australia 2013 New √ √ √ √  
13. National 
Comprehensive 
Cancer  
Network 
NCCN Clinical 
Practice Guidelines in 
Oncology. Head and 
Neck Cancers. 
Version 2.2013  
 
The 
United 
States of 
America 
 
2013 Updated for 
version 
1.2012 
 √ √ √ The guideline had been replaced 
by a more recent version (The 
NCCN Clinical Practice 
Guidelines in Oncology (NCCN 
Guidelines). Head and Neck 
Cancers Version 1.2015). 
 
14. Spanish Society 
for Medical 
Oncology 
(SEOM) 
SEOM clinical 
guidelines for the 
treatment of head and 
neck cancer (HNC) 
  
Spain 2013 New  √ √ √  
15. (Minneapolis 
(MN): 
HealthPartners. 
 
HealthPartners Dental 
Group and Clinics 
oral cancer guideline  
The 
United 
states of 
America 
 
2012 
 
 
 
 
Updated for 
version 2011 
√ √   The guideline focussed on the 
prevention procedure: screening, 
risk assessment. 
 
 
 
16. National 
Comprehensive 
Cancer  
Network  
NCCN Guidelines. 
Head and Neck 
Cancer. Version 
1.2012  
United 
States of 
America 
 
2012 Updated for 
version 
2.2011 
 √ √ √ The guideline had been replaced 
by a more recent version (The 
NCCN Clinical Practice 
Guidelines in Oncology (NCCN 
Guidelines). Head and Neck 
Cancers Version 1.2015). 
 
 
 
 Excluded guideline 
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No Organizations Guideline Title Country 
 
Publication 
year 
Status Identified Clinical Area Reason to exclude 
Prevention  Diagnosis Treatment Follow-
up care 
17. German Cancer 
Society  
Clinical practice 
guideline: The 
diagnosis and 
treatment of oral 
cavity Cancer 
German 
 
 
 
 
 
 
2012 New  √ √ √  
18. British 
Association of 
Otorhinolaryngo
-logy 
Head and neck cancer: 
Multidisciplinary 
management 
guidelines  
4
th
 edition 
United 
Kingdom 
 
 
2011 
      
Updated for 
version 
2002 
√ √ √ √  
19. National 
Comprehensive 
Cancer  
Network  
NCCN Head and Neck 
Cancers Clinical 
Practice Guidelines in 
Oncology  
2.2011 
United 
States of 
America 
 
2011 Updated for 
version 
1.2010 
 √ √ √ The guideline had been replaced 
by a more recent version (The 
NCCN Clinical Practice 
Guidelines in Oncology (NCCN 
Guidelines). Head and Neck 
Cancers Version 1.2015). 
 
20. Minneapolis 
(MN): 
HealthPartners. 
HealthPartners Dental 
Group and Clinics oral 
cancer guideline 
United 
states of 
America 
2011 Updated for 
version 
2007 
 
√ 
 
 
 
 
 
√   The guideline focussed on the 
prevention procedure: screening, 
risk assessment. 
21. European 
Society Medical 
Oncology 
Squamous cell 
carcinoma of the head 
and neck: EHNS–
ESMO–ESTRO 
Clinical Practice 
Guidelines for 
diagnosis, treatment, 
and follow-up. 
 
 
Europe 2010 
 
Updated for 
version 
2009 
 √ √ √  
 Excluded guidelines. 
245 
 
No Organizations Guideline Title Country 
 
Publication 
year 
Status Identified Clinical Area Reason to exclude 
Prevention  Diagnosis Treatment Follow-
up care 
22. National 
Comprehensive 
Cancer  
Network  
NCCN Head and 
Neck Cancers 
Clinical Practice 
Guidelines in 
Oncology  
1.2010 
United 
States of 
America 
 
2010 New  √ √ √ The guideline had been replaced 
by a more recent version (The 
NCCN Clinical Practice 
Guidelines in Oncology (NCCN 
Guidelines). Head and Neck 
Cancers Version 1.2015). 
23. Cancer Care 
Ontario 
The Management of 
Head and Neck 
Cancer in Ontario 
 
Canada 2009 New  √ √ √  
24. European 
Society Medical 
Oncology 
Squamous cell 
carcinoma of the 
head and neck: 
ESMO Clinical 
Recommendations 
for diagnosis, 
treatmen,t and 
follow- up 
Europe 2009 Updated 
for version 
2008 
 √ √ √ The guideline had been replaced 
by a more recent version 
(Squamous cell carcinoma of the 
head and neck: EHNS–ESMO–
ESTRO Clinical Practice 
Guidelines for diagnosis, 
treatment, and follow-up, 2010). 
25. Cancer Care 
Nova Scotia 
 
Guidelines for the 
management of head 
and neck cancers 
(excluding Thyroid) 
Canada 2007 New 
 
 
 √ √ √  
26. European 
Society Medical 
Oncology 
Squamous cell 
carcinoma of the 
head and neck: 
ESMO Clinical 
Recommendations 
for diagnosis, 
treatment, and 
follow-up 
Europe 2008 Updated 
for 
version 
2007. 
 √ √ √ The guideline had been replaced 
by a more recent version 
(Squamous cell carcinoma of the 
head and neck: EHNS–ESMO–
ESTRO Clinical Practice 
Guidelines for diagnosis, 
treatment, and follow-up, 2010). 
 
 
 
 Excluded guideline 
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No Organizations Guideline Title Country 
 
Publication 
year 
Status Identified Clinical Area Reason to exclude 
Prevention  Diagnosis Treatment Follow-
up care 
27. European 
Society Medical 
Oncology 
Squamous cell 
carcinoma of the 
head and neck: 
ESMO Clinical 
Recommendations 
for diagnosis, 
treatment, and 
follow-up.  
 
Europe 2007 Updated 
for 
Version 
2005 
 √ √ √ The guideline had been replaced 
by a more recent version 
(Squamous cell carcinoma of the 
head and neck: EHNS–ESMO–
ESTRO Clinical Practice 
Guidelines for diagnosis, 
treatment, and follow-up, 2010). 
28. Minneapolis 
(MN): 
HealthPartners. 
. 
 
HealthPartners 
Dental Group and 
Clinics oral cancer 
guideline 
United 
states of 
America 
 
2011 Update for 
version 
2007 
√ √   The guideline focussed on the 
prevention procedure for example 
screening, risk assessment. 
29. Scottish 
Intercollegiate 
Guideline 
Network 
Diagnosis and 
management of head 
and neck cancer. A  
national clinical 
guideline  
Scotland 2006 
 
New  √ √ √  
30. European 
Society Medical 
Oncology 
ESMO Minimum 
Clinical 
Recommendations 
for diagnosis, 
treatment, and 
follow-up of 
squamous cell 
carcinoma of the 
head and neck 
(SCCHN)  
Europe 2005 New  √ √ √ The guideline had been replaced 
by a more recent version 
(Squamous cell carcinoma of the 
head and neck: EHNS–ESMO–
ESTRO Clinical Practice 
Guidelines for diagnosis, 
treatment, and follow-up (2010)). 
31. National 
Institute for 
Clinical 
Excellence 
Guidance on Cancer 
Services – Improving 
Outcomes in Head 
and Neck Cancers – 
The Manual  
United 
Kingdom 
2004 New  √ √ √  
 
 Ecxcluded guidelines 
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No Organizations Guideline Title Country 
 
Publication 
year 
Status Identified Clinical Area Reason to exclude 
Prevention  Diagnosis Treatment Follow-up 
care 
32. University of 
York, 2004 
 
University of  York, 
The Management of 
Head and Neck 
Cancers  
United 
Kingdom 
2004 Not  a 
guideline 
    The document could not 
considered as a guideline. It is a 
buletin on summaries of evidence 
that informed the guidance 
‗Improving Outcomes in Head 
and Neck Cancer. 
 
33. British 
Association of 
Otorhinolaryngo
logists 
 
EFFECTIVE 
HEAD AND 
NECK CANCER 
MANAGEMENT. 
Third Consensus 
Document. 
United 
Kingdom 
2002 New  √ √ √ The guideline had been replaced 
by a more recent version (The 
most recent version is Head and 
neck cancer: Multidisciplinary 
management guidelines  
4
th
 edition, 2011). 
 
 
 
 Excluded guideline 
248 
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Appendix D 
Guideline Currency Survey 
 
 
 
DEVELOPING BEST PRACTICE GUIDELINES FOR ORAL CANCER 
MANAGEMENT IN MALAYSIA 
 
 
Dear colleague, 
I am conducting a study entitled Developing best practice guidelines for oral cancer management in Malaysia 
as a partial fulfillment for the degree of Doctorate in Dental Public Health. 
 
The aim of the study is to develop best practice guidelines for oral cancer management in Malaysia for use by 
healthcare professional in managing oral cancer patients in the country. 
 
Objectives of the study are: 
a. To review existing ‗best practice guidelines‘ and ‗systematic reviews‘ on oral cancer management.  
b. To prepare a draft of guidelines for oral cancer management in Malaysia. 
c. To obtain feedback from a multidisciplinary group consisting of dental and non-dental personnel 
regarding the draft guidelines for oral cancer management in Malaysia. 
d. To formulate best practice guidelines for oral cancer management in Malaysia including diagnosis, 
treatment, and follow-up care.  
 
The guideline as stated in the section A has been chosen to be included in this study. As a guideline 
developer, you are invited to participate in this guideline currency survey by answering all questions in the 
section B. This survey intent to ascertain whether the guideline is still considered current or still in use by 
your organization. Your input is crucial in ensuring the most current evidence will be used in developing 
recommendations for the guidelines. 
 
Please email me at aznila_aziz@yahoo.com  of your completed survey by Friday, 5 August 2016. 
 
Thank you for your participation in this study.  Your co-operation and inputs are much appreciated 
 
Should you need further clarifications, do not hesitate to contact me, 
Dr. Aznilawati Abdul Aziz, 
Doctorate in Dental Public Health Candidate  2014-2017, 
Faculty of Dentistry, University of Malaya, 
50603, Kuala Lumpur, 
Malaysia. 
 :    +60-192537677 
 Email: aznila_aziz@yahoo.com 
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SECTION A: GUIDELINE DETAILS 
A1 Guideline Title: 
A2 Organization: 
A3 Publication Year: 
 
SECTION B: CURRENCY SURVEY OF GUIDELINE DEVELOPER 
Please tick (  ) your answer in the box. 
B1. Are you aware of any new evidence relevant to this clinical practice 
guidelines statement? 
 
Yes No 
  
If yes, please provide a reference for this new evidence. 
 
 
 
 
B2. Is there any new evidence to invalidate any of the recommendations 
comprising the guideline? 
Yes No 
  
If yes, please indicate which recommendation(s) are in need of updating and provide the 
reference for this new evidence. 
 
 
 
 
B3 When was the clinical practice guideline last updated? 
B4. Are there any plans to update the guideline in the near future? 
 
Yes No 
  
If yes, when? 
(Adapted from Guideline Adaptation: A resource kit (Adapte Collaboration, 2009 ). 
END OF SURVEY 
THANK YOU FOR YOUR COOPERATION 
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Appendix E 
Recommendations matrix of oral cancer management_NCCN,BKCE,SIGN 
1. Diagnosis and Staging 
Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
1.1 Patient information 
and consultation. 
Multidisciplinary consultation as indicated. 
 
Low The patient must be kept fully informed about his condition, the 
treatment options and consequences. Information should be complete 
and communicated in a clear and unambiguous way. Patient 
preferences should be taken into account when deciding on a 
treatment option. 
 
Low   
1.2 Clinical 
Examination  
The following investigation are recommended at 
diagnosis and staging of oral cancer: 
 Complete head and neck exam; mirror 
and fiberoptic examination as clinically 
indicated.  
 
Low     
1.3 Biopsy The following investigation is recommended at 
diagnosis and staging of oral cancer: 
 Biopsy.  
Low 
 
a. A biopsy should be taken from the most suspect part of the 
tumour. The pathologist should be provided with any clinically 
relevant information. If the result is inconclusive, or negative 
but the tumour is suspect, the biopsy should be repeated. 
  
b. When a patient with a diagnosis of oral squamous cell 
carcinoma is referred to another centre for work-up completion 
and treatment, and if no additional biopsies need to be 
performed in the reference centre, pathology specimens (slices 
and/or blocks) should be sent for revision to the reference 
laboratory for diagnosis confirmation upon request from the 
reference centre. Every uncommon tumour diagnosis beside 
classical squamous cell carcinoma should be reviewed by an 
expert from a reference laboratory. 
 
c. The biopsy report should include: tumour localization, tumour 
histology, tumour grade, depth of invasion (if assessable), 
lymphatic, vascular and perineural invasion. Some other 
prognostic factors, such as growing pattern (infiltrative vs. 
pushing border), can be considered. 
 Low 
 
 
 
 
Low  
 
 
 
 
 
 
 
 
 
Low 
Fine needle aspiration (FNA) cytology 
should be used in the investigation of 
head and neck masses. 
 
Low 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation  
GPP (Recommended best practice based on the clinical experience of the guideline development group). 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
1.4 Conventional 
imaging of the primary 
tumour 
The following investigation are recommended at 
diagnosis and staging of oral cancer: 
 Computerized tomography (CT) with 
contrast and/or Magnetic resonance imaging 
(MRI) with contrast of primary as indicated.  
 
 
 
 
 
 
 
Low a. Perform an MRI for primary T- and N-staging 
(i.e. before any treatment) in patients with newly 
diagnosed oral cavity cancer. 
 
b. In case MRI is technically impossible (e.g. 
pacemaker, cochlear implant, etc.), likely 
disturbed (e.g. anticipated motion artefacts, etc.) 
or not timely available, perform a contrast-
enhanced CT for primary T- and N-staging in 
patients with oral cavity cancer.  
 
Low 
 
 
 
Low 
a. CT or MRI of the primary tumour site 
should be performed to help define the T 
stage of the tumour.  
 
b. MRI should be used to stage oral tumours.  
 
c. MRI should be used in assessing:   
 laryngeal cartilage invasion 
 tumour involvement of the skull base, 
orbit, cervical spine or neurovascular 
structures (most suprahyoid tumours). 
Low 
 
 
 
Low 
 
Low 
 
1.5 Imaging of 
advanced stage tumour 
Consider Fluorodeoxy glucose positron emission 
tomography-computed tomography (FDG-PET/CT) for 
stage III-IV disease. 
Low In patients with stage III and IV oral cavity cancer, and 
in patients with high-risk features irrespective of the 
locoregional staging (e.g. heavy smokers), perform a 
whole-body FDG-PET/CT for the evaluation of 
metastatic spread and/or the detection of second 
primary tumours.  
 
Low a. In patients presenting with cervical lymph 
node metastases, where CT or MRI does 
not demonstrate an obvious primary 
tumour, FDG-PET should be performed as 
the next investigation of choice.  
 
b. In patients presenting with suspected 
recurrent head and neck cancer, where 
CT/MRI does not demonstrate a clear cut 
recurrence, FDG-PET should be performed 
as the next investigation of choice. 
  
Low 
 
 
 
 
 
Low 
1.6 Imaging of neck 
lumps and nodes 
The following investigation are recommended at 
diagnosis and staging of oral cancer: 
 CT with contrast and/or MRI with contrast of 
neck as indicated.  
Low   a. CT or MRI from skull-base to 
sternoclavicular joints should be performed 
in all patients at the time of imaging the 
primary tumour to stage the neck for nodal 
metastatic disease. 
 
b. Where the nodal staging on CT or MRI is 
equivocal, USFNA and/or FDG-PET 
increase the accuracy of nodal staging. 
 
Low 
 
 
 
 
 
Low 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation  
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
1.7 Other staging 
interventions 
(identification of 
synchronous tumour 
and distant metastases) 
The following investigation are recommended at 
diagnosis and staging of oral cancer: 
 
a. Chest imaging as clinically indicated.  
b. Examination under anesthesia (EUA) with 
endoscopy, if indicated.  
c. Preanesthesia studies as clinically indicated.  
 
 
 
 
Low 
Low 
 
Low 
To exclude synchronous secondary tumours in the head 
and neck area, all patients with oral cavity cancer 
should undergo clinical examination (including 
fiberoptic examination) of the upper aerodigestive tract. 
Endoscopy under general anaesthesia should be 
considered for better local staging of large tumours.  
 
 
Low 
 
 
 
 
 
 
a. All patients with head and neck cancer 
should have direct pharyngolaryngoscopy 
and chest X-ray with symptom-directed 
endoscopy where indicated.  
 
b. All patients with head and neck cancer 
should undergo CT of the thorax, imaging 
for distant metastases and synchronous 
tumour. 
 
Low 
 
 
 
Low 
1.8 HPV Testing   Due to insufficient evidence, routine p16 testing is not 
recommended in patients with oral cavity cancer. In 
patients without any of the common risk factors (e.g. 
smoking, alcohol abuse) for oral cavity cancer, testing 
for p16 can be considered, although there is no evidence 
at present that it alters treatment decisions in these 
patients. 
Low   
1.9 Histopathology 
 
1.9.1 Resection margin 
  a. To avoid a positive resection margin (which is 
associated with a poorer prognosis), frozen 
sections taken intraoperatively may be useful.  
 
b. A distance of at least 10 mm from the palpable 
tumour margin, whenever technically or 
anatomically possible, should be taken as a guide 
for resection to allow a minimal distance of 3-5 
mm from the margin of the resected tissue to the 
primary tumour in the formalin-fixed specimen.  
Low 
 
 
 
Low 
 
 
 
 
 
 
  
 
 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
1.9.2 Primary site 
reporting. 
  For discussion with the clinician, the 
histopathological findings must describe the exact 
localization of any existing R+ status. The anatomical 
topography must be clearly indicated when sending 
the tumour specimen to the pathologist. This may be 
done with suture markers or colour-coding.  
The histopathological result must include:  
 tumour localization,  
 macroscopic tumour size,  
 histological tumour type,  
 histological tumour grade,  
 depth of invasion,  
 lymphatic,  
 vascular and perineural invasion,  
 locally infiltrated structures,  
 pT classification,  
 details of affected areas and infiltrated 
structures,  
 R status and p16 (if not done on biopsy).  
 
Low 
 
 
 
 
Histopathology reporting of specimens from the 
primary site of head and neck cancer should 
include:  
 tumour site, 
 tumour grade, 
 maximum tumour dimension,  
 maximum depth of invasion,  
 margin involvement by invasive and/or 
severe dysplasia, 
 pattern of infiltration,  
 perineural involvement  
 Tumour type 
                  and 
 lymphatic/vascular permeation. 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
GPP 
1.9.3 Neck and 
metastatic disease 
reporting. 
  The histopathological findings from a neck dissection 
specimen must describe: 
 the anatomical topography, 
 the side of the neck,  
 type of neck dissection,  
 eliminated levels,  
 total number of lymph nodes plus number 
of lymph nodes affected,  
 number of lymph nodes per level,  
 level of the affected lymph nodes,  
 diameter of the largest tumour deposit,  
 additionally removed structures, 
 extracapsular spread (if present). 
 
Low a. The reporting of nodal dissections should 
include a description of the type of dissection 
(comprehensive, selective or extended), the 
levels and structures included in the 
specimen  
 
b. Histopathology reporting of specimens from 
areas of metastatic disease in patients with 
head and neck cancer should include:  
 number of involved nodes, 
 level of involved nodes, 
 extracapsular spread of tumour 
and 
 type of nodal dissection  and size of 
largest tumour mass.  
 
GPP 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
GPP 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
2.1 Multidisciplinary involvement. 
 
 The management of patients with head and neck cancers 
is complex. All patients need access to the full range of 
support services and specialists with expertise in the 
management of patients with head and neck cancer for 
optimal treatment and follow-up. Outcomes are 
improved when patients with head and neck cancers are 
treated in high volume centers.  
• Head and neck surgery  
• Radiation oncology  
• Medical oncology  
• Plastic and reconstructive surgery 
• Specialized nursing care  
• Dentistry/prosthodontics  
• Physical medicine and rehabilitation  
• Speech and swallowing therapy  
• Clinical social work  
• Clinical nutrition  
• Pathology (including cytopathology) 
• Diagnostic radiology  
• Adjunctive services (Neurosurgery,     
 Ophthalmology,  Psychiatry, Addiction services, 
Audiology, (Palliative care). 
Low Oral cavity carcinoma must be treated on an 
interdisciplinary basis after upfront discussion of the 
case in question by a tumour board (MOC/COM), 
comprising the specialist disciplines of: 
 oral and maxillofacial surgery,  
 ENT,  
 radiation oncology,  
 medical oncology, 
 pathology,  
 radiology  
 nuclear medicine.  
The general practitioner, Dentist and Paramedical 
disciplines (speech therapist, nutritional therapist, and 
psychosocial worker) are recommended to be present. 
Continuity of care should be guaranteed through 
cooperation between the hospital and the home care 
team. 
 
 
Low a. Treatment plans should be formulated by a 
multidisciplinary team in consultation with 
the patient. As part of this process, dental, 
speech and language and nutritional 
assessments are essential.  
 
b. Individual patient characteristics, local 
expertise and patient preference should guide 
management of head and neck cancer. 
 
GPP 
 
 
 
 
GPP 
2.2 Pre-treatment assessments. 
 
 
2.2.1 Dental evaluation 
Dental/prosthodontic evaluation,d including Panorex or 
CT ± contrast as clinically indicated, radiograph of all 
teeth and risk assessment of caries and periodontal 
disease. 
 
Low Patients with carcinoma of the oral cavity should be 
examined by a dedicated dental practitioner prior to 
commencing oncological treatment. The dentist 
should give preventive advice and perform necessary 
restorative work. 
 
Low Patients with head and neck cancer, especially 
those planned for resection of oral cancers or 
whose teeth are to be included in a radiotherapy 
field, should have the opportunity for a pre-
treatment assessment by an appropriately 
experienced dental practitioner. 
 
Low 
2.2.2 Nutritional, 
speech and swallowing 
evaluation. 
Nutrition, speech, and swallowing evaluation/therapy 
before and after treatment as indicated and should 
involve a registered dietitian and a speech-
language/swallowing therapist. 
Low 
 
  All head and neck cancer patients should be 
screened at diagnosis for nutritional status using a 
validated screening tool appropriate to the patient 
population. Patients at risk of undernutrition should 
be managed by an experienced dietitian. 
GPP 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
2.3 Treatment of primary non-metastatic oral cancer. 
 
2.3.1 General 
recommendations 
    Factors to be considered in treatment plan: 
 Management of early oral cavity tumours 
should be individualised for each patient.  
 Decisions regarding the choice of primary 
treatment modality should be made in 
consultation with the patient and should 
take into account the anatomical location 
of the tumour and availability of local 
expertise. 
 In those patients where surgical resection 
is possible, the likelihood of obtaining 
adequate surgical margins with acceptable 
morbidity, functional outcome and quality 
of life must be considered.  
 The likely short and long term morbidity 
resulting from radiotherapy must be 
considered. 
 
 
GPP 
 
2.3.2 Early stage of oral 
cancer (Stage I and II) 
a. Resection of primary site is the preferred 
treatment +  ipsilateral (guided by tumour 
thickness) or bilateral (guided by location of 
primary) neck dissection. 
 
b. Resection of primary ± sentinel lymph node 
(SLN) biopsy may be used to identify occult 
cervical metastases. Sentinel lymph node biopsy 
should be done in centers with expertise in this 
technique. 
 
c. For patients with resected oral cavity cancers 
who have no positive nodes and no adverse 
features, he or she should proceed with follow–
up. 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
a. Provided the patient's general condition permits it 
and the oral cavity carcinoma can be curatively 
resected, surgical resection of the tumour should be 
performed and followed by immediate 
reconstruction, when required. 
 
b. In case of a microscopically residual tumour (R1 
resection), targeted follow-up resection should ensue 
with the aim of improving the patient's prognosis, 
whenever possible.         
 
c. Continuity of the mandible should be preserved on 
tumour resection or restored post-resection, 
provided no radiological or intraoperative evidence 
has been found of tumour invasion of the bone. 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
a. Patients with early oral cavity cancer may be 
treated by surgical resection, where rim rather 
than segmental resection should be performed, 
where possible, in situations where removal of 
bone is required to achieve clear histological 
margins. 
 
b. Reconstruction should be performed where 
necessary following surgical resection to 
achieve a good functional and cosmetic result.   
 
c. Patients with early oral cavity cancer may be 
treated by: 
Brachytherapy in accessible, well demarcated 
lesions to a dose of 65-70 Gy at a dose rate of 
less than 0.55 Gy/hour . 
 
 
Low 
 
 
 
 
 
 
GPP 
 
 
 
Low 
 
 
 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or 
cohort studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
 
2.3.2 Early stage of oral 
cancer (Stage I and II) 
 
d. Definitive radiotherapy (RT) may be offered to 
early stage patients (T1-2, N0) who are 
medically inoperable or refuse surgery. Patients 
who go on to develop residual disease after 
definitive RT should be considered for surgery.   
(If definitive RT is chosen for treatment of T1–
2, N0 disease, the fraction size to the 
intermediate-and low-risk sites ranges from 44 
Gy (2.0 Gy/fraction) to 60 Gy (1.6 Gy fraction). 
 
e. For patients with resected oral cavity cancers 
who have one positive node without adverse 
features, consider RT  
 
f. For patients with resected oral cavity cancers, 
who have positive margins, options include: 
1) re-resection or RT 
2) consider chemotherapy/RT (for T2 only).  
 
g. For patients with resected oral cavity cancers, 
who have the adverse pathologic features of 
extracapsular nodal spread with [or without] a 
positive mucosal margin, the preferred treatment 
is postoperative chemotherapy/RT. 
 
h. For patients with resected oral cavity cancer, 
who have other risk features such as perineural 
invasion, or vascular embolism (lymphovascular 
invasion), options include: 
1) RT or  
2) Consider chemotherapy/RT. 
 
 
Low 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
High 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
d. Reconstructive measures should from the onset be 
integrated in the surgical approach. When planning 
reconstruction, consideration must be given to the 
entire oncological scenario. The anticipated 
functional or cosmetic improvement must justify the 
efforts involved in reconstruction. 
 
e. Patients with small but accessible tumours (T1/T2) 
in the oral cavity may be treated with interstitial 
brachytherapy in selected cases. 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
d. Interstitial brachytherapy should be 
performed by experienced teams in centres 
with adequate radiation protection facilities. 
 
e. Re-resection should be considered to achieve 
clear histological margins if the initial 
resection has positive surgical margins or if 
inadequate initial excision biopsy has been 
performed. 
 
f. If re-resection is not possible, postoperative 
radiotherapy should be considered. 
 
g. Postoperative radiotherapy should be 
considered for patients with clinical and 
pathological features that indicate a high risk 
of recurrence. 
 
h. Administration of cisplatin chemotherapy 
concurrently with postoperative radiotherapy 
should be considered, particularly in patients 
with extracapsular spread and/or    positive 
surgical margins  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
GPP 
 
 
Low 
 
 
 
 
High 
 
 
 
 
 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
2.3.3 Advanced stage of 
oral cancer (Stage III 
and IV) 
a. For patients with N0, N1, N2a-b, N3: resection 
of primary is with ipsilateral, or bilateral neck 
dissection. 
 
b. For patients with N2c (bilateral): resection of 
primary and bilateral neck dissection. 
 
c. For patients with resected oral cavity, cancers 
who have no adverse features, consider RT. 
 
d. For patients with resected oral cavity cancers 
who have the adverse pathologic features of 
extracapsular nodal spread and/or a positive 
mucosal margin, recommended postoperative 
adjuvant options include:  
1) chemotherapy/RT (preferred) or 
2) re-resection of positive margins (if technically 
feasible); or 
3) RT  
 
d. For other risk features such as pT3 or pT4 
primary, N2 or N3 nodal disease, nodal disease 
in levels IV or V, perineural invasion, or 
vascular tumor embolism: clinical judgment 
should be used when deciding to either use RT 
alone or add chemotherapy to RT. 
Low 
 
 
 
Low 
 
 
Low 
 
 
 
 
 
 
 
 
High 
Low 
 
 
Low 
 
 
a. The decision to perform surgery must be made on 
the basis of the ability to achieve tumour-free 
resection margins and postoperative quality of life. 
For locally advanced tumours, the postoperative 
functional consequences need to be prospectively 
and carefully assessed. For instance, when a total 
glossectomy (+/- total laryngectomy) is the only 
oncologically suitable surgical option, non-surgical 
organ preservation protocols must be seriously 
considered.   
 
b. In view of the favourable benefit/risk balance, 
IMRT is recommended in patients with advanced 
oral cavity cancer. 
 
c. Patients with advanced and non-metastatic oral 
cavity carcinoma who are not eligible for curative 
surgery (T4b, N3, unacceptable functional 
consequences, excessive comorbidity should 
preferably be administered primary 
radiochemotherapy rather than radiotherapy alone. 
 
d. Postoperative radiotherapy should be performed for 
advanced T categories (T3/T4), close (< 4 mm) or 
positive resection margins, tumour thickness > 10 
mm, lymph node involvement (> pN1) and extra-
capsular rupture/soft tissue infiltration. It should be 
considered for peri-neural extension or lymphatic 
vessels infiltration. For high-risk patients (e.g. close 
or positive resection margins, extracapsular spread) 
postoperative radiochemotherapy can be considered.                                             
 
e. Postoperative radiotherapy should be fractionated 
conventionally (e.g. 60-66 Gy in 6 to 6.5 weeks, 2 
Gy per day, 5 times a week).  
 
 
Low 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
 
High 
 
 
 
 
 
 
 
 
High 
 
 
a. Patient with resectable disease, who are fit for 
surgery, should have surgical resection with 
reconstruction. 
 
b. The likelihood of obtaining adequate surgical 
margins with acceptable morbidity, functional 
outcome and quality of life must be 
considered before undertaking surgical 
resection. 
 
c. Radical external beam radiotherapy with 
concurrent cisplatin chemotherapy should be 
considered when:  
 the tumour cannot be adequately 
resected.  
 the patient‘s general condition precludes 
surgery. 
 the patient does not wish to undergo 
surgical resection. 
 
d. In patients medically unsuitable for 
chemotherapy, concurrent administration of 
cetuximab with radiotherapy should be 
considered. 
 
e. Where radiotherapy is being used as a single 
modality without concurrent chemotherapy or 
cetuximab, a modified fractionation schedule 
should be considered. 
 
f. Postoperative radiotherapy should be 
considered for patients with clinical and 
pathological features that indicate a high risk 
of recurrence. 
 
 
 
 
Low 
 
 
 
GPP 
 
 
 
 
 
High 
 
 
 
 
 
 
 
 
 
High 
 
 
 
 
High 
 
 
 
 
Low 
 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
2.3.3 Advanced stage of 
oral cancer (Stage III 
and IV)  
  f. Postoperative radiotherapy should be commenced as 
early as possible, i.e. within 6 weeks after surgery, 
and should be completed within 12-13 weeks after 
surgery.  
 
g. In concurrent (primary or postoperative) 
radiochemotherapy, radiotherapy should be 
fractionated conventionally (i.e. 2 fractions per day, 
5 days per week) and chemotherapy should be 
platinum-based (100 mg/m² three times weekly in 
case of postoperative radiochemotherapy). 
 
h. Interruption of radiotherapy will be detrimental to 
tumour control and should be avoided. 
 
i. Radiochemotherapy should only be performed at 
facilities in which radiotherapy- or chemotherapy-
induced acute toxicities can be adequately managed. 
 
j. Due to insufficient evidence the combination of 
radiotherapy with EGFR inhibitors is not 
recommended in patients with oral cavity cancer. 
 
k. In patients with oral cavity cancer, induction 
chemotherapy is not recommended. 
Low 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
Low 
 
 
 
Low 
 
 
 
Low 
g. Postoperative radiotherapy should be 
conventionally fractionated: 54-60Gy in 27-
30 fractions over 5.5-6 weeks to the primary 
site and nodes at risk 66Gy in 33 fractions 
over 6.5 weeks to areas of very high risk). 
 
h. Administration of cisplatin chemotherapy 
concurrently with postoperative radiotherapy 
should be considered, particularly in patients 
with extracapsular spread and/or    positive 
surgical margins. 
 
i. Interrupting and prolonging a course of 
radical radiotherapy should be avoided. 
 
j. Overall treatment time from surgery to 
completion of radiotherapy should be 10-11 
weeks or less in the absence of postoperative 
medical or surgical complications. 
 
k. Concurrent chemoradiotherapy should only 
be administered where there are appropriate 
facilities for monitoring toxicity, with rapid 
access to appropriate outpatient and inpatient 
support for the treatment of acute 
radiotherapy and chemotherapy toxicity 
 
l. The routine use of neo-adjuvant 
chemotherapy in oral cavity cancer is not 
recommended. 
 
 
 
 
 
 
 
 
 
High 
 
 
 
 
 
High 
 
 
 
 
 
Low 
 
 
Low 
 
 
 
 
High 
 
 
 
 
 
 
High 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
2.3.4 Management of 
the neck lymph nodes 
  a. Management of the neck lymph nodes should follow 
the same treatment principles as those applied for 
the primary tumour (e.g. if the primary tumour is 
surgically treated, a neck dissection should be 
performed). 
  
b. Perform a selective neck dissection of at least level 
I, II and III in all patients with a cN0M0 oral cavity 
SCC that is treated surgically.  
 
c. A neck dissection can be omitted exceptionally in 
some patients with a cT1N0M0 oral cavity SCC, 
depending on the localisation and thickness of the 
tumour.  
 
d. Perform a selective ipsilateral neck dissection of at 
least level I, II, III and IV with – if oncologically 
feasible – preservation of the sternocleidomastoid 
muscle, jugular vein and spinal accessory nerve in 
all patients with a cN+M0 oral cavity SCC that is 
treated surgically. 
 
e. Consider a contralateral neck dissection in patients 
with a non-metastatic oral cavity SCC that is at or 
crossing the midline or not clearly localized 
laterally.   
 
f. Consider performing a diagnostic evaluation of the 
neck with conventional imaging techniques (CT or 
MRI) or PET/CT three months after completion of 
primary (chemo)radiotherapy.  
 
g. In patients with oral cavity cancer (N1-3) and 
complete response to chemoradiotherapy (assessed 
by FDGPET/CT, CT or MRI), there is no data to 
support an additional lymph node dissection. 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
Low 
a. The clinically N0 neck (levels I-III) should be 
treated prophylactically either by external 
beam radiotherapy or selective neck 
dissection.  
 
b. Patients with node positive disease should be 
treated by modified radical neck dissection. 
Elective dissection of the contralateral neck 
should be considered if the primary tumour is 
locally advanced, arises from the midline, or 
if there are multiple ipsilateral nodes. 
involved. 
 
c. Nodal levels I-IV should be irradiated 
bilaterally. 
 
d. Patients with N1 disease who are receiving 
radiotherapy to the primary tumour should 
treated with chemoradiotherapy where there 
is clinical evidence of residual disease 
following completion of therapy.  
 
e. Patients with N2 and N3 nodal disease who 
are receiving radiotherapy to the primary 
tumour should be treated with 
chemoradiotherapy followed by planned neck 
dissection. 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
 
 
Low 
 
 
Low 
 
 
 
 
 
Low 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
2.4 Treatment of very advanced-stage oral cancer (M0) T4b, any N or unresectable nodal disease or unfit for surgery) 
 
 a. Participation in clinical trials is preferred for all 
patients with very advanced cancers. 
 
b. Patients should undergo standard therapy based 
on their PS = Performance Status (Eastern 
Cooperative Oncology Group [ECOG]).  
 
c. For patients with a PS of 0 or 1, the standard 
treatment is concurrent chemotherapy and 
radiotherapy. Other options are induction 
chemotherapy followed by RT or 
chemotherapy/RT  
 
d.  PS 0-2: Definitive RT with or without 
concurrent chemotherapy.  
 
e. PS 0-3: Palliative RT or single-agent 
chemotherapy or best supportive care. 
 
f. Perform neck dissection following the above 
treatment (if feasible) in the instance of residual 
neck disease and primary site are controlled. 
 
 
 
 
 
 
 
 
 
 
 
 
 
.  
Low 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
Low 
 
 
Low 
    
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2015). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
2.5 Treatment of  locoregional recurrence disease. 
 
2.5.1 General 
evaluation 
  In patients with suspected recurrence in the head and 
neck that could not be confirmed or ruled out by CT 
and/or MRI, FDG-PET/CT may be performed. 
 
Low a. Decisions regarding the appropriate 
management of a locoregional recurrence of 
head and neck cancer should be made on an 
individual basis taking into account:  
 The stage of recurrent tumour and its 
potential resectability. 
 Previous treatment 
 Likely treatment efficacy 
 Likely treatment-related morbidity and 
functional outcome and consequent 
effects on quality of life  
 patient‘s general health  
 patient‘s wishes.  
 
b. Decisions regarding the management of 
locoregional recurrence of head and neck 
cancer should be made by the 
multidisciplinary team in consultation with 
the patient following histological 
confirmation of recurrence and full restaging 
(clinical and radiological). 
 
c. Patients and their relatives/carers should be 
carefully counselled about the likely outcome 
of surgical and radiotherapeutic salvage, with 
respect to survival, risk of treatment-related 
morbidity and mortality, and likely resulting 
quality of life.  
 
d. Early referral to palliative care for symptom 
control should be considered. 
 
 
 
 
 
GPP 
 
 
 
 
 
 
 
 
 
 
 
 
 
GPP 
 
 
 
 
 
 
 
GPP 
 
 
 
 
 
 
 
GPP 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations  Recommendations LOE 
2.5.2 Resectable 
locoregional recurrence 
a. Enrollment in a clinical trial is preferred.  
 
b. Surgery is recommended for resectable recurrent 
or persistent locoregional disease. 
 
c.  For patients with resected oral cavity cancers 
who have the adverse features of extracapsular 
nodal spread and/or positive margin and the 
patients did not have prior RT the treatment is 
postoperative chemotherapy/RT.  
 
d. For patients with resected oral cavity cancers 
and who have other risk features such as pT3 or 
pT4 primary, N2 or N3 nodal disease, nodal 
disease in levels IV or V, perineural invasion, or 
vascular tumor embolism and the patients did 
not have prior RT, the options include RT or 
consider chemotherapy/RT. 
 
e. For patients with resected oral cavity cancers 
with prior RT, the options include surgery with 
or without postoperative reirradiation or 
chemotherapy/RT. 
 
Low 
 
Low 
 
 
High 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
Low 
Salvage surgery should be considered in any patient 
with a resectable locoregional recurrence having 
previously undergone radiotherapy or surgery. The 
procedure should only be performed by a surgical team 
with adequate experience of reconstructive techniques, 
and at a facility that offers suitable intensive care 
support. 
 
 
Low a. Salvage surgery should be considered in any 
patient with a resectable locoregional 
recurrence of oral cavity cancer following 
previous radiotherapy or surgery.  
 
b. Salvage surgery should only be performed by 
an experienced surgical team with adequate 
experience in reconstructive techniques, in 
centres with appropriate facilities for medical 
support and rehabilitation.  
 
 
Low 
 
 
 
 
GPP 
2.5.3 Unresectable 
loceregional recurrence 
 
a. If the recurrence is unresectable and the patients 
did not have prior RT, then RT with 
concurrent chemotherapy is recommended, 
depending on the PS. 
 
b. If the recurrence is unresectable and the patients 
have prior RT, the treatment option include 
reirradiation with or without chemotherapy, or 
chemotherapy alone. 
Low 
 
 
 
 
Low 
Re-irradiation, possibly with curative intent, should be 
considered in any patient with a non-resectable 
locoregional recurrence having already undergone 
irradiation. Irradiation should take place only at 
facilities with adequate expertise and ideally as part of a 
clinical therapeutic study. 
 
Low a. External beam radiotherapy should be 
considered as potentially curative salvage 
treatment for patients with locoregionally 
recurrent disease after previous surgery,    
particularly if the recurrence is unresectable, 
or resection would result in unacceptable loss 
of function or cosmesis. 
 
b. Selected patients who have unresectable 
locally recurrent disease following previous 
radiotherapy may be considered for 
potentially curative re-irradiation.  
 
 
GPP 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
2.5.3 Unresectable 
loceregional recurrence 
 
    c. Patients with small accessible recurrences in a 
previously irradiated region may be 
considered for interstitial brachytherapy in 
centres with appropriate facilities and 
expertise. 
 
d. Re-irradiation should only be performed in 
centres with adequate expertise, and ideally 
only in the context of a clinical trial. Centres 
must be experienced in the recognition and 
management of acute and late radiation 
toxicity. 
 
Low 
 
 
 
 
 
GPP 
2.6 Treatment of metastatic or recurrent disease not eligible for curative treatment. 
 
2.6.1 General 
recommendation 
    a. The care of patients with incurable head and 
neck cancer should be managed by the 
palliative care services in conjunction with 
the multidisciplinary team.  
 
b. All modalities of therapy should be 
considered as options for the palliation of 
head and neck cancer. 
  
c. Short term toxicity and length of hospital stay 
should be balanced against likely 
symptomatic relief.  
  
d. A documented pathway of care should be 
discussed and agreed with the patient, 
relatives, carers and GP. 
 
 
 
 
 
 
 
GPP 
 
 
 
 
GPP 
 
 
 
GPP 
 
 
 
GPP 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
2.6.2 Palliative 
chemotherapy 
a. Patients should undergo standard chemotherapy 
based on their PS = Performance Status (Eastern 
Cooperative Oncology Group [ECOG]). 
 
b. For patients with a PS of 0 or 1, the standard 
systemic therapy includes:  
1) Platinum + 5-FU + cetuximab (RL 1) or  
2) Combination chemotherapy or  
3) Single-agent chemotherapy or  
4) Surgery or RT or chemoradiotherapy/RT 
for selected patients with limited 
metastases or  
5) Best supportive care. 
 
c. PS 2: Single-agent chemotherapy followed by 
best supportive care or best supportive care 
alone   
 
d. PS 3: Best supportive care.  
 
 
Low 
 
 
 
 
 
High 
Low 
Low 
Low 
 
 
Low 
 
Low 
 
 
Low 
In patients with metastatic oral cavity cancer or 
recurrent disease that is not eligible for curative 
treatment, palliative chemotherapy or targeted treatment 
can be considered after discussion with the patient. 
Low 
 
a. Patients of adequate performance status 
should be considered for palliative 
chemotherapy which may reduce tumour 
volume. 
 
b. Single agent methotrexate, single agent 
cisplatin, or cisplatin/5Fu combination should 
be considered for palliative chemotherapy in 
patients with head and neck cancer.  
         
c. A excessive toxicity from intensive 
chemotherapeutic combination regimens 
should be avoided. 
 
High 
 
 
 
 
High 
 
 
 
 
High 
2.6.3 Palliative 
radiotherapy 
NA 
 
 
 
 NA  Radiotherapy may be considered for palliative 
treatment in patients with locally advanced 
incurable head and neck cancer. 
 
Low 
2.6.4 Palliative surgery NA 
 
 
 
 
 
 
 
 
 
 NA  Appropriate surgical procedures should be 
considered for palliation of particular symptoms, 
taking local expertise into consideration. 
 
GPP 
 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
 
267 
 
Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
3.1 Clinical and 
imaging evaluation 
a. The ranges are based on risk of relapse, second 
primaries, treatment sequelae, and toxicities. 
 
b. Perform head and neck examination; mirror and 
fiberoptic examination as clinically indicated:  
Year 1, every 1–3 months. 
Year 2, every 2–6 months 
Years 3–5, every 4–8 months 
>5 years, every 12 months 
 
c. Post-treatment baseline imaging of primary 
tumour (and neck, if treated) recommended 
within 6 months of treatment. Further reimaging 
as indicated based on worrisome or equivocal 
signs/symptoms, smoking history, and areas 
inaccessible to clinical examination.   
 
d. Chest imaging as clinically indicated for patients 
with smoking history.  
 
e. Thyroid-stimulating hormone (TSH) every 6–12 
months if neck irradiated. 
Low 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
Low 
 
 
An individually structured follow-up schedule should be 
devised for each patient. The quality of life, side effects of 
treatment, nutritional status, speech, dental status, thyroid 
function, smoking and alcohol consumption, etc. should be 
surveyed periodically. There is no evidence to support 
routine use of imaging techniques for the detection of 
locoregional or metastatic recurrence during follow-up. 
Follow-up frequency, even in symptom-free individuals, 
should be at least every 3 months in the first and second 
year, every 6 months in the third to fifth year, and annually 
afterwards. 
Low a. Patients should be seen frequently and 
regularly within the first three years post-
treatment. 
 
b. Patients should be offered multidisciplinary 
follow up. 
 
c. Patients should have access to PET 
scanning, if appropriate, when recurrence is 
suspected.  
 
d. Patients‘ weight should be monitored at 
follow up.  
 
e. Patients‘ complaints of pain should be 
investigated.  
 
f. Routine use of chest X-rays or serum 
markers is not recommended.  
 
g. During follow up, routine supplementation 
with beta carotene is not recommended.  
Low 
 
 
 
GPP 
 
 
Low 
 
 
 
Low 
 
 
Low 
 
 
High 
 
 
High 
3.2 Dental 
rehabilitation 
Dental evaluation is recommended for oral cavity and 
sites exposed to significant intraoral radiation 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
Low a. In patients having undergone surgery and/or 
irradiation for carcinoma of the oral cavity, the 
masticatory function should be restored with the help 
of functional masticatory rehabilitation, using 
conventional prosthetics and/or implants. Surgical 
interventions (e.g. extractions) should be performed by 
professionals with experience in treating patients with 
head and neck cancer. The patients should undergo 
routine dental check-ups at a frequency depending on 
the individual patient case (usually every 4-6 months). 
 
b. Infected osteoradionecrosis of the jaw is a serious 
treatment complication that should be managed in 
specialized centres. 
Low 
 
 
 
 
 
 
 
 
 
 
Low 
 
a. Patients receiving oral surgery or 
radiotherapy to the mouth (with or without 
adjuvant chemotherapy) should have post-
treatment dental rehabilitation. 
 
b. Patients should access lifelong dental 
follow up and dental rehabilitation. 
 
c. Dental extractions in irradiated jaws should 
be carried out in hospital by a specialist 
practitioner.  
 
d. Patients should have access to a consultant 
restorative dentist. 
 
Low 
 
 
 
 
Low 
 
 
Low 
 
 
 
GPP 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
3.2 Dental 
rehabilitation 
    e. Hyperbaric oxygen facilities an adjuvant 
treatment to prevent osteoradionecrosis 
should be available for selected patients.  
 
f. Pilocarpine (5-10 mg three times per day) 
may be offered to improve radiation-
induced xerostomia in those patients with 
evidence of some intact salivary function, 
providing    there are no medical 
contraindications to its use.  
Low 
 
 
 
High 
3.3 Speech and 
swallowing 
rehabilitation. 
Speech/hearing and swallowing evaluation and 
rehabilitation as clinically indicated.  
Low a. Patients with chewing, speaking and swallowing 
problems should be timely provided with appropriate 
functional therapy. The patients should be introduced 
to suitably qualified therapists prior to commencing 
treatment if the scheduled surgical or conservative 
procedures (e.g. radiotherapy) are likely to cause 
problems with chewing, swallowing and/or speech. 
 
b. Patients with dysphagia should undergo appropriate 
diagnostic procedures, e.g. clinical exam by the speech 
therapist, videofluoroscopy or fiber-optic endoscopy. 
 
c. Patients having eating and speaking problems due to 
carcinoma of the oral cavity and/or its management 
should have access to speech therapists and nutritional 
therapists with experience of such pathologies before, 
during and after treatment. 
 
 
Low 
 
 
 
 
 
 
 
Low 
 
 
 
Low 
 
a. Head and neck cancer patients with 
dysphagia should receive appropriate 
speech and language therapy to optimise 
residual swallow function and reduce 
aspiration risk.  
 
b. All patients with oral cancer should have 
access to instrumental investigation for 
dysphagia.  
 MBS and FEES are both valid 
methods for assessing dysphagia. 
  the SLT should consider which is the 
most appropriate for different patients 
in different settings.  
 
c. All patients undergoing chemoradiation 
should have access to a specialist speech 
and language therapist before, during and 
after treatment.  
 
d. Where communication problems are likely 
to occur, patients should be seen by a 
specialist head and neck speech and 
language therapist soon after diagnosis and 
before treatment commences.  
 
e. Patients with communication impairment 
should have access to a speech and 
language therapist.  
Low 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
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Context (National Comprehensive Cancer Network, 2016). 
 
(Belgian Health Care Knowledge Centre, 2014). (Scottish Intercollegiate Guideline Network, 2006). 
Recommendations LOE Recommendations LOE Recommendations LOE 
3.4 Nutritional therapy Nutritional evaluation and rehabilitation as clinically 
indicated until nutritional status is stabilized. 
 
Low Patients should be regularly screened for malnutrition due to 
oral cavity cancer or its treatment. Patients at risk for 
malnutrition should receive timely and ongoing professional 
dietary counselling and nutritional therapy. 
Low 
 
a. All head and neck cancer patients should be 
screened at diagnosis for nutritional status 
using a validated screening tool appropriate 
to the patient population. 
 
b. After screening, at-risk patients should 
receive early intervention for nutritional 
support by an experienced dietitian.  
 
c. The multidisciplinary team should include 
healthcare professionals skilled in 
gastrostomy placement. 
  
d. Patients should be offered information 
about feeding tube alternatives, including 
possible complications.  
 
GPP 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
GPP 
3.5 Psychosocial 
counselling and support 
Ongoing surveillance for depression. 
 
Low Patients with oral cavity cancer (and their family, carers) 
should be offered dedicated psychosocial support on a 
continuous basis within the context of a multidisciplinary 
team.  
 
Low 
 
a. Head and neck cancer patients should be 
offered emotional support, which may be 
provided by clinical nurse specialists and 
non-clinically trained counsellors. 
  
b. In some situations it may be appropriate to 
refer patients to a clinical psychologist.  
 
c. Leaflets about risk factors, prevention and 
early detection of head and neck cancer 
should be available in primary care. 
 
d. Patients should be given information about 
their diagnosis and treatment at separate 
meetings. Individualised information 
should be made available. 
 
 
 
 
 
 
GPP 
 
 
 
 
GPP 
 
 
High 
 
 
 
GPP 
Note: Levels of evidence (LOE) listed by the guideline developers were reclassified into high level evidence (High) and low level evidence (Low) for comparison within the matrix: 
High level evidence: evidence from meta-analysis, systematic review of randomized control trials (RCT), high quality systematic reviews of case control or cohort studies, RCT and high quality case control or cohort 
studies with a very low risk of confounding or bias.  
Low level evidence: evidence from non-randomized trials, well conducted case controls, cohort studies, case reports, case series, expert opinion, clinical observation. 
GPP: Recommended best practice based on the clinical experience of the guideline development group. 
 
270 
 
Appendix F 
 
Search strategies for ‗systematic reviews‘ on oral cancer management. 
database cochrane library trip databases dare medline 
Date  13.10.2016 25.10.2016 26.10.2016 27.10.2016 
Search strategy Search under Cochrane 
database: 
 
1) Search for Cochrane 
Review, browse by 
topic, Cancer and Oral 
(12). 
2) Search for Cochrane 
Review, browse by 
topic, Cancer and Head 
and Neck (25). 
 
TRIP DATABASE search engine> search Trip 
Database. 
6. ―(title:Oral or mouth) and (cancer or carcinoma or 
neoplasm or nodule or mass or tumour))‖ Filters: 
Systematic Reviews, since 2015 (4). 
7. ―(title:(Head and neck) and (cancer or carcinoma 
or neoplasm or nodule or mass or tumour))‖ 
Filters: Systematic Reviews, since 2015 (5). 
8. ―(title:Oral or mouth) and (cancer or carcinoma or 
neoplasm or nodule or mass or 
tumour))(title:Diagnostic test or treatment or 
follow-up care)‖ Filters: Systematic Reviews, 
since 2015 (2). 
9. ―(title:(Head and neck) and (cancer or carcinoma 
or neoplasm or nodule or mass or 
tumour)(title:Diagnostic test or treatment or 
follow-up care)‖ Filters: Systematic reviews, since 
2015  (1). 
10.  ―(title:Oral or mouth) and (cancer or carcinoma or 
neoplasm or nodule or mass or 
tumour))(title:surgery or radiotherapy or 
chemotherapy)‖ Filters: Systematic Reviews, since 
2015  (2). 
11. ―(title:(Head and neck) and (cancer or carcinoma 
or neoplasm or nodule or mass or tumour) (cancer 
or carcinoma or neoplasm or nodule or mass or 
tumour)) (title:surgery or radiotherapy or 
chemotherapy)‖ Filters: Systematic Reviews, since 
2015  (2). 
CRD search engine > DARE 
Database 
 
1. (oral or mouth) AND (Cancer or 
carcinoma or neoplasm or 
nodule or mass or tumour):TI IN 
DARE FROM 2015 TO 2016 
(3). 
2. (head and neck) AND (Cancer or 
carcinoma or neoplasm or 
nodule or mass or tumour):TI IN 
DARE FROM 2015 TO 2016 
(0). 
3.  (surgery) IN DARE FROM 
2015 TO 2016 (3). 
4. #1 or #2 and #3 (0). 
5. (diagnosis) IN DARE FROM 
2015 TO 2016 (12). 
6. #1 or #2 and #5 (0). 
7. (treatment) IN DARE FROM 
2015 TO 2016 (22). 
8. #1 or #2 and #7(0). 
9.  (follow up) IN DARE FROM 
2015 TO 2016 (2). 
10. #1 or #2 and #9 (0). 
11.  (radiotherapy) IN DARE FROM 
2015 TO 2016 (5). 
12. #1 or #2 and #11 (0). 
13. (chemotherapy) IN DARE 
FROM 2015 TO 2016 (1). 
14. #1 or #2 and #13 (0). 
PUBMED search engine 
 
1. (((oral or mouth) AND (Cancer or 
carcinoma or neoplasm or nodule or mass or 
tumour)) OR((head and neck) AND (Cancer 
or carcinoma or neoplasm or nodule or mass 
or tumour))) Filters: Systematic Reviews; 
Publication date from 2015/01/01 to 
2016/12/31; Humans; English (85). 
2. (((oral or mouth) AND (Cancer or 
carcinoma or neoplasm or nodule or mass or 
tumour) OR ((head and neck) AND (Cancer 
or carcinoma or neoplasm or nodule or mass 
or tumour))) AND (surgery[Title] Filters: 
Systematic Reviews; Publication date from 
2015/01/01 to 2016/12/31; Humans; English 
(6). 
3. (((oral or mouth) AND (Cancer or 
carcinoma or neoplasm or nodule or mass or 
tumour) OR ((head and neck) AND (Cancer 
or carcinoma or neoplasm or nodule or mass 
or tumour))) AND (diagnosis[Title] Filters: 
Systematic Reviews; Publication date from 
2015/01/01 to 2016/12/31; Humans; English 
(2). 
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     4. (((oral or mouth) AND (Cancer or carcinoma 
or neoplasm or nodule or mass or tumour) OR 
((head and neck) AND (Cancer or carcinoma 
or neoplasm or nodule or mass or tumour))) 
AND (treatment[Title] Filters: Systematic 
Reviews; Publication date from 2015/01/01 to 
2016/12/31; Humans; English (12). 
5. (((oral or mouth) AND (Cancer or carcinoma 
or neoplasm or nodule or mass or tumour) OR 
((head and neck) AND (Cancer or carcinoma 
or neoplasm or nodule or mass or tumour))) 
AND (radiotherapy[Title] Filters: Systematic 
Reviews; Publication date from 2015/01/01 to 
2016/12/31; Humans; English (3). 
6. (((oral or mouth) AND (Cancer or carcinoma 
or neoplasm or nodule or mass or tumour) OR 
((head and neck) AND (Cancer or carcinoma 
or neoplasm or nodule or mass or tumour))) 
AND (chemotherapy[Title] Filters: Systematic 
Reviews; Publication date from 2015/01/01 to 
2016/12/31; Humans; English (1). 
7. (((oral or mouth) AND (Cancer or carcinoma 
or neoplasm or nodule or mass or tumour)) OR 
((head and neck) AND (Cancer or carcinoma 
or neoplasm or nodule or mass or tumour))) 
AND (follow up[Title] Filters: Systematic 
Reviews; Publication date from 2015/01/01 to 
2016/12/31; Humans; English (4) 
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Appendix G 
 
Characteristics of the selected systematic reviews for full-text review 
No. Title Author, Year Journal Citation Reason for exclusion 
1. Therapeutic exercises for affecting post-treatment 
swallowing in people treated for advanced-stage head 
and neck cancers (Review).  
 
Perry A, Lee SH, Cotton S, Kennedy C., 
2016. 
 
Cochrane Database of  
Systematic Reviews  
(Issue 8).   
 
2. Gemcitabine-Based Chemoradiation in the Treatment of 
Locally Advanced Head and Neck Cancer: Systematic 
Review of Literature and Meta-Analysis 
Vanderveken Olivier M., Petr Szturz, Pol 
Specenier, Marco C. Merlano, Marco 
Benasso, Dirk Van Gestel, Kristien 
Wouters et al., 2016. 
 
The oncologist, 21(1), 59-71.  
3. Interventions for the treatment of oral and oropharyngeal 
cancers: targeted therapy and immunotherapy (Review).  
 
Chan KKW, Glenny AM, Weldon JC, 
Furness S, Worthington HV, Wakeford 
H., 2015. 
Cochrane Database of Systematic 
Reviews (Issue 12).  
 
4. Diagnostic tests for oral cancer and potentially malignant 
disorders in patients presenting with clinically evident 
lesions (Review).  
 
Macey R, Walsh T, Brocklehurst P, Kerr 
AR, Liu JLY, Lingen MW, Ogden GR, 
Warnakulasuriya S, Scully C., 2015. 
Cochrane Database of Systematic 
Reviews (Issue 5).  
 
5. Diagnostic capability of salivary biomarkers in the 
assessment of head and neck cancer: a systematic review 
and meta-analysis. 
Guerra, Eliete Neves Silva, Ana Carolina 
Acevedo, André Ferreira Leite, David 
Gozal, Hélène Chardin, and Graziela De 
Luca Canto, 2015. 
 
Oral oncology 51, no. 9   
6. Induction chemotherapy prior to surgery with or without 
postoperative radiotherapy for oral cavity cancer 
patients: Systematic review and meta-analysis. 
Marta, Gustavo N., Rachel Riera, Paolo 
Bossi, Lai-ping Zhong, Lisa Licitra, 
Cristiane R. Macedo, Gilberto de Castro, 
André L. Carvalho, William N. William, 
and Luis Paulo Kowalski, 2015. 
European Journal of  
Cancer, 51(17), 2596- 
2603.   
 
 
7. Techniques for early diagnosis of oral squamous cell 
carcinoma: Systematic review. 
 
Carreras-Torras, Clàudia, and Cosme 
Gay-Escoda, 2015. 
Med Oral Patol Oral Cir Bucal, 
20(3), e305-315. 
 
8. 18 FDG-PET/CT for the detection of regional nodal 
metastasis in patients with head and neck cancer: a meta-
analysis. 
 
Sun, Rong, Xinye Tang, Yang Yang, and 
Cheng Zhang, 2015. 
Oral oncology, 51(4), 314-320   
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No. Title Author, Year Journal Citation Reason for exclusion 
9. Induction chemotherapy with concurrent 
chemoradiotherapy versus concurrent chemoradiotherapy 
for locally advanced squamous cell carcinoma of head 
and neck: a meta-analysis.  
 
Zhang, L., Jiang, N., Shi, Y., Li, S., 
Wang, P., & Zhao, Y., 2015. 
Scientific Reports, 5  
10. Swallowing assessment and management pre and post 
head and neck cancer treatment. 
Riffat, Faruque, Dakshika A. Gunaratne, 
and Carsten E. Palme 
Current opinion in otolaryngology 
& head and neck surgery 23, no. 6: 
440-447 
 
Not a systematic review 
(Review of current 
opinion) 
11. Nutritional support via prophylactic gastrostomy versus 
therapeutic support in patients with head and neck cancer 
(Health Technology assessments). 
Petruson K, Aust J, Koinberg I, Liljegren 
A, Nyman J, Sjövall H, Svanberg T, 
Samuelsson O., 2015 
Regional activity-based HTA 
2015:79 
Not a systematic review 
(Health technology 
assessment report) 
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Appendix H 
 
Summary of selected systematic reviews 
Study Objective Study Characteristics Method 
 
Intervention Results Conclusion 
1) Perry A, Lee 
SH, Cotton S, 
Kennedy C. 
Therapeutic 
exercises for 
affecting post-
treatment 
swallowing in 
people treated 
for advanced-
stage head and 
neck cancers. 
Cochrane 
Database of 
Systematic 
Reviews 
2016, Issue 8 
To determine 
the effects of 
therapeutic 
exercises, 
undertaken 
before, during 
and/or 
immediately 
after HNC 
treatment, on 
swallowing, 
aspiration and 
adverse events 
such as chest 
infections, 
aspiration 
pneumonia and 
profound 
weight loss, in 
people treated 
curatively for 
advanced-stage 
(stage III, stage 
IV) squamous 
cell carcinoma 
of the head and 
neck. 
Type of study: 
Randomized controlled trials 
(RCTs)  
 
Population: 
Adults with squamous cell 
carcinoma of the head and neck 
cancer (stage III, stage IV) who 
underwent therapeutic 
exercises for swallowing 
before, during and/or 
immediately after HNC 
treatment (surgery and 
radiation therapy, surgery and 
chemoradiotherapy or 
chemoradiotherapy without 
surgery). 
 
Type of intervention: 
Therapeutic exercise consist of: 
Swallowing exercise or  
Neuromuscular exercises or 
both. 
 
Comparison 
Usual treatment. 
 
Outcome measured: 
1. Reduced/no aspiration;  
2. Oropharyngeal swallowing 
efﬁciency (OPSE) measures,  
3. Adverse events, such as 
chest infections, aspiration 
pneumonia, profound weight 
loss. 
 
The outcomes were measured 
in 2 times of period: 
 Short term 
(3 months or less). 
 Long term 
(More than 6 months) 
Literature search: 
 
Searched was carried out on the 
selected electronic databases on1 
July 2016. 
 
Inclusion criteria: 
No restrictions on the language or 
date of publication. 
 
Data collection. 
1. Two reviewers independently 
screened the results the searches, 
extracted data and assessed the 
risk of bias of the included 
studies using Cochrane 
methodology.  
 
2. Quality of evidence were 
assessed using GRADE method. 
 
Data analysis. 
 
RR and 95% CI were calculated 
for dichotomous outcomes. 
 
Mean difference (MD) / std mean 
difference (SMD) and 95% CI 
were calculated for continuous 
outcomes. 
 
Data from  the identiﬁed trials 
could not be combined due to 
differences: 
 The choice of primary 
outcomes. 
 The difference measurement 
tools. 
 The differing baseline and 
endpoints across studies. 
 
(i) Therapeutic 
exercises versus 
treatment as 
usual (TAU);  
 
 
TAU consist of 
nasogastric tube 
or percutaneous 
endoscopic 
gastrostomy. 
 
 
Therapeutic 
exercises: 
1. Swallowing 
exercise.  
Using a ball of 
food or fluid. 
 
2. 
Neuromuscular 
exercises. 
Exercise to 
increase tongue 
range of motion 
to keep the 
tongue mobile 
during, after 
HNC treatment. 
It directly 
improved the 
oral bolus 
transit. 
 
 
Included studies. 
Six studies (326 participants whose ages ranged from 39 to 83 years, 
with a gender bias towards men (73% to 95% across studies), 
reﬂecting the characteristics of patients with HNC.  
 
Risk of bias. 
The risk of bias in the studies was generally high. 
 
Main results. 
1. Swallowing function/efficiency. 
 MD: -8.06 (95% CI: -25.37 to 9.25) 
 Quality of evidence: very low. 
 Swallowing function (OPSE) improved following 
treatment. However, the effect did not reach statistical 
significance. 
 
2. Adverse event: weight loss (>10%). 
 Weight loss at 6 weeks: RR 0.62 (95% CI 0.22 to 1.71). 
 Quality of evidence: very low. 
 The risk of weight loss (>10%) is around 40% lower in 
the Pharyngocise  group compared to the TAU group . 
However, the estimate has a wide confidence interval and 
is not statistically significant. 
 
3. Adverse event: weight change 
 MD1.34 (95% CI-0.46 to3.14). 
 120 (intervention group 60; TAU group 60). 
 Quality of evidence: very low. 
 The weight change estimate has a wide confidence 
interval and is not statistically.  
significant. Therefore the effect is uncertain.  
  
 4. Aspiration. 
 Quality of evidence: very low. 
 Results were reported as a percentage-not estimable 
(Scored as present, trace or absent, for any consistency). 
 
5.Penetration 
 Results were reported as a percentage-not estimable 
(Scored as present, trace or absent, for any consistency). 
 
No statistical 
difference 
was found by 
undertaking 
therapeutic 
exercises 
before, during 
and/or 
immediately 
after HNC 
treatment 
leads to 
improvement 
in swallowing 
function, 
weight loss or 
change and 
reduced in 
aspiration. 
 
 
This absence 
of evidence 
may be due to 
the small 
participant 
numbers in 
trials, 
resulting in 
insufﬁcient 
power to 
detect any 
difference.  
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Study 
 
Objective Study Characteristics Method Intervention Results Conclusion 
2) Vanderveken  
et. al., 2016. 
Gemcitabine-
Based 
Chemoradiati
on in the 
Treatment of 
Locally 
Advanced 
Head and 
Neck Cancer: 
Systematic 
Review of 
Literature and 
Meta-
Analysis. The 
oncologist, 
21(1), 59-71. 
  
 
 
 
 
 
 
 
To review the 
efficacy and toxicity 
of gemcitabine used 
together with 
radiation as a single 
agent and as part of 
multiagent-based 
chemoradiotherapy, 
in combination with 
other cytotoxic 
agents in the 
treatment of 
locoregionally 
advanced squamous 
cell carcinoma of 
head and neck (LA)-
SCCHN. 
Type of study: 
Phase 1, II trials and 
clinical investigation. 
 
Population:  
Locoregionally 
advanced squamous 
cell carcinoma of head 
and neck (LA)-
SCCHN. 
 
Intervention: 
Radiotherapy 
combined with either 
single-agent 
gemcitabine or 
gemcitabine/cisplatin-
based 
polychemotherapy for 
the treatment of 
patients with LA-
SCCHN. 
 
Outcome measures: 
 Complete 
response (CR). 
 Toxicity (Gred 
3-4 acute 
mucositis rate)  
 3-years overall 
survival. 
 
Literature search: 
 MEDLINE 
 COCHRANE LIBRARY 
(up to May 5, 2015). 
 BIBLIOGRAPHIC 
SEARCH: 
Abstracts in the field of 
interest presented at top 
scientific meetings within 
the past 20 years. 
 References in the included 
studies were reviewed. 
 
Inclusion criteria: 
1. Restricted papers in English. 
 
Exclusion criteria: 
1.Nasopharynx carcinoma 
2. Full text not available 
3. Trials or substudies that were 
investigational;  
4. Trials or sub studies that had 
induction chemotherapy (ICT) as 
part of the therapeutic regimen. 
5. Gemcitabine was part of 
multiagent-based chemoradiation 
in combination with other 
cytotoxic agent. 
 
Data analysis. 
A meta-analysis was performed 
to calculate pooled proportions 
with 95% confidence intervals 
(CIs) for complete response (CR) 
rate and grade 3–4 acute 
mucositis rate. 
 
2.A generalized linear mixed 
model with logit link was used to 
study the relationship between 
dose of gemcitabine, dose of 
cisplatin and occurrence of CR, 
mucosal toxicity, and 
hematologic toxicity. 
1) Chemoradiation 
with gemcitabine 
using a very low-dose 
of  gemcitabine (<50 
mg/m2  per week). 
 
2) Chemoradiation 
with gemcitabine 
using a higher dose of  
gemcitabine (>50 
mg/m2  per week). 
 
Included studies. 
A total of 13 papers were eligible for the 
literature reviews. The quality of the studies 
included were heterogeneity in quality. 
 
For schedules using very low-dose 
gemcitabine (<50 mg/m2  per week), 
 CR rate:  86% (95% CI, 74%–93%),  
 Grade 3–4 acute mucositis rate38% (95% 
CI, 27%–50%)  
 Acceptable late toxicity  
 One study showed 3-year overall survival 
of 50%.  
 
For higher dose intensity (DI) (>50mg/m2 per 
week)  
 
 CR rate: 71% (95% CI, 55%–83%),  
 Significantly (p<0.001) greater acute 
mucositis rate: 74% (95% CI, 62%–83%) 
and often leading to treatment interruptions. 
 
Association between  DI and toxicity and CR 
rate 
 At those DIs, there was not any correlation 
found between the cumulative dose of 
gemcitabine and the severity of acute local 
toxicity.  
 In terms of the CR rate, the difference 
between very low-dose and higher-dos 
gemcitabine did not reach statistical 
significance (P=0 .087).  
 Correspondingly, based on survival data 
provided  in 8 studies testing higher-dose 
gemcitabine, a 3-year overall survival 
ranged from 27% to 63%. 
1.Gemcitabine had a 
radiosensitizing potential in the 
treatment of LA-SCCHN 
 
2. The results suggested that, 
Gemicitabine given together 
with radiation provide a 
sufficient therapeutic ratio  
either as single-agent 
gemcitabine or 
gemcitabine/cisplatin-based 
polychemotherapy. 
 
3. Although there seems to be 
no difference in efficacy 
between very low-dose 
(<50mg/m2 per week)and 
higher dose 
(>50mg/m2per week) 
regimens, a significantly 
increased rate of severe acute 
mucositis can be observed 
(38%vs.74%,   P< 0.001) with 
the higher dose. 
  
4. .However further 
investigation is needed to 
further improve the outcome in 
terms of efficacy and toxicity, 
particularly with respect to the 
incidence of acute mucositis 
and late dysphagia, refinements 
in radiation schemes, the use of 
novel drug combinations, and a 
better selection of patients on 
the basis of validated 
biomarkers for a more 
personalized treatment 
approach are worth 
considering. 
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Study 
 
Objective Study Characteristics Method Intervention Results Conclusion 
3) Chan KKW, 
Glenny AM, 
Weldon JC, 
Furness S, 
Worthington 
HV, Wakeford 
H. Interventions 
for the treatment 
of oral and 
oropharyngeal 
cancers: 
targetedtherapy 
and 
immunotherapy. 
Cochrane 
Databaseof 
Systematic 
Reviews 2015, 
Issue 12 
To assess the 
effects of 
molecularly 
targeted 
therapies and 
immunotherapie
s, in addition to 
standard 
therapies, for 
the treatment of 
oral cavity or 
oropharyngeal 
cancers. 
 
 
Type of study, 
population, intervention 
and comparison. 
Randomized controlled 
trials where more than 50% 
of participants have 
primary tumours of the oral 
cavity or oropharynx, and 
compared targeted therapy 
or immunotherapy, plus 
standard therapy with 
standard therapy alone. 
 
Inclusion criteria: 
1. Primary squamous cell 
carcinomas,  
2. Histological variants of 
squamous cell carcinomas 
(adenosquamous, 
verrucous, basaloid, 
papillary).  
3. Carcinoma in situ.  
 
Exclusion criteria: 
1. Epithelial malignancies 
of the salivary glands, 
2. Odontogenic tumours,  
3. All sarcomas and 
lymphomas (these have a 
different aetiology and are 
managed differently). 
 
Type of outcome 
measured:  
 Overall survival/total 
mortality (and 
disease-related 
mortality if possible).  
 Locoregional control. 
 Disease-free survival 
(DFS). 
 Progression-free 
survival (PFS) or 
time to recurrence. 
Literature search: 
Searched were carried out on the 
following electronic databases:  
 Cochrane Oral Health 
Group Trials Register (to 3 
February 2015), 
  Cochrane Central Register 
of Controlled Trials 
(CENTRAL) (The 
Cochrane Library, 2015, 
Issue 1),  
 MEDLINE via Ovid (1946 
to 3 February 2015) 
 EMBASE via Ovid (1980 to 
3 February 2015),  
 US National Institutes of 
Health Trials Register 
(clinicaltrials.gov) (to 3 
February 2015), 
 The World Health 
Organization Clinical Trials 
Registry Platform, the 
American Society of 
Clinical Oncology 
conference abstracts (to 3 
February 2015), 
 The Radiation Therapy 
Oncology Group clinical 
trials protocols for ongoing 
trials (to 3 February 2015). 
 
Inclusion criteria: 
No restrictions on the language or 
date of publication. 
Targeted therapy: 
 
1. EGFR mAb. 
Standard therapy 
(Radiotherapy 
(RT) or 
chemotherapy 
(CRT)) plus 
epidermal 
growth factor 
receptor 
monoclonal 
antibody (EGFR 
mAb) such as 
cetuximab or 
nimotuzumab 
therapy (follow-
up period 24 to 
70 months);  
         VS 
         RT or CRT  
         alone. 
 
2. TKIs 
Standard therapy 
(RT or CRT) 
plus tyrosine 
kinase or 
vascular 
endothelial 
growth factor 
(VEGF) 
inhibitors such as 
erlotinib, 
gefitinib or 
lapatinib (follow-
up period 40 to 
60 months). 
         VS 
         RT or CRT     
         alone. 
 
 
Studies included: 
 
12 trials (2488 participants) were included. 12% of 
participants (298 participants) had tumours of the oral cavity 
and 59% (1468 participants) had oropharyngeal tumours. 
The remaining 29% had  tumours of the larynx or 
hypopharynx and  less than 1% had tumours at other sites. 
 
Main Results: 
 
1. EGFR mAb. 
 
Overall survival (5 years) 
 1421 (3studies) 
 HR: 0.82 (95% CI 0.69 to 0.97). 
 Overall effect Z= 2.31, P=0.021. 
 Quality of evidence: moderate 
 18% reduction in death for the participants treated 
with EGFR mAb therapies in addition to standard 
therapies. 
 
Locoregional control (EGFR  mAB + RT vs RT alone) 
 424 (1study) 
 HR0.68 (95% CI 0.52 to 0.89) 
 Overall effect Z= 2.82, P=0.0048. 
 Quality of evidence: moderate 
 32% reduction in recurrence of cancer in the 
participant treated with EGFR mAb therapies 
(cetuximab) in addition to radiotherapy. 
 
Progression-free survival  
(A subgroup analysis separating studies of RT and CRT. 
Unable to pool these subgroups due to high subgroup 
heterogeneity). 
The sub group comparing mAb therapy + RT VS RT alone. 
 424 participants (1 study). 
 Unclear risk of bias. 
 HR 0.70; (95% CI 0.54 to 0.91).  
 Z= 2.69, P value =0.0071. 
 30% reduction in the number of people whose disease 
progresses if treated with EGFR mAb in addition to 
RT. 
1. Adding EGFR 
mAB to RT may 
increase overall 
survival 
progression-free 
survival and 
locoregional 
control, while 
resulting in an 
increase in skin 
toxicity for some 
mAb (cetuximab). 
 
The quality of 
evidence for for 
both therapies are 
unclear risk of 
bias and high risk 
of bias 
respectively. 
 
2.There is 
insufﬁcient 
evidence to 
determine whether 
adding TKIs to 
standard therapies 
changes any of 
our primary 
outcomes. 
 
3.Very low 
quality evidence 
from a single 
study suggests 
that rIL-2 
combined with 
surgery may 
increase overall 
survival compared 
with surgery 
alone. 
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  Data collection: 
1. Two reviewers independently 
screened the results of the 
electronic searches, extracted data 
and assessed the risk of bias of 
the included studies. 
 
2. Quality of evidence were 
assessed using GRADE method. 
 
 
Data analysis:  
 
1.Hazard ratio (HR) and  95% 
conﬁdence interval (CI) for the 
primary outcomes were 
calculated. 
 
 2. Dichotomous outcomes were 
reported as risk ratios (RR) and 
95% CIs. 
 
3.Similar studies were combined 
in meta-analyses using random-
effects models when there were at 
least four studies and ﬁxed-effect 
models when fewer than four 
studies 
 
Immune-boosting 
therapy: 
 
3. rIL-2 
Standard therapy 
(surgery) plus 
immunotherapy 
such as 
recombinant 
Interleukin (rIL-
2) (follow-up 
period 24 to 70 
months),  
         VS 
         surgery alone. 
 
 
The sub group comparing mAb therapy + CRT  Vs CRT 
alone. 
 891 participants (1 study). 
 High risk of bias. 
 HR1.08; (95% CI 0.89 to1.32) 
 Z=0.80, P value =0.46. 
 No evidence of a difference in progression free 
survival 
 
Adverse effect 
There was evidence that adding cetuximab to standard 
therapy may result in increased skin toxicity and rash (RR 
6.56; 95% CI 5.35 to 8.03; 1311 participants, two studies). 
 
2. TKIs. 
No evidence to determine whether TKIs added  to standard 
therapy impacts on overall survival, locoregional control, 
disease-free control and progression-free survival. 
 
Overall survival 
 HR 0.99; 95% CI 0.62 to 1.57. 
 Z=0.06, P= 0.95. 
 271 participants, two studies;  
 Very low quality evidence  
 
Locoregional control  
 HR 0.89; 95% CI 0.53 to 1.49. 
 Z=0.45, P= 0.65. 
 271 participants, two studies. 
 Very low quality evidence. 
 
Disease-free survival  
 HR 1.51; 95% CI 0.61 to 3.71. 
 Z=0.89, P= 0.37. 
 60 participants, one study;  
 Very low quality evidence 
 
Progression-free survival  
 HR 0.80; 95% CI 0.51 to 1.28. 
 Z=0.92, P= 0.36. 
 271 participants, two studies; 
 Very low quality evidence. 
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Continued 
3. rIL-2 
 
Overall survival 
 201 participants, 1 study. 
 Very low quality of evidence. 
 HR 0.52; 95% CI 0.31 to 0.87. 
 Z= 2.50, p= 0.012. 
 48% reduction in death in the group treated with rIL-2 
in addition to standard therapy (surgery). 
 
 
Disease-free survival  
 201 participants, 1 study. 
 Very low quality of evidence. 
 HR 0.66, 95% CI 0.43 to 1.02.y low quality. 
 Z= 1.86, p= 0.062. 
 There is no evidence of a difference in the length of 
time that participants survived without signs or 
symptoms of cancer when treated withrIL-2 in 
addition to surgery 
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4) Macey R, Walsh 
T, Brocklehurst 
P, Kerr AR, Liu 
JLY, Lingen 
MW, Ogden 
GR, 
Warnakulasuriy
a S, Scully C. 
Diagnostic tests 
for oral cancer 
and potentially 
malignant 
disorders in 
patients 
presenting with 
clinically 
evident lesions. 
Cochrane 
Database of 
Systematic 
Reviews 2015, 
Issue 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To estimate the 
diagnostic 
accuracy of a 
number of tests 
that can be used 
as adjuncts to 
oral 
examination to 
detect 
squamous cell 
carcinoma 
(OSCC) and 
potentially 
malignant 
disorders 
(PMD).  
 
These tests 
were; vital 
staining 
(toluidine blue), 
oral cytology, 
and light-based 
detection, and 
blood and saliva 
analysia. 
Type of studies: 
Cross-sectional studies that 
reported  on the diagnostic 
test accuracy for the 
individual with clinically 
evident lesions. 
 
Populations: 
Adult (16 years and above) 
presenting with clinically 
evident oral lesions and 
referred to a secondary 
care for further 
investigation. 
 
Intervention: 
Conventional oral 
examination  and 
adjunctive test in detecting 
PMD or oral squamous cell 
carcinoma of the lip or oral 
cavity:  
1. Vital staining,  
2. Oral cytology,  
3. Light-based 
detection. 
4. Blood and saliva 
analysis. 
 
Comparison: 
Scalpel biopsy and 
histological assessment by 
experienced oral 
pathologist. 
 
Outcomes: 
Sensitivity and specificity 
Literature search 
The electronic databases were 
searched on 30 April 2013: 
 MEDLINE (OVID) range: 
1946 to April 2013)  
 The Cochrane Diagnostic 
Test Accuracy Studies 
Register,  
 The Cochrane Oral Health 
Group‘s Trials Register,  
 EMBASE (OVID) 
 MEDION (Ovid) 
 Screened reference lists of 
included studies. 
 
Inclusion criteria: 
No restrictions on language. 
 
Data collection  
 Two review authors 
independently screened 
titles, abstract and full text 
for relevance.  
 Eligibility, data extraction 
and quality assessment were 
carried out by two authors, 
independently. 
 Third reviewer was 
involved when 
disagreement emerged 
 Studies were assessed for 
methodological quality 
using QUADAS.  
 
Data analysis 
 Meta-analysis was used to 
combine the results of 
studies for each index test 
using the bivariate approach 
to estimate the expected 
values of sensitivity and 
speciﬁcity. 
 
 
 
 
Reference test:  
Scalpel biopsy and 
histology assessment 
by experienced oral 
pathologist. 
 
Index test: 
Conventional oral 
examination and 
adjunctive test. 
 Vital staining,  
 Oral cytology,  
 Light-based 
detection and 
oral pectroscopy 
 Blood or saliva 
analysis (no 
eligible studies 
were found) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Included studies: 
Forty-one studies involving 4002 participants 
referred to a secondary care, published between 
1980 and 2012. 
 
Main results: 
 
Vital staining 
 No of studies/participants: 14/1248. 
 Sensitivity: 0.84 (95% CI 0.74 to 0.90). 
 Specificity: 0.70 (95% CI 0.59 to 0.79). 
 Mete-regression analysis showed: Neither 
sensitivity or specificity were associated with 
prevalence of disease  (p= 0.14) 
 
Oral cytology 
 No of studies/participants: 12/1507. 
 Sensitivity: 0.91(95% CI 0.81 to 0.96). 
 Specificity: 0.91(95% CI 0.81 to 0.95). 
 Covariate analysis showed:  
Neither sensitivity or specificity were 
associated with prevalence of disease  (p= 
0.45) 
 
Light-based detection 
 No of studies/participants: 12/1021. 
 Sensitivity 0.91 (95% CI 0.77 to 0.97) 
 Specificity 0.58 (95% CI 0.22 to 0.87) 
 
Quality of studies: All studies at high risk of bias 
1. None of the adjunctive 
index tests evaluated in this 
review can be 
recommended as a 
replacement for the 
currently used standard of 
a scalpel biopsy and 
histological assessment. 
 
2.Among the three 
diagnostic test, oral 
cytology would appear to 
be the most potential index 
test , however further 
investigation is needed 
because quality of all 
studies included are at high 
risk of bias 
 
However the authors note 
in the discussion that this 
finding should be 
interpreted with caution. 
This is because the overall 
quality of the studies 
included is poor (Cross 
sectional studies). 
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5) Eliete Neves 
Silva Guerra, 
Ana Carolina 
Acevedo, 
Andrea Ferreira 
Leita, David 
Gozal, Helene 
Chardin, 
Graziela De 
Luca Canto. 
2015. 
Diagnostic 
capability of 
salivary 
biomarkers in 
the assessment 
of head and neck 
cancer. A 
systematic 
review and 
meta-analysis. 
Oral Oncol, 1-
14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To evaluate the 
diagnostic value 
of salivary 
biological 
biomarkers in 
the diagnosis of 
head and neck 
cancer 
(HNSCC). 
Type of studies: 
Case -control 
 
Population: 
HNSCC including lip 
and/or oral cavity, 
pharynx, larynx, nasal 
cavity, paranasal sinuses. 
 
Intervention: 
Salivary biological 
markers. 
 
Comparison: 
Salivary biological markers 
as diagnostic media in non-
HNSCC patients. 
 
Outcomes measured: 
The diagnostic sensitivity 
and specificity of salivary 
biomarkers. 
. 
 
 
 
 
 
 
 
Literature search: 
Electronic databases such as 
MEDLINE, Cochrane, EMBASE, 
LILACS, MEDLINE , PubMed 
and Google Scholar. 
References list of the retrieved 
guidelines was also checked. 
 
Inclusion criteria: 
1.Articles focused on salivary 
biological markers in the 
diagnosis of HNSCC. 
2.All articles published on and 
before 13, 2014. 
3. No language restriction. 
4. Article reported the sensitivity 
and specificity that enable the 
diagnostic assessment to be 
extrapolated. 
 
Exclusion criteria: 
1. Studies used blood or other 
fluids as biologic media. 
2. Not research article (book 
chapter, personal opinion). 
3. Those reported association 
between saliva and cancer in 
experimental studies. 
 
Data collection: 
Two review authors selected the 
studies and extracted data. Third 
author involved when 
disagreement emerged. 
The methodological quality was 
evaluated using QUADAS 
 
Data analysis 
The studies were homogenous 
and all had high methodological 
quality. 
Meta-analysis was used to 
evaluate the capability of the 
identified salivary biomarkers in 
accurately identifying HNSCC 
patients and  non HNSCC 
(control) 
The studies were 
grouped into: 
1) Combined 
salivary 
biomarkers 
2) Single salivary 
biomarkers  
3) Combined 
biomarkers for 
the detection of 
the early and 
advanced stages 
of HNSCC. 
 
 
Included article 
 15 articles (case-control studies) were 
included. 
 Sample size: 16-169 for each case (HNSCC) 
and control group. 
 
Main results: 
1) Combined salivary biomarkers 
 6 studies involved. 
 The sensitivity ranged from 82%  to 100%, 
specificity ranged 78%  to 100%. 
 Studies combine biomarkers PMAIP1 and 
PTPNI reported 100% for both sensitivity and 
specificity (PPV: 100%, NPV: 100%). 
2)  Single salivary biomarkers  
 The sensitivity ranged from 14%  to 100%, 
specificity ranged 38%  to 100%. 
 4 studies that used choline, pipecolinic acid 
and S-carboxymethyl-L-cysteine to assess to 
the early and advanced stages of HNSCC and 
L-phenylalanine to assess advanced stage 
reported excellent sensitivity and specificity 
(>80%). 
 pipecolinic acid demonstrated the highest 
sensitivity(92.3%) and specificity (96.7%) 
(PPV: 92.93%, NPV: 96.59%) 
3) Combined biomarkers for the detection of the 
early and advanced stages of HNSCC. 
 Four studies assessed 18 different biomarkers 
 The sensitivity ranged from 67% -100%, 
specificity ranged 75% -96.7%. 
 Studies reported combination biomarkers of 
(Choline, betaine, pipecolonic acid and L-
carnitine) and (Propionylcholine, N-Acetyl-L-
phenylalanine, sphinganine, 
phytosphingosine)  s-carboxymethyl-L-
systeine) were able to diagnose early HNSCC 
with high sensitivity (100%) and specificity 
(96.7%) , (PPV:93.46%, NPV 100%) for both 
groups. 
 
1. The systematic review 
demonstrated the potential 
value of a selected set of 
salivary biomarkers as 
diagnostic tools for head 
and neck carcinoma. 
 
2.Combined biomarkers 
resulted in higher 
sensitivity and specificity 
as compared to use of 
single biomarkers. 
 
3.Choline, pipecolinic acid, 
S-carboxymethyl-L-
cysteine and L-
phenylalanine identified as 
accurate singke biomarkers 
for the diagnosis of 
HNSCC. 
 
The evidence was 
insufficient (case-control 
studies) to enable a 
recommendation to be 
made on the use of salivary 
biomarkers in the diagnosis 
of head and neck cancer. 
 
Further research using a 
well-structured study 
(cohort) is required to 
validate these biomarkers. 
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6) Gustavo N. 
Marta, Rachel 
Riera, Paolo 
Bossi, Lai-ping 
Zhong, Lisa 
Licitra, Cristiane 
R. Macedo, 
Gilberto de 
Castro Junior, 
Andre L. 
Carvalho, 
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William Jr., Luis 
Paulo Kowalski.  
Induction 
chemotherapy 
prior to surgery 
with or without 
postoperative 
radiotherapy for 
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cancer patients: 
Systematic 
review and 
meta-analysis. 
(2015) 
European 
Journal of 
Cancer, 51, 
2596-2603. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To assess the 
effectiveness 
and safety of 
induction 
chemotherapy 
prior to surgery 
for untreated 
oral cavity SCC 
patients 
Type of studies: 
Randomized controlled 
trials. 
 
Population included:  
Oral cavity SCC patients 
(any age) who had not 
received prior treatment. 
 
Intervention: 
Induction chemotherapy 
followed by surgery with 
or without postoperative 
radiotherapy. 
 
Comparison: 
Surgery with or without 
postoperative radiotherapy 
(control group). 
 
Outcome: 
Overall survival (OS), 
local control (LC) and 
toxicity as assessed at any 
point after the treatment. 
 
 
Literature search 
The electronic databases were 
searched on 30 April 2013: 
 MEDLINE  via OVID 
(1966 to January 2015)  
 Cochrane Central Register 
of Controlled Trials 
(CENTRAL 2014, Issue 
10);  
 EMBASE via Elsevier 
(1980 to Jan 2015). 
 LILACS via Biblioteca 
Virtual em Saude‘(1982 to 
January 2015) 
 Reference list screened. 
 
Inclusion criteria: 
There were no restrictions on 
language, publication years and 
publication status.  
 
Data collection  
 Two authors independently 
selected and assessed the 
eligibility criteria. 
 Risk of bias was evaluated 
using Cochrane tool.  
 
Data analysis 
 RR and 95% CI were 
calculated for dichotomous 
outcomes. 
 Mean difference (MD) were 
calculated for continuous 
outcome. 
 HR and 95% CI was 
calculated for the size effect 
of the interventions 
 Similar studies were 
combined in meta-analyses 
using random-effects 
models. 
Case group: 
Induction 
chemotherapy 
followed by surgery 
with or without 
postoperative 
radiotherapy. 
 
Control group: 
Surgery with or 
without postoperative 
radiotherapy. 
 
Included studies: 
 Two studies were selected. 
 451 patients were randomly assigned to 
induction chemotherapy group (n=226) and 
control groups (n=225). 
 Most patients had tumour at stage III/IV 
(89.1%) 
 Both trials are classified at low risk of bias. 
 
1. Local regional relapse /local control (LC) 
 Heterogeneity: Chi2: 0.14, df=1 
(p=0.71),  I2: 0%,  
 Overall effect: Z=0.13, (P=0.90). 
 No significant benefit between the two 
groups. 
 
2. Disease-free survival (DS) 
 Heterogeneity: Chi2: 0.64, df=1 
(p=0.42), I2: 0%,  
 Overall effect: Z=0.52, (P=0.60). 
 No significant benefit between the two 
groups. 
 
3. Overall survival (OS) 
 Heterogeneity: Chi2: 0.04, df=1 
(p=0.78), I2: 0%,  
 Overall effect: Z=0.06, (P=0.94). 
 No significant benefit between the two 
groups. 
 
4. Overall survival for cN2 patients. 
 Heterogeneity: Chi2: 0.05, df=1 
(p=0.82),  I2: 0%,  
 Overall effect: Z=2.00, (P=0.04). 
 Statistically significant benefit between 
the two groups was observed. 
 
5. Toxicity 
Included studies not performed any statistical 
analysis regarding the safety outcomes.  
1. Induction chemotherapy 
when administered before 
surgery with curative intent 
did not improve clinical 
outcomes in locoregionally 
advanced oral cavity 
cancers. 
 
2.Induction chemotherapy 
when administered before 
surgery may increase 
survival benefit in the cN2 
subgroup. As only 2 
studies included in the 
analysis, further validated 
using prospective trials 
were needed. 
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7) Carreras-
Torras, C., 
& Gay-
Escoda, C. 
(2015). 
Techniques 
for early 
diagnosis of 
oral 
squamous 
cell 
carcinoma: 
Systematic 
review. 
Medicina 
oral, 
patologia 
oral y 
cirugia 
bucal, 
20(3), e305. 
 
To assess the current 
situation and 
progress in the early 
diagnosis of oral 
squamous cell 
carcinoma (OSCC) 
and oral potentially 
malignancy disorder 
(OPMD). 
Type of studies: 
Meta-analysis, 
systematic reviews, 
prospective studies, 
retrospective studies, 
consensus and  semi-
structured interviews. 
 
Population:  
OSCC 
 
Intervention: 
Diagnostic test including 
vital staining, light-based 
detection system, 
histological technique, 
cytological technique, 
molecular analysis, 
imaging technique and  
Onco-chip. 
 
Comparison: 
Conventional oral 
examination (COE) 
including visual 
inspection and tactile 
examination of head and 
neck lymph nodes. 
 
Outcome: 
Sensitivity and 
specificity 
Literature search: 
The literature search 
was carried out in 
Cochrane and 
MEDLINE (PubMed) 
databases (January 
2006 to December 
2013). 
 
Inclusion criteria: 
 The use of 
techniques for 
early diagnosis 
of OSCC or 
OPMD,  
 7 years aged 
articles  
 Publications in 
English, French 
or Spanish.  
 
Exclusion criteria: 
 
 Case reports  
 Article in other 
languages.  
 
Data collection: 
Selection of  the 
articles was agreed by 
consensus between the 
two authors;  
1.Vital staining: 
-5% Acetic acid (AA) 
-Toluidine Blue (TB) 
-Methylene Blue (MB) 
-Lugol‘s Iodine (LI) 
-Rose Bengal (RB) 
-Iodine staining (IS) 
-Tolonium chloride (TC) 
 
2.Light-based detection system 
(LDS): 
-Tissue fluorescence imaging 
(Velscope, identafi 3000) (TFI) 
-Chemiluminiscence (ViziLite plus, 
Microlux/DL) 
-Tissue fluorescence spectroscopy 
(NBI) 
 
3.Histological technique. 
-Incisional biopsy (IB) 
-Excisional biopsy (EB) 
 
4.Cytological technique. 
-Oral Brush biopsy (Oral CDX)  
-Liquid Based Cytology (LBC)   
-Laser Microdisection (LCMd) 
 
5.Molecular analysis. 
-Gene alterations (GA) 
-Epigenetic alterations (EA), 
-Loss of Heterozygosity (LH) 
-Microsatellite instability (MI) 
-Viral genome studies (VGS) 
-Proliferation index (PI) 
-AgNOR Analysis (AgNOR) 
-Immunohistochemical identification 
of tumor markers (IITM). 
 
6.Imaging technique. 
-FDG-PET  
-Optical Coherence Tomography 
(OCT) 
 
7.Other technique: Onco-chip 
Included studies 
60 articles were selected to be included in the 
systematic review: 1 meta-analysis, 17 
systematic reviews, 35 prospective studies, 5 
retrospective studies, 1 consensus and 1 semi-
structured interviews. 
 
Diagnostic test 
Diagnostic 
test 
SEN SPEC 
COE 93% 31% 
1.Vital 
staining 
AA 
TB 
MB 
LI 
MB+LI 
RB 
IS 
TC 
83-88% 
72-97% 
90% 
34.5-87% 
97.7% 
93.9% 
100% 
93.5% 
100% 
93.5% 
78-
84.21% 
63.2-
92.9% 
69% 
84-100% 
100% 
73.7% 
59.6% 
73.3% 
2.LDS: 
Velscope 
Identify 3000 
ViziLite 
 
97-100% 
82-100% 
100% 
 
74-95.8% 
87-96% 
0-14% 
3.Histology 98% 100% 
4.Cytological 
Technique 
Oral CDX 
LBC 
 
 
83.1% 
88.8% 
 
 
100% 
100% 
5.Molecular 
analysis 
GA 
 
 
70-76% 
 
 
100% 
6.Imaging 
Technique 
OCT 
 
 
85% 
 
 
78% 
 
 
Tissue biopsy and 
histopathological 
examination should remain 
the gold standard for oral 
cancer diagnose. 
 
In this systematic review it 
has not been found 
sufficient scientific 
evidence on the majority of 
proposed techniques for 
early diagnosis of OSCC, 
therefore more extensive 
and exhaustive studies are 
needed. 
 
Low quality of Systematic 
review: 
No reporting on data 
extraction and not 
mentioned on quality 
assessment of the studies 
involved. 
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8) Sun, R., Tang, 
X., Yang, Y., 
& Zhang, C. 
(2015). 18 
FDG-PET/CT 
for the 
detection of 
regional nodal 
metastasis in 
patients with 
head and neck 
cancer: a 
meta-analysis. 
Oral 
oncology, 
51(4), 314-
320. 
To evaluate the 
accuracy of the    
FDG-PET/CT for 
detection of 
regional nodal 
metastasis in head 
and neck cancer 
patients and to 
compare its 
accuracy against 
the conventional 
imaging tools: 
Computerized 
tomography (CT) 
magnetic 
resonance 
imaging (MRI) 
Type of study: 
Randomized 
control trials 
 
Population:  
Primary head and 
neck cancer 
(HNC) 
 
Intervention: 
FDG-PET/CT  
 
Comparison: 
Conventional 
imaging tools 
(CT, MRI and 
CT/MRI) 
 
Outcome: 
Diagnostic 
performance. 
Literature search: 
 
 The electronic search includes 
MEDLINE, EMBASE. 
 References list were manually screened. 
 
Inclusion criteria: 
 Published article from January 2000 to 
December 2014. 
 No language restriction. 
 FGD-PET/CT was used in primary HNC 
patient before treatment. 
 Histopathology findings served as the 
reference standard. 
 Studies based on per-patient, per-neck-
side, per-neck-level analysis. 
 Studies including at least 10 patients. 
 
Data Collection. 
 
 2 independent reviewers completed the 
study selection, data extraction and 
quality assessment using Cochrane 
Methods Working Group on Diagnostic 
Meta-analysis  
 Any disagreement was resolved by 
consensus. 
 
Data analysis. 
 
 Meta- analysis was performed using Stata 
12.0. 
 Accuracy of FGD-PET/CT was 
calculated the sensitivity, specificity, 
positive likelihood ratio (PLR), negative 
likelihood ratio (NLR) and diagnostic 
odds ratio (DOR) using the bivariate 
model. 
 The per-patient, per-neck-side, per-neck-
level data were calculated. 
 The performance of FGD-PET/CT was 
compared against the conventional 
imaging tools (CT, MRI, CT/MRI) using 
the same bivariate model. 
FDG-PET/CT 
for detection 
of regional 
nodal 
metastasis in 
head and neck 
cancer 
patients  
24 articles were included. In total, the meta-analysis analysis 
included 1270 patients. 
The total number of patients in a study ranged from 15-157 
(median: 39 patients) 
 
Diagnostic performance of FGD-PET/CT 
1. Per-neck-level data (with 95% CI) 
SEN 0.80(0.71-0.87) 
SPEC 0.96(0.94-0.97) 
DOR 92.0(50.1-168.70) 
PLR 19.1(14.5-25.0) 
NLR 0.21(0.14-0.32) 
AUC 0.97 (0.95-0.98) 
 
2. Per-patient data (with 95% CI) 
SEN 0.91(0.82-0.95) 
SPEC 0.87(0.80-0.92) 
DOR 68(24-191) 
PLR 7.2(14.5-11.5) 
NLR 0.11(0.05-0.22) 
AUC 0.93 (0.90-0.95) 
 
3.Per-neck-site data 
SEN 0.84(0.75-0.90) 
SPEC 0.83(0.77-0.88) 
DOR 25.9(15.4-43.4) 
PLR 5.1 (3.8-6.8) 
NLR 0.20(0.13-0.30) 
AUC 0.90 (0.87-0.93) 
 
Comparison against conventional imaging (per-neck –level 
data 
1. FGD-PET/CT  
SEN 0.84(0.72-0.91) 
SPEC 0.96(0.95-0.97) 
DOR 130.0(53-317) 
PLR 22.2(15.0-33.0) 
NLR 0.17(0.09-0.31) 
 
2. (CT, MRI, CT/MRI) 
SEN 0.63(0.53-0.72) 
SPEC 0.96(0.95-0.97) 
DOR 44.0(25-78) 
PLR 16.8(11.4-24.8) 
NLR 0.38(0.29-0.49) 
 
1.FDG-PET/CT 
has good 
diagnostic 
performance for 
detection of 
regional nodal 
metastasis in 
primary head and 
neck cancer 
patients. 
 
2.Compared with 
conventional 
imaging,  FDG-
PET/CT may have 
higher per-neck-
level sensitivity 
for the detection 
of  
regional nodal 
metastasis in the 
primary head and 
neck cancer 
patients. 
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9) Zhang, L., 
Jiang, N., Shi, 
Y., Li, S., 
Wang, P., & 
Zhao, Y. 
(2015). 
Induction 
chemotherapy 
with 
concurrent 
chemoradioth
erapy versus 
concurrent 
chemoradioth
erapy for 
locally 
advanced 
squamous cell 
carcinoma of 
head and 
neck: a meta-
analysis. 
Scientific 
reports, 5, 
10798. 
To evaluate the 
efficacy and 
toxicity of IC 
followed by 
CCRT versus 
CCRT alone in 
the treatment of 
LA-SCCHN. 
Type of study: 
Randomized 
control trials 
 
Population:  
Locally advanced 
squamous cell 
carcinoma of head 
and neck (Stage 
III-IV MO 
SCCHN). 
 
Intervention: 
Induction 
chemotherapy 
with concurrent 
chemoradiotherap
y  
 
Comparison: 
Concurrent 
chemoradiotherap
y alone. 
 
Outcome: 
Efficacy 
Overall survival 
(OS) and/or 
progression-free 
survival (PFS) 
which reported as 
hazard ratios 
(HRs) with 95% 
confidence 
intervals (CIs) . 
 
Toxicity 
Leukopenia, 
Febrile 
neutropenia, and  
Mucocitis which 
reported as 
relative risks (RR) 
and 95% 
confidence 
intervals (CIs) . 
Literature search: 
 
The electronic search includes PubMed, 
EMBASE, Cochrane Library and Chinese 
Biology Medicine (CBM). 
 
Manual search on the references of the 
included studies to identify any eligible 
studies. 
 
Inclusion criteria: 
Article up to 23 November 2014 with no 
language restriction. 
 
Data Collection. 
 
2 independent reviewers completed the study 
inclusion, data extraction and quality 
assessment using Cochrane tools for 
assessment risk of bias 
Any disagreement was resolved by the third 
reviewer. 
 
Data analysis. 
 Results were expressed as hazard ratios 
(HRs) or relative risks (RRs) with 95% 
confidence intervals (CIs). 
 Meta-analysis was conducted using 
Review Manager Version 5.2 (Revman, 
5.2). A two-sided P-value of < 0.05 was 
considered significant for all analyses 
except heterogeneity tests. 
 I2 was used to explore statistical 
heterogeneity. 
 If I2 >50% or P<0.10 a random-effect 
model was used. 
 If I2 <50% or P>0.10 a fixed-effect model 
was used. 
Induction 
chemotherapy 
with concurrent 
chemoradiother
apy  
 
Included studies: 
5 RCT is included. In total, the meta-analysis included 922 
patients, 473 patients in IC followed by CCRT arm, and 449 
patients in CCRT alone arm. 
 
Quality of the studies: 
3 studies assigned in low risk of bias and 2 in moderate risk of 
bias. 
 
The rate of complete treatment in IC followed by CCRT arm 
ranged from 80% to 92% and in CCRT arm the rate was 84%–
96%. 
 
 
Efficacy of IC followed by CCRT Vs CCRT alone. 
 
1. Overall survival. 
Meta-analysis showed that no significant beneficial effect was 
observed for: 
2-year OS  
(HR = 0.95, 95% CI 0.77–1.18, P = 0.64.  
The 3-year OS 
(HR =  0.99, 95% CI 0.81– 1.21, P = 0.92)  
5-year OS 
(HR = 1.00, 95% CI 0.82–1.20, P = 0.9). 
 
Heterogeneity among the trials 
No statistical significant among the studies. 
(I2 = 0%, P = 0.88). 
 
2. Progression-free survival. 
Meta-analysis showed that no significant beneficial effect was 
observed for: 
2-year PFS 
(HR = 0.89, 95% CI 0.73–1.08, P = 0.25). The 3-year PFS  
(HR = 0.92, 95% CI 0.75–1.12, P = 0.41)  
5-year PFS  
(HR = 0.91, 95% CI 0.75–1.11, P = 0.36). 
 
3. Distant metastases rate (DMR) 
Significantly lower distant metastasis rate (DMR) for IC 
followed by CCRT, RR: 0.58 (95% CI 0.39–0.85, P = 0.006). 
 
 
 
 
 
1.IC followed by 
CCRT for patients 
with LA-SCCHN 
was not 
statistically 
significant 
superior to CCRT 
alone in OS, PFS, 
and LRR but 
could decrease the 
incidences of 
DMR . 
 
2.IC followed by 
CCRT for patients 
with LA-SCCHN 
could increase 
risks of grade 3–4 
febrile 
neutropenia and 
leukopenia.  
 
The current 
studies do not 
support the use of 
IC followed by 
CCRT over CCRT 
alone, and the 
further positioning 
of IC followed by 
CCRT as standard 
treatment for LA-
SCCHN will 
come from more 
RCTs directly 
comparing IC 
followed by 
CCRT with CCRT 
alone. 
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4. Locoregional recurrence rate (LRR) 
No significantly different between these two arms (RR = 1.10, 
95% CI 0.82–1.47, P = 0.54).  
There was no statistically significant heterogeneity among the 
trials (I2: 0%, P=0.70). 
 
Toxicity of IC followed by CCRT versus CCRT alone. 
1.Adverse event during IC periods: 
 Leukopenia (21.45%) 
 Febrile neutropenia (16.99%) 
 Mucocitis (12.11%). 
 
 2.According to the pooled analysis for toxic effects, adding IC 
before CCRT significantly increase the risk febrile 
neutropenia and leukopenia compared with CCRT alone and 
no statistical significance difference between two arms for 
mucositis : 
 Febrile neutropenia: 
(RR =  11.41, 95% CI 2.71–48.03, P =0.0009)  
 Leukopenia: 
(RR = 1.46, 95% CI 1.01–2.10,   P = 0.04). 
 Mucocitis: 
(RR = 1.30, 95% CI 0.86–1.97,    P = 0.22) . 
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Appendix I 
 
Assessment form_(National Comprehensive Cancer Network, 2016) 
1) Diagnosis and Staging 
Context (National Comprehensive Cancer Network, 2016). 
 
Accept 
(no. of panel) 
 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
1.1 Patient 
information and 
consultation 
Multidisciplinary consultation as indicated. 
 
Low 4    Omitted. 
Accepted the BKCE 
recommendation. 
1.2 Clinical 
Examination and 
consultation 
The following investigation are recommended at diagnosis 
and staging of oral cancer: 
 
 Complete head and neck exam; mirror and fiberoptic 
examination as clinically indicated. 
 
Low 4    Accepted. 
1.3 Biopsy The following investigation is recommended at diagnosis 
and staging of oral cancer: 
 Biopsy  
 
Low 
 
4    Omitted. 
Accepted the BKCE 
recommendation. 
1.4 Conventional 
Imaging of the 
primary tumour 
The following investigation are recommended at diagnosis 
and staging of oral cancer: 
 Computerized tomography (CT) with contrast and/or 
Magnetic resonance imaging (MRI) with contrast of 
primary as indicated. 
 
Low 3 1  Panel 2 
If undergoing CT for primary, to 
include TAP as well. 
Accepted with modification. 
 
CT  of the thorax, abdomen and 
pelvis was added to the 
recommendations (Arya et al., 2014). 
  
1.5 Imaging of 
advanced stage 
tumour 
Consider Fluorodeoxyglucose positron emission 
tomography-computed tomography (FDG-PET/CT) for 
stage III-IV disease. 
 
Low 3  1 Panel 3 
PET is expensive and not widely 
available. Limit use to diagnosis of 
distant metastases/ recurrent/ residual/ 
diseases following treatment. 
 
Omitted. 
Accepted the SIGN recommendation. 
1.6 Imaging of  
neck lumps and 
nodes 
The following investigation are recommended at diagnosis 
and staging of oral cancer: 
 CT with contrast and/or MRI with contrast of neck as 
indicated. 
Low 4    
 
 
 
Omitted. 
Accepted the SIGN recommendation. 
 
 
 
Y(M): Accepted with modification 
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Context (National Comprehensive Cancer Network, 2016). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
1.7 Other staging 
interventions 
(identification of 
synchronous tumour 
and distant 
metastases) 
The following investigation are recommended at diagnosis 
and staging of oral cancer: 
 
a. Chest imaging as clinically indicated. 
  
b. Examination under anesthesia (EUA) with endoscopy, 
if indicated. 
  
c. Preanesthesia studies as clinically indicated. 
 
 
 
 
Low 
 
Low 
 
 
Low 
 
 
 
4 
 
4 
 
 
3 
  
 
 
 
 
 
 
 
1 
Panel 3 
 
Not sure the objective of the 
preanesthesia studies. 
Accepted. 
 
To include preanesthesia studies as 
well. The purpose of the 
preanesthesia is to discovery or 
identification of a disease or disorder 
that may affect perioperative. 
1.8 HPV Testing NA      
 
 
1.9 Histopathology 
1.9.1 Resection 
margin 
NA       
1.9.2 Primary site 
reporting. 
NA       
1.9.3 Neck and 
metastatic disease 
reporting. 
NA       
 
 
 
 
 
 
 
 
 
 
Y(M): Accepted with modification 
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2)Treatment 
Context (National Comprehensive Cancer Network, 2016). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
2.1 Multidisciplinary involvement.       
 The management of patients with head and neck cancers is 
complex. All patients need access to the full range of support 
services and specialists with expertise in the management of 
patients with head and neck cancer for optimal treatment and 
follow-up. Outcomes are improved when patients with head 
and neck cancers are treated in high volume centers.  
• Head and neck surgery   
• Radiation oncology  
• Medical oncology  
• Plastic and reconstructive surgery 
• Specialized nursing care  
• Dentistry/prosthodontics  
• Physical medicine and rehabilitation  
• Speech and swallowing therapy  
• Clinical social work  
• Clinical nutrition  
• Pathology (including cytopathology) 
• Diagnostic radiology  
• Adjunctive services  
  (Neurosurgery, Ophthalmology, Psychiatry,   
  Addiction services, Audiology,  
  Palliative care 
Low 2 1 
 
1 
 
Panel 1 
It is difficult to get all these 
specialists at the same time. 
Primary team can call the others as 
when necessary. Some are not 
needed for early tumour 
management. The main player 
would be the ENT, Oro-
maxillofacial Surgeon, Plastic 
Surgeon for every patient. Some 
other can get involved in the 
follow-up if needed. 
 
Panel 3 
Need to add oral and maxillofacial 
surgery because head and neck 
surgery only refer to ENT. 
Accepted with modification. 
 
The recommendations of the three 
guidelines (NCCN, BKCE and SIGN) 
were combined. The composition of 
the multidisciplinary team is divided 
into core member and non-core 
member. 
2.2 Pre-treatment assessments. 
2.2.1 Dental 
evaluation 
Dental/prosthodontic evaluation including Panorex or CT ± 
contrast as clinically indicated, radiograph of all teeth and risk 
assessment of caries and periodontal disease. 
Low 4    Accepted with modification 
 
The recommendations of the three 
guidelines (NCCN, BKCE and SIGN) 
were combined and modified into 
new wording. 
 
2.2.2 Nutritional, 
speech and 
swallowing 
evaluation 
Nutrition, speech, and swallowing evaluation/therapy before 
and after treatment as indicated and should involve a registered 
dietitian and a speech-language/swallowing therapist. 
Low 
 
3 1  Panel 3 
To perform electively as the service 
is not widely available in Malaysia 
Accepted. 
 
It should be the standard procedure in 
pre-treatment assessment. 
Y(M): Accepted with modification 
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Context (National Comprehensive Cancer Network, 2016). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
2.3 Treatment of primary non-metastatic oral cancer. 
2.3.1 General 
recommendation. 
NA       
2.3.2 Early stage of 
oral cancer (Stage I 
and II) 
a.  Resection of primary site is the preferred treatment +    
     ipsilateral (guided by tumour thickness) or bilateral  
     (guided by location of primary) neck dissection. 
 
 
 
b. Resection of primary ± sentinel lymph node (SLN) biopsy 
may be used to identify occult cervical metastases. 
Sentinel lymph node biopsy should be done in centers 
with expertise in this technique. 
 
 
 
 
 
 
 
 
c. For patients with resected oral cavity cancers who have no 
positive nodes and no adverse features, he or she should 
proceed with follow–up. 
 
 
d. Definitive radiotherapy (RT) may be offered to early stage 
patients (T1-2, N0) who are medically inoperable or 
refuse surgery. Patients who go on to develop residual 
disease after definitive RT should be considered for 
surgery.   
(If definitive RT is chosen for treatment of T1–2, N0 
disease, the fraction size to the intermediate-and low-risk 
sites ranges from 44 Gy (2.0 Gy/fraction) to 60 Gy (1.6 
Gy fraction). 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
Low 
4 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
4 
 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
1 
 
 
 
 
 
 
Panel 4 
The panel not sure of its 
usefulness in Malaysia with 
regards sentinel node biopsy in 
view of the fact that more than 
50% are late stage and depending 
on the surgeon‘s practice in 
Malaysia, selective neck 
dissection maybe practiced for 
early stage lesions of the tongue.  
 
 
 
 
 
 
 
Panel 4 
No comment. 
 
 
 
 
 
 
Omitted. 
Accepted the BKCE 
recommendation. 
 
 
 
Omitted. 
Accepted the BKCE 
recommendation. 
 
 
 
 
 
 
 
 
 
Omitted. 
Accepted the BKCE 
recommendation. 
 
 
Accepted but the fraction size was 
removed. 
 
 
 
 
 
 
 
 
 
 
 
Y(M): Accepted with modification 
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Context (National Comprehensive Cancer Network, 2016). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
 
2.3.2 Early stage of 
oral cancer (Stage I 
and II) 
 
e. For patients with resected oral cavity cancers who have 
one positive node without adverse features, consider RT. 
 
 
 
f. For patients with resected oral cavity cancers, who have 
positive margins, options include: 
1) re-resection or RT 
2) consider chemotherapy/RT  
(for T2 only).. 
 
 
g. For patients with resected oral cavity cancers, who have 
the adverse pathologic features of extracapsular nodal 
spread with [or without] a positive mucosal margin, the 
preferred treatment is postoperative chemotherapy/RT. 
 
 
h. For patients with resected oral cavity cancer, who have 
other risk features such as perineural invasion, or vascular 
embolism (lymphovascular invasion), options include: 
1) RT or  
2) Consider chemotherapy/RT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
 
High 
 
 
 
 
 
Low 
 
 
 
 
 
 
3 
 
 
 
 
3 
 
 
 
 
 
 
3 
 
 
 
 
 
3 
 
1 
 
 
 
 
1 
 
 
 
 
 
 
1 
 
 
 
 
 
1 
 
 
 
 
 
 
  
Panel 4 
 Needs the decision of the 
oncology team with the patient 
 
 
Panel 4 
 Needs the decision of the 
oncology team with the patient 
 
 
 
 
Panel 4 
 Needs the decision of the 
oncology team with the patient 
 
 
 
Panel 4 
 Needs the decision of the 
oncology team with the patient 
 
 
Omitted. 
Accepted the SIGN recommendation. 
 
 
 
Omitted. 
Accepted the SIGN recommendation. 
 
 
 
 
 
Omitted. 
Accepted the SIGN recommendation. 
 
 
 
 
Omitted. 
Accepted the SIGN recommendation. 
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Context (National Comprehensive Cancer Network, 2016). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
 
2.3.3 Advanced 
stage of oral cancer 
(Stage III and IV) 
 
a. For patients with N0, N1, N2a-b, N3: resection of primary 
is with ipsilateral, or bilateral neck dissection. 
 
 
b. For patients with N2c (bilateral): resection of primary and 
bilateral neck dissection. 
 
 
 
c. For patients with resected oral cavity, cancers who have 
no adverse features, consider RT. 
 
 
 
d. For patients with resected oral cavity cancers who have 
the adverse pathologic features of extracapsular nodal 
spread and/or a positive mucosal margin, recommended 
postoperative adjuvant options include:  
1) chemotherapy/RT (preferred) or 
2) re-resection of positive margins (if technically 
feasible); or 
3) RT 
 
 
e. For other risk features such as pT3 or pT4 primary, N2 or 
N3 nodal disease, nodal disease in levels IV or V, 
perineural invasion, or vascular tumor embolism: clinical 
judgment should be used when deciding to either use RT 
alone or add chemotherapy to RT. 
 
Low 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
High 
 
Low 
 
 
Low 
 
2 
 
 
 
3 
 
 
 
 
4 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
4 
 
2 
 
 
 
1 
 
 
 
 
 
 
 
 
 
1 
  
Panel 3 
Primary tumour site specific 
recommendation. 
 
 
Panel 4 
No comment. 
 
 
 
 
 
 
 
Panel 4 
Needs the decision of the 
oncology team with the patient 
 
 
 
 
 
 
 
Omitted. 
Accepted the BKCE 
recommendation. 
 
 
Omitted. 
Accepted the BKCE 
recommendation. 
 
 
Omitted. 
Accepted the SIGN recommendation. 
 
 
 
Omitted. 
Accepted the SIGN and BKCE 
recommendations. 
 
 
 
 
 
 
Omitted. 
Accepted the SIGN and BKCE 
recommendations 
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Context (National Comprehensive Cancer Network, 2016). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
2.3.4 Management 
of the neck lymph 
nodes. 
NA       
2.4 Treatment of very advanced-stage oral cancer (M0) T4b, any N or unresectable nodal disease or unfit for surgery. 
 a. Participation in clinical trials is preferred for all patients 
with very advanced cancers. 
 
 
 
b. Patients should undergo standard therapy based on their 
PS = Performance Status (Eastern Cooperative Oncology 
Group [ECOG])  
 
 
c. For patients with a PS of 0 or 1, the standard treatment is 
concurrent chemotherapy and radiotherapy. Other options 
are induction chemotherapy followed by RT or 
chemotherapy/RT  
 
d. PS 0-2: Definitive RT with or without concurrent 
chemotherapy. 
 
 
 
e. PS 0-3: Palliative RT or single-agent chemotherapy or 
best supportive care. 
 
 
 
f. Perform neck dissection following the above treatment is 
feasible in the instance of residual neck disease and 
primary site are controlled. 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
Low 
 
4 
 
 
 
 
3 
 
 
 
 
3 
 
 
 
 
3 
 
 
 
 
2 
 
 
 
 
4 
 
 
 
 
 
1 
 
 
 
 
1 
 
 
 
 
1 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
Panel 4 
Needs the decision of the 
oncology team with the patient. 
 
 
Panel 4 
Needs the decision of the 
oncology team with the patient. 
 
 
Panel 4 
Needs the decision of the 
oncology team with the patient. 
 
 
Panel 4 
Needs the decision of the 
oncology team with the patient. 
 
Accepted: 
 
All recommendations were accepted. 
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Context (National Comprehensive Cancer Network, 2016). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
2.5 Treatment of  locoregional recurrence disease. 
2.5.1 General 
evaluation 
       
2.5.2 Resectable 
locoregional 
recurrence 
a..     Enrollment in a clinical trials is preferred. 
  
b. Surgery is recommended for resectable recurrent or 
persistent locoregional disease. 
 
c. For patients with resected oral cavity cancers who have 
the adverse features of extracapsular nodal spread and/or 
positive margin and the patients did not have prior RT 
the treatment is postoperative chemotherapy/RT  
 
d. For patients with resected oral cavity cancers and who 
have other risk features such as pT3 or pT4 primary, N2 or 
N3 nodal disease, nodal disease in levels IV or V, 
perineural invasion, or vascular tumor embolism and the 
patients did not have prior RT, the options include RT or 
consider chemotherapy/RT. 
 
e. For patients with resected oral cavity cancers with prior 
RT, the options include surgery with or without 
postoperative reirradiation or chemotherapy/RT. 
 
 
Low 
 
Low 
 
 
High 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
3 
 
4 
 
 
4 
 
 
 
 
4 
 
 
 
 
 
 
4 
1  Panel 3  
Resection is preferred than 
enrolment in clinical trial 
Accepted 
 
All recommendation were accepted 
but the first recommendation (a) were 
modified to enrolment in a clinical 
trials can be considered and is placed 
as the last recommendation.   
2.5.3 Unresectable 
locoregional 
recurrence. 
a. If the recurrence is unresectable and the patients did not 
have prior RT, then RT with concurrent chemotherapy is 
recommended, depending on the PS. 
 
b. If the recurrence is unresectable and the patients have 
prior RT, the treatment option include reirradiation with 
or without chemotherapy, or chemotherapy alone. 
Low 
 
 
 
 
Low 
4 
 
 
 
 
3 
 
 
 
 
 
1 
  
 
 
 
 
Panel 3 
Depends on when the recurrent 
appeared (i.e how long after the 
last radiotherapy). 
 
 
 
Accepted. 
 
 
 
 
Accepted. 
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Context (National Comprehensive Cancer Network, 2015). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
2.5 Treatment of  
locoregional 
recurrence disease. 
c. If the recurrence is unresectable and the patients did not 
have prior RT, then RT with concurrent chemotherapy is 
recommended, depending on the PS. 
 
d. If the recurrence is unresectable and the patients have 
prior RT, the treatment option include reirradiation with 
or without chemotherapy, or chemotherapy alone. 
Low 
 
 
 
 
Low 
4 
 
 
 
 
3 
 
 
 
 
 
1 
  
 
 
 
 
Panel 3 
Depends on when the recurrent 
appeared (i.e how long after the 
last radiotherapy). 
Accepted. 
 
 
 
 
Accepted. 
2.6 Treatment of metastatic or recurrent disease not eligible for curative treatment. 
2.6.1General 
recommendation 
NA       
2.6.2 Palliative 
chemotherapy 
a.   Patients should undergo standard chemotherapy  
      based on their PS = Performance Status (Eastern  
      Cooperative Oncology Group [ECOG]) 
 
b. For patients with a PS of 0 or 1, the standard systemic 
therapy includes  
2) Platinum + 5-FU + cetuximab (RL 1) or  
3) Combination chemotherapy or  
4) Single-agent chemotherapy or  
5) Surgery or RT or chemoradiotherapy/RT for selected 
patients with limited metastases or  
6) Best supportive care 
 
c. PS 2: Single-agent chemotherapy followed by best 
supportive care or best supportive care alone   
 
d. PS 3: Best supportive care. 
Low 
 
 
 
 
 
High 
Low 
Low 
Low 
 
Low 
 
Low 
 
 
Low 
3 
 
 
 
 
 
3 
 
 
 
 
 
 
4 
 
 
4 
1 
 
 
 
 
 
1 
 Panel 4 
Needs the decision of the 
oncology team with the patient. 
 
 
Panel 4 
Needs the decision of the 
oncology team with the patient. 
 
All recommendations were omitted 
and accepted the SIGN 
recommendation. 
2.6.3 Palliative 
radiotherapy 
NA       
2.6.4 Palliative 
surgery 
NA       
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3) Follow-up care 
Context (National Comprehensive Cancer Network, 2015). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
3.1 Clinical 
evaluations 
a. The ranges are based on risk of relapse, second 
primaries, treatment sequelae, and toxicities. 
 
b. Perform head and neck examination; mirror and 
fiberoptic examination as clinically indicated:  
Year 1, every 1–3 months. 
 
Year 2, every 2–6 months 
 
Years 3–5, every 4–8 months 
 
>5 years, every 12 months. 
 
c. Post-treatment baseline imaging of primary tumour (and 
neck, if treated) recommended within 6 months of 
treatment. Further reimaging as indicated based on 
worrisome or equivocal signs/symptoms, smoking 
history, and areas inaccessible to clinical examination.   
 
d. Chest imaging as clinically indicated for patients with 
smoking history.  
 
e. Thyroid-stimulating hormone (TSH) every 6–12 months 
if neck irradiated. 
 
Low 
 
 
Low 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
Low 
3 
 
 
4 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
4 
 
 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
1 Panel 3 
Risk of further CA or complication 
can never be accurately predicted 
and it is a need to keep a long term 
review for all patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel 4 
Needs the decision of the oncology 
team with the patient. 
 
 
 
 
 
 
 
 
 
 
 
All recommendations in this section 
were omitted and accepted all BKCE 
recommendations. 
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Context (National Comprehensive Cancer Network, 2015). 
 
Accept 
(no. of panel) 
Comment(s) 
 
Decisions 
Recommendations LOE Yes Yes 
(M) 
No 
3.2 Dental 
rehabilitation 
Dental evaluation is recommended for oral cavity and sites 
exposed to significant intraoral radiation treatment  
 
Low 4    Omitted. 
Accepted BKCE recommendations. 
3.3 Speech and 
swallowing 
rehabilitation. 
Speech/hearing and swallowing evaluation4 and rehabilitation 
as clinically indicated. 
Low 4    Omitted. 
Accepted BKCE recommendations. 
3.4 Nutritional 
therapy 
Nutritional evaluation and rehabilitation as clinically 
indicated until nutritional status is stabilized. 
 
Low 4    Omitted. 
Accepted BKCE recommendations. 
3.5 Psychosocial 
counselling and 
support 
Ongoing surveillance for depression. 
 
 
Low 4    Omitted. 
Accepted BKCE recommendations. 
 
 
 
 
 
 
 
 
 
 
 
Y(M): Accepted with modification 
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Appendix J 
 
Assessment form_(Belgian Health Care Knowledge Centre, 2014). 
1)Diagnosis and Staging 
Context (Belgian Health Care Knowledge Centre, 2014) Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
1.1 Patient information The patient must be kept fully informed about his condition, the 
treatment options and consequences. Information should be 
complete and communicated in a clear and unambiguous way. 
Patient preferences should be taken into account when deciding 
on a treatment option. 
 
Low 4    Accepted 
1.2 Clinical 
Examination and 
consultation 
NA       
1.3 Biopsy a. A biopsy should be taken from the most suspect part of the 
tumour. The pathologist should be provided with any 
clinically relevant information. If the result is inconclusive, 
or negative but the tumour is suspect, the biopsy should be 
repeated. 
 
b. When a patient with a diagnosis of oral squamous cell 
carcinoma is referred to another centre for work-up 
completion and treatment, and if no additional biopsies need 
to be performed in the reference centre, pathology 
specimens (slices and/or blocks) should be sent for revision 
to the reference laboratory for diagnosis confirmation upon 
request from the reference centre. Every uncommon tumour 
diagnosis beside classical squamous cell carcinoma should 
be reviewed by an expert from a reference laboratory. 
 
c. The biopsy report should include: tumour localization, 
tumour histology, tumour grade, depth of invasion (if 
assessable), lymphatic, vascular and perineural invasion. 
Some other prognostic factors, such as growing pattern 
(infiltrative vs. pushing border), can be considered. 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
Low 
4 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel 4 
Current protocols should 
also be referred to where 
other parameters such as 
pattern of invasion 
(cohesive and non-
cohesive) may form part of 
the core reporting. 
Accepted. 
 
 
 
 
 
Accepted. 
 
 
 
 
 
 
 
 
Accepted with slight modification 
based on current protocol from 
previous study. 
Some other prognostic factors, 
such as growing pattern 
(infiltrative vs. pushing border), 
pattern of invasion (cohesive and 
non-cohesive) can be considered. 
(Li, et al., 2013; Almungush, et 
al., 2015). 
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Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
1.4 Conventional 
Imaging of the primary 
tumour 
c. Perform an MRI for primary T- and N-staging (i.e. before 
any treatment) in patients with newly diagnosed oral cavity 
cancer. 
 
d. In case MRI is technically impossible (e.g. pacemaker, 
cochlear implant, etc.), likely disturbed (e.g. anticipated 
motion artefacts, etc.) or not timely available, perform a 
contrast-enhanced CT for primary T- and N-staging in 
patients with oral cavity cancer. 
 
Low 
 
 
 
Low 
3 
 
 
 
4 
 1 Panel 3 
The service is not widely 
available 
Omitted. 
Accepted the NCCN 
recommendation. 
 
Omitted. 
Accepted the NCCN 
recommendation. 
 
1.5 Imaging of 
advanced stage tumour 
In patients with stage III and IV oral cavity cancer, and in 
patients with high-risk features irrespective of the locoregional 
staging (e.g. heavy smokers), perform a whole-body FDG-
PET/CT for the evaluation of metastatic spread and/or the 
detection of second primary tumours.  
Low 3  1 Panel 3 
Not feasible to be 
implemented. 
Omitted. 
Accepted the SIGN 
recommendation. 
 
1.6 Imaging of neck 
lumps and nodes 
 
NA 
 
    
 
  
1.7 Other staging 
interventions 
(identification of 
synchronous tumour 
and distant metastases) 
To exclude synchronous secondary tumours in the head and neck 
area, all patients with oral cavity cancer should undergo clinical 
examination (including fiberoptic examination) of the upper 
aerodigestive tract. Endoscopy under general anaesthesia should 
be considered for better local staging of large tumours.  
Low 
 
 
 
 
 
3  1 Panel 3 
Not feasible because of 
shortage of OT time and 
this procedure may delay 
the CA surgery. 
Omitted. 
 
Accepted the NCCN 
recommendation. 
1.8 HPV Testing Due to insufficient evidence, routine p16 testing is not 
recommended in patients with oral cavity cancer. In patients 
without any of the common risk factors (e.g. smoking, alcohol 
abuse) for oral cavity cancer, testing for p16 can be considered, 
although there is no evidence at present that it alters treatment 
decisions in these patients. 
 
 
Low 4   Panel 1 
For future analysis on 5-10 
years- time frame because it 
is correlate with the 
treatment and prognosis. 
Accepted with slight 
modification. 
 
Routine p16 was changed to HPV 
testing based on experts‘ opinion. 
To include HPV18 subtype apart 
of HPV 16. 
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Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
1.9 Histopathology 
 
1.9.1 Resection margin 
 
 
a. To avoid a positive resection margin (which is associated 
with a poorer prognosis), frozen sections taken 
intraoperatively may be useful. 
 
b. A distance of at least 10 mm from the palpable tumour 
margin, whenever technically or anatomically possible, 
should be taken as a guide for resection to allow a minimal 
distance of 3-5 mm from the margin of the resected tissue to 
the primary tumour in the formalin-fixed specimen.  
 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
 
 
 
3 
 
 
 
4 
  
 
1 
 
 
Panel 3 
Only useful if sampling 
accurate 
 
 
Accepted. 
 
 
 
 
Accepted 
1.9 Histopathology, 
cont… 
 
1.9.2 Primary site 
reporting. 
For discussion with the clinician, the histopathological findings 
must describe the exact localization of any existing R+ status. 
The anatomical topography must be clearly indicated when 
sending the tumour specimen to the pathologist. This may be 
done with suture markers or colour-coding. The histopathological 
result must include:  
 tumour localization,  
 macroscopic tumour size,  
 histological tumour type,  
 histological tumour grade,  
 depth of invasion,  
 lymphatic,  
 vascular and perineural invasion,  
 locally infiltrated structures,  
 pT classification,  
 details of affected areas and infiltrated structures,  
 R status and p16 (if not done on biopsy).  
 
 
 
 
 
 
Low 3 1  Panel 3.  
To add pattern of 
infiltration, tumour margin 
and dysplasia as mention in 
the SIGN guidelines. 
and evaluation of P16 may 
not be economical. 
Accepted with slight 
modification. 
 
Pattern of invasion was added as 
core reporting based on the 
following references:  
Li, et al., 2013; Almungush, et al., 
2015). 
 
Refer to comment for SIGN 
guideline. 
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Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
1.9.3 Neck and 
metastatic disease 
reporting. 
The histopathological findings from a neck dissection specimen 
must describe: 
 the anatomical topography, 
 the side of the neck,  
 type of neck dissection,  
 eliminated levels,  
 total number of lymph nodes plus number of 
lymph nodes affected,  
 number of lymph nodes per level,  
 level of the affected lymph nodes,  
 diameter of the largest tumour deposit,  
 additionally removed structures, 
 extracapsular spread (if present). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 4    Accepted. 
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Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.1 Multidisciplinary involvements  
 Oral cavity carcinoma must be treated on an interdisciplinary 
basis after upfront discussion of the case in question by a tumour 
board (MOC/COM), comprising the specialist disciplines of: 
 oral and maxillofacial surgery,  
 ENT,  
 radiation oncology,  
 medical oncology, 
 pathology,  
 radiology  
 nuclear medicine.  
The general practitioner, Dentist and Paramedical disciplines 
(speech therapist, nutritional therapist, and psychosocial worker) 
are recommended to be present. Continuity of care should be 
guaranteed through cooperation between the hospital and the 
home care team. 
 
Low 3 1  Panel 3 
Add plastic & 
reconstructive surgeon. 
Nuclear medicine is 
optional and not widely 
available. 
Accepted with modification. 
 
The recommendations of the three 
guidelines (NCCN, BKCE and 
SIGN) were combined. The 
composition of the 
multidisciplinary team is divided 
into core member and non-core 
member. 
2.2 Pre-treatment assessments  
2.2.1 Dental evaluation Patients with carcinoma of the oral cavity should be examined by 
a dedicated dental practitioner prior to commencing oncological 
treatment. The dentist should give preventive advice and perform 
necessary restorative work. 
 
Low 4    Accepted with modification. 
 
The recommendations of the three 
guidelines were combined and 
modified into new wording. 
2.2.2 Nutritional, 
speech and swallowing 
evaluation 
NA 
 
 
 
 
 
      
2.3 Treatment of primary non-metastatic oral cancer 
2.3.1 General 
recommendations 
NA 
 
 
 
 
 
 
 
      
2)Treatment 
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Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.3.2 Early stage of oral 
cancer (Stage I and II) 
a. Provided the patient's general condition permits it and the 
oral cavity carcinoma can be curatively resected, surgical 
resection of the tumour should be performed and followed 
by immediate reconstruction, when required. 
 
 
b. In case of a microscopically residual tumour (R1 resection), 
targeted follow-up resection should ensue with the aim of 
improving the patient's prognosis, whenever possible.        
 
c. Continuity of the mandible should be preserved on tumour 
resection or restored post-resection, provided no radiological 
or intraoperative evidence has been found of tumour 
invasion of the bone. 
 
 
d. Reconstructive measures should from the onset be integrated 
in the surgical approach. When planning reconstruction, 
consideration must be given to the entire oncological 
scenario. The anticipated functional or cosmetic 
improvement must justify the efforts involved in 
reconstruction. 
 
e. Patients with small but accessible tumours (T1/T2) in the 
oral cavity may be treated with interstitial brachytherapy in 
selected cases. 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
4 
 
 
 
 
 
3 
 
 
 
3 
 
 
 
 
 
4 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
Panel 2 
No comment 
 
 
Panel 3 
Strength and height of 
mandible left behind must 
be considered to prevent 
fracture later. 
 
 
 
 
 
 
 
 
Panel 2 
Such expertise is not 
available locally. 
. 
Panel 3 
Insufficient number of cases 
to justify storage of brachy 
needle. 
 
 
 
 
 
 
 
 
Accepted. 
 
 
 
 
 
Accepted. 
 
 
 
Accepted 
 
 
 
 
 
Accepted  
 
 
 
 
 
 
Omitted. 
Accepted the SIGN 
commendation. 
 
303 
 
Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.3.3 Advanced 
stage of oral cancer 
(Stage III and IV) 
a. The decision to perform surgery must be made on the basis of 
the ability to achieve tumour-free resection margins and 
postoperative quality of life. For locally advanced tumours, the 
postoperative functional consequences need to be prospectively 
and carefully assessed. For instance, when a total glossectomy 
(+/- total laryngectomy) is the only oncologically suitable 
surgical option, non-surgical organ preservation protocols must 
be seriously considered.   
 
b. In view of the favourable benefit/risk balance, IMRT is 
recommended in patients with advanced oral cavity cancer. 
 
 
c. Patients with advanced and non-metastatic oral cavity 
carcinoma who are not eligible for curative surgery (T4b, N3, 
unacceptable functional consequences, excessive comorbidity 
should preferably be administered primary radiochemotherapy 
rather than radiotherapy alone. 
 
d. Postoperative radiotherapy should be performed for advanced T 
categories (T3/T4), close (< 4 mm) or positive resection 
margins, tumour thickness > 10 mm, lymph node involvement 
(> pN1) and extra-capsular rupture/soft tissue infiltration. It 
should be considered for peri-neural extension or lymphatic 
vessels infiltration. For high-risk patients (e.g. close or positive 
resection margins, extracapsular spread) postoperative 
radiochemotherapy can be considered.                                     
 
e. Postoperative radiotherapy should be fractionated 
conventionally (e.g. 60-66 Gy in 6 to 6.5 weeks, 2 Gy per day, 5 
times a week).  
 
 
 
Low 
 
 
 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
High 
 
 
 
 
 
 
 
 
High 
4 
 
 
 
 
 
 
 
 
3 
 
 
 
3 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
1 
 
 
 
1 
  
 
 
 
 
 
 
 
 
Panel 4 
No comment. 
 
 
Panel 4 
No comment 
Accepted 
 
 
 
 
 
 
 
 
Omitted. 
Accepted the SIGN 
recommendation. 
 
Omitted. 
Accepted the SIGN the 
commendation. 
 
 
 
Accepted. 
 
 
 
 
 
 
 
 
Omitted. 
The panel member decided not to 
specify the dose. 
 
Accepted the SIGN the 
commendation. 
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Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
 
2.3.3 Advanced 
stage of oral cancer 
(Stage III and IV) 
 
f. Postoperative radiotherapy should be commenced as early as 
possible, i.e. within 6 weeks after surgery, and should be 
completed within 12-13 weeks after surgery.  
 
g. In concurrent (primary or postoperative) radiochemotherapy, 
radiotherapy should be fractionated conventionally (i.e. 2 
fractions per day, 5 days per week) and chemotherapy should be 
platinum-based (100 mg/m² three times weekly in case of 
postoperative radiochemotherapy). 
 
 
h. Interruption of radiotherapy will be detrimental to tumour 
control and should be avoided. 
 
 
i. Radiochemotherapy should only be performed at facilites in 
which radiotherapy- or chemotherapy-induced acute toxicities 
can be adequately managed. 
 
 
j. Due to insufficient evidence the combination of radiotherapy 
with EGFR inhibitors is not recommended in patients with oral 
cavity cancer. 
 
k. In patients with oral cavity cancer, induction chemotherapy is 
not recommended. 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
Low 
 
2 
 
 
 
2 
 
 
 
 
 
 
2 
 
 
 
3 
 
 
 
 
3 
 
 
 
3 
 
1 
 
 
 
1 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel 3 
No respond. 
Panel 2 
Within 6-8 weeks. 
 
Panel 3 
No respond. 
 
Panel 2 
Weekly Cisplastin 
40mg/m2.. 
 
Panel 3 
No respond. 
 
 
Panel 3 
No respond. 
 
 
 
Panel 3 
No respond 
 
 
Panel 2 
No comment 
 
 
Omitted. 
Accepted the SIGN the 
commendation. 
 
 
Omitted. 
Accepted the SIGN the 
commendation. 
 
 
 
Omitted. 
Accepted the SIGN the 
commendation. 
 
Omitted. 
Accepted the SIGN the 
commendation. 
 
 
Omitted. 
Accepted the SIGN the 
commendation. 
 
Omitted. 
Accepted the SIGN the 
commendation. 
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Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.3.4 Management 
of the neck lymph 
nodes 
a. Management of the neck lymph nodes should follow the same 
treatment principles as those applied for the primary tumour 
(e.g. if the primary tumour is surgically treated, a neck 
dissection should be performed). 
  
b. Perform a selective neck dissection of at least level I, II and III 
in all patients with a cN0M0 oral cavity SCC that is treated 
surgically  
 
c. A neck dissection can be omitted exceptionally in some patients 
with a cT1N0M0 oral cavity SCC, depending on the localisation 
and thickness of the tumour . 
 
d. Perform a selective ipsilateral neck dissection of at least level I, 
II, III and IV with – if oncologically feasible – preservation of 
the sternocleidomastoid muscle, jugular vein and spinal 
accessory nerve in all patients with a cN+M0 oral cavity SCC 
that is treated surgically. 
 
e. Consider a contralateral neck dissection in patients with a non-
metastatic oral cavity SCC that is at or crossing the midline or 
not clearly localized laterally. 
 
f. Consider performing a diagnostic evaluation of the neck with 
conventional imaging techniques (CT or MRI) or PET/CT three 
months after completion of primary (chemo) radiotherapy.  
 
g. In patients with oral cavity cancer (N1-3) and complete response 
to chemoradiotherapy (assessed by FDGPET/CT, CT or MRI), 
there is no data to support an additional lymph node dissection. 
Low 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
Low 
 
4 
 
 
 
 
3 
 
 
 
3 
 
 
 
4 
 
 
 
 
 
4 
 
 
 
3 
 
 
 
4 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel 2 
6/12 post adjuvant 
radiotherapy. 
 
Accepted 
 
 
 
 
Accepted 
 
 
 
Accepted 
 
 
 
Accepted 
 
 
 
 
 
Accepted 
 
 
 
Accepted with modification on 
the time frame to three to six 
month base (expert opinion).  
 
Accepted 
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Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No   
2.4 Treatment of very advanced-stage oral cancer (M0) T4b, any N or unresectable nodal disease or unfit for surgery). 
 NA       
2.5 Treatment of  locoregional recurrence disease  
2.5.1 General 
evaluation. 
In patients with suspected recurrence in the head and neck that could 
not be confirmed or ruled out by CT and/or MRI, FDG-PET/CT may 
be performed. 
Low 4 
 
 
 
 
 
   Omitted. 
 
Accepted the SIGN 
recommendation. 
2.5.2 Resectable 
locoregional 
recurrence 
Salvage surgery should be considered in any patient with a resectable 
locoregional recurrence having previously undergone radiotherapy or 
surgery. The procedure should only be performed by a surgical team 
with adequate experience of reconstructive techniques, and at a 
facility that offers suitable intensive care support 
 
Low 4    Omitted. 
 
Accepted the NCCN 
recommendation. 
2.5.3 Unresectable 
loceregional 
recurrence 
 
Re-irradiation, possibly with curative intent, should be considered in 
any patient with a non-resectable locoregional recurrence having 
already undergone irradiation. Irradiation should take place only at 
facilities with adequate expertise and ideally as part of a clinical 
therapeutic study. 
 
Low 4    Omitted. 
 
Accepted the NCCN 
recommendation. 
2.6 Treatment of metastatic or recurrent disease not eligible for curative treatment 
2.6.1 General 
recommendation 
NA       
2.6.2 Palliative 
chemotherapy 
In patients with metastatic oral cavity cancer or recurrent disease that 
is not eligible for curative treatment, palliative chemotherapy or 
targeted treatment can be considered after discussion with the patient. 
 
Low 
 
4    Omitted. 
 
Accepted the SIGN 
recmmendation. 
2.6.3 Palliative 
radiotherapy 
       
2.6.4 Palliative 
surgery 
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3) Follow-up 
Context (Belgian Health Care Knowledge Centre, 2014). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
3.1 Clinical and 
imaging evaluation 
An individually structured follow-up schedule should be devised 
for each patient. The quality of life, side effects of treatment, 
nutritional status, speech, dental status, thyroid function, smoking 
and alcohol consumption, etc. should be surveyed periodically. 
There is no evidence to support routine use of imaging techniques 
for the detection of locoregional or metastatic recurrence during 
follow-up. Follow-up frequency, even in symptom-free 
individuals, should be at least every 3 months in the first and 
second year, every 6 months in the third to fifth year, and 
annually afterwards. 
 
Low 4    Accepted. 
3.2 Dental 
rehabilitation 
a. In patients having undergone surgery and/or irradiation for 
carcinoma of the oral cavity, the masticatory function should 
be restored with the help of functional masticatory 
rehabilitation, using conventional prosthetics and/or 
implants. Surgical interventions (e.g. extractions) should be 
performed by professionals with experience in treating 
patients with head and neck cancer. The patients should 
undergo routine dental check-ups at a frequency depending 
on the individual patient case (usually every 4-6 months) 
 
 
b. Infected osteoradionecrosis of the jaw is a serious treatment 
complication that should be managed in specialized centres. 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
Low 
 
4 
 
 
 
 
 
 
 
 
 
 
4 
   Accepted. 
 
 
 
 
 
 
 
 
 
 
Accepted. 
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Context (Belgian Health Care Knowledge Centre, 2014) Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
3.3 Speech and 
swallowing 
rehabilitation. 
a. Patients with chewing, speaking and swallowing problems 
should be timely provided with appropriate functional 
therapy. The patients should be introduced to suitably 
qualified therapists prior to commencing treatment if the 
scheduled surgical or conservative procedures (e.g. 
radiotherapy) are likely to cause problems with chewing, 
swallowing and/or speech. 
 
 
b. Patients with dysphagia should undergo appropriate 
diagnostic procedures, e.g. clinical exam by the speech 
therapist, videofluoroscopy or fiber-optic endoscopy. 
 
 
c. Patients having eating and speaking problems due to 
carcinoma of the oral cavity and/or its management should 
have access to speech therapists and nutritional therapists 
with experience of such pathologies before, during and after 
treatment. 
 
Low 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
4 
 
 
 
 
 
 
 
 
4 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel 3 
Only feasible in selected 
centres 
Accepted. 
 
 
 
 
 
 
 
 
Accepted. 
 
 
 
 
Accepted. 
3.4 Nutritional 
therapy 
Patients should be regularly screened for malnutrition due to oral 
cavity cancer or its treatment. Patients at risk for malnutrition 
should receive timely and ongoing professional dietary 
counselling and nutritional therapy. 
 
Low 
 
4    Accepted. 
3.5 Psychosocial 
counselling and 
support 
Patients with oral cavity cancer (and their family, carers) should 
be offered dedicated psychosocial support on a continuous basis 
within the context of a multidisciplinary team.  
 
Low 
 
4    Accepted. 
 
 
 
 
Y(M): Accepted with modification 
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Appendix K 
Assessment Form_(Scottish Intercollegiate Guideline Network, 2006). 
1)Diagnosis and Staging 
Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
1.1 Patient 
information 
NA       
1.2 Clinical 
Examination and 
consultation 
NA       
1.3 Biopsy Fine needle aspiration (FNA) cytology should be used in the 
investigation of head and neck masses. 
 
 
Low 
 
4    Omitted. 
Accepted the BKCE 
recommendation. 
1.4 Conventional 
Imaging of the 
primary tumour 
a. CT or MRI of the primary tumour site should be performed 
to help define the T stage of the tumour.  
 
 
b. MRI should be used to stage oral tumours.  
 
 
 
 
c. MRI should be used in assessing:   
 laryngeal cartilage invasion 
 tumour involvement of the skull base, orbit, cervical 
spine or neurovascular structures (most suprahyoid 
tumours). 
 
Low 
 
 
 
Low 
 
 
 
 
Low 
 
4 
 
 
 
3 
 
 
 
 
4 
  
 
 
 
1 
 
 
 
 
Panel 3. 
Long appointment as not 
widely available in 
Malaysia. 
Omitted. 
Accepted the NCCN 
recommendation. 
 
Omitted. 
Accepted the NCCN 
recommendation 
 
 
Omitted. 
Accepted the NCCN 
recommendation 
1.5 Imaging of 
advanced stage 
tumour 
a. In patients presenting with cervical lymph node metastases, 
where CT or MRI does not demonstrate an obvious primary 
tumour, FDG-PET should be performed as the next 
investigation of choice.  
 
b. In patients presenting with suspected recurrent head and 
neck cancer, where CT/MRI does not demonstrate a clear cut 
recurrence, FDG-PET should be performed as the next 
investigation of choice. 
Low 
 
 
 
 
Low 
4 
 
 
 
 
4 
   Accepted  
 
 
 
 
Accepted 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No   
1.6 Imaging of neck 
lumps and nodes 
a. CT or MRI from skull-base to sternoclavicular joints should 
be performed in all patients at the time of imaging the 
primary tumour to stage the neck for nodal metastatic 
disease. 
 
b. Where the nodal staging on CT or MRI is equivocal, 
USFNA and/or FDG-PET increase the accuracy of nodal 
staging. 
 
Low 
 
 
 
 
Low 
4 
 
 
 
 
4 
   Accepted. 
 
 
 
 
Accepted. 
 
1.7 Other staging 
interventions 
(identification of 
synchronous tumour 
and distant 
metastases) 
a. All patients with head and neck cancer should have direct 
pharyngolaryngoscopy and chest X-ray with symptom-
directed endoscopy where indicated.  
 
b. All patients with head and neck cancer should undergo CT of 
the thorax, imaging for distant metastases and synchronous 
tumour. 
Low 
 
 
 
Low 
4 
 
 
 
4 
 
 
 
   Omitted. 
Accepted the NCCN 
recommendation 
 
Omitted. 
Accepted the NCCN 
recommendation 
1.8 HPV Testing 
 
NA       
1.9 Histopathology 
 
1.9.1 Resection 
margin 
NA       
1.9.2 Primary site 
reporting. 
Histopathology reporting of specimens from the primary site of 
head and neck cancer should include:  
 tumour site, 
 tumour grade, 
 maximum tumour dimension,  
 maximum depth of invasion,  
 margin involvement by invasive and/or severe 
dysplasia, 
 pattern of infiltration,  
 perineural involvement  
 tumour type 
 lymphatic/vascular permeation 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
GPP 
4   Panel 4. 
Current dataset (currently in 
draft) has now included 
under pattern of invasion 
‗worst pattern of invasion‘  
in addition to cohesive and 
non-cohesive pattern of 
invasion (Li, et al 2013; 
Almungush, et al 2015), as 
core reporting. These 
parameters have been 
shown to be of prognostic 
value. 
 
Omitted. 
Accepted the BKCE 
recommendation. 
 
311 
 
Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(no. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
1.9.3 Neck and 
metastatic disease 
reporting. 
a. The reporting of nodal dissections should include a description 
of the type of dissection (comprehensive, selective or 
extended), the levels and structures included in the specimen  
 
b. Histopathology reporting of specimens from areas of 
metastatic disease in patients with head and neck cancer 
should include:  
 number of involved nodes, 
 level of involved nodes, 
 extracapsular spread of tumour 
and 
 type of nodal dissection  and size of largest tumour mass  
GPP 
 
 
 
 
 
 
 
Low 
 
 
GPP 
 
4    Omitted. 
Accepted the BKCE 
recommendation. 
 
2) Treatment 
Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(√) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.1 Multidisciplinary involvement.  
 a. Treatment plans should be formulated by a multidisciplinary 
team in consultation with the patient. As part of this process, 
dental, speech and language and nutritional assessments are 
essential  
 
b. Individual patient characteristics, local expertise and patient 
preference should guide management of head and neck cancer. 
 
GPP 
 
 
 
 
GPP 
4 
 
 
 
 
4 
 
 
 
 
   Accepted with modification. 
 
The recommendations of the 
three guidelines (NCCN, 
BKCE and SIGN) were 
combined. The composition 
of the multidisciplinary team 
is divided into core member 
and non-core member 
2.2 Pre-treatment assessments.  
2.2.1 Dental 
evaluation 
Patients with head and neck cancer, especially those planned for 
resection of oral cancers or whose teeth are to be included in a 
radiotherapy field, should have the opportunity for a pre-treatment 
assessment by an appropriately experienced dental practitioner 
 
 
Low 4    Accepted with modification. 
The recommendations of the 
three guidelines were 
combined and modified into 
new wording. 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.2.2 Nutritional, 
speech and 
swallowing 
evaluation 
All head and neck cancer patients should be screened at diagnosis 
for nutritional status using a validated screening tool appropriate to 
the patient population. Patients at risk of undernutrition should be 
managed by an experienced dietitian. 
 
GPP 4    
 
Omitted. 
Accepted the NCCN 
recommendation. 
2.3 Treatment of primary non-metastatic oral cancer 
2.3.1 General 
recommendations 
Factors to be considered in treatment plan: 
 Management of early oral cavity tumours should be 
individualised for each patient.  
 Decisions regarding the choice of primary treatment 
modality should be made in consultation with the patient 
and should take into account the anatomical location of 
the tumour and availability of local expertise. 
 In those patients where surgical resection is possible, the 
likelihood of obtaining adequate surgical margins with 
acceptable morbidity, functional outcome and quality of 
life must be considered.  
 The likely short and long term morbidity resulting from 
radiotherapy must be considered. 
 
 
GPP 
 
 
4 
  Panel 1. 
This is important factor in 
which close family should 
be involved in the decision 
making. Home management 
should involve the family 
member.  
Accepted. 
2.3.2 Early stage of 
Oral Cancer (Stage I 
and II). 
a. Patients with early oral cavity cancer may be treated by 
surgical resection, where rim rather than segmental resection 
should be performed, where possible, in situations where 
removal of bone is required to achieve clear histological 
margins. 
 
 
b. Reconstruction should be performed where necessary 
following surgical resection to achieve a good functional and 
cosmetic result  
 
 
c. Patients with early oral cavity cancer may be treated by: 
Brachytherapy in accessible, well demarcated lesions to a dose 
of 65-70Gy at a dose rate of less than 0.55Gy/hour  
 
 
 
 
Low 
 
 
 
 
 
GPP 
 
 
 
 
 
Low 
 
 
 
 
 
3 
 
 
 
 
 
4 
 
 
 
 
 
1 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
Panel 3 
To consider remaining 
mandible height to prevent 
fracture. 
 
 
Panel 2 and 3 
Brachytherapy is not 
available locally. 
 
 
 
Panel 4. 
Decision by oncology team 
and patient. 
 
 
Omitted. 
Accepted the BKCE 
recommendation. 
 
 
 
Omitted. 
Accepted the BKCE 
recommendation. 
 
 
 
Omitted. 
Panel members decided not to 
specify the dose. 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.3.2 Early stage of 
Oral Cancer (Stage I 
and II). 
d. Interstitial brachytherapy should be performed by experienced 
teams in centres with adequate radiation protection facilities 
 
 
 
 
 
 
e. Re-resection should be considered to achieve clear histological 
margins if the initial resection has positive surgical margins or 
if inadequate initial excision biopsy has been performed. 
 
f. If re-resection is not possible, postoperative radiotherapy 
should be considered.  
 
g. Postoperative radiotherapy should be considered for patients 
with clinical and pathological features that indicate a high risk 
of recurrence. 
 
h. Administration of cisplatin chemotherapy (CRT) concurrently 
with postoperative radiotherapy should be considered, 
particularly in patients with extracapsular spread and/or 
positive surgical margins. 
 
Low 
 
 
 
 
 
 
 
Low 
 
 
 
GPP 
 
 
Low 
 
 
 
High 
2 
 
 
 
 
 
 
 
3 
 
 
 
4 
 
 
4 
 
 
 
4 
1 1 Panel 2 
Brachytherapy is not 
available locally. 
 
Panel 4 
Decision by oncology team 
and patient. 
 
Panel 2 
If cosmetic/function not 
affected by the re-resection. 
 
 
 
 
 
 
 
 
Accepted: 
Currently the service is not 
available in Malaysia. 
However the recommendation 
was accepted for future 
consideration. 
 
 
Accepted 
 
 
 
Accepted 
 
 
Accepted 
 
 
 
Accepted 
2.3.3 Advanced stage 
of Oral Cancer 
(Stage III and IV) 
a. Patient with resectable disease, who are fit for surgery, should 
have surgical resection with reconstruction. 
 
b. The likelihood of obtaining adequate surgical margins with 
acceptable morbidity, functional outcome and quality of life 
must be considered before undertaking surgical resection. 
 
c. Radical external beam radiotherapy with concurrent cisplatin 
chemotherapy should be considered when:  
 the tumour cannot be adequately resected.  
 the patient‘s general condition precludes surgery. 
 the patient does not wish to undergo surgical resection. 
 
 
 
Low 
 
 
GPP 
 
 
 
High 
4 
 
 
4 
 
 
 
4 
 
 
   Accepted. 
 
 
Omitted. 
Accepted the BKCE 
recommendation. 
 
Accepted 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.3.3 Advanced stage 
of Oral Cancer 
(Stage III and IV) 
d. In patients medically unsuitable for chemotherapy, concurrent 
administration of cetuximab with radiotherapy should be 
considered. 
 
e. Where radiotherapy is being used as a single modality without 
concurrent chemotherapy or cetuximab, a modified 
fractionation schedule should be considered.  
 
f. Postoperative radiotherapy should be considered for patients 
with clinical and pathological features that indicate a high risk 
of recurrence. 
 
g. Postoperative radiotherapy should be conventionally 
fractionated: 54-60Gy in 27-30 fractions over 5.5-6 weeks to 
the primary site and nodes at risk 66Gy in 33 fractions over 6.5 
weeks to areas of very high risk). 
 
h. Administration of cisplatin chemotherapy concurrently with 
postoperative radiotherapy should be considered, particularly 
in patients with extracapsular spread and/or positive surgical 
margins. 
 
i. Interrupting and prolonging a course of radical radiotherapy 
should be avoided. 
 
j. Overall treatment time from surgery to completion of 
radiotherapy should be 10-11 weeks or less in the absence of 
postoperative medical or surgical complications. 
 
 
 
k. Concurrent chemoradiotherapy should only be administered 
where there are appropriate facilities for monitoring toxicity, 
with rapid access to appropriate outpatient and inpatient 
support for the treatment of acute radiotherapy and 
chemotherapy toxicity. 
 
l. The routine use of neo-adjuvant chemotherapy in oral cavity 
cancer is not recommended. 
High 
 
 
 
High 
 
 
Low 
 
 
 
High 
 
 
 
High 
 
 
 
 
Low 
 
 
Low 
 
 
 
 
High 
 
 
 
 
High 
3 
 
 
 
3 
 
 
4 
 
 
 
3 
 
 
 
 
4 
 
 
 
 
4 
 
 
 
3 
 
 
 
 
4 
 
 
 
 
 
4 
1 
 
 
1 
 
 Panel 1 
No comment 
 
 
Panel 2 
No comment 
 
 
 
 
 
 
Panel 2 
60-70mg to primary site 60-
66mg for nodul site 
 
 
 
 
 
 
 
 
Panel 2 
6-8 weeks post surgery. 
OTT 6-7 weeks 
 
Omitted 
Accepted the BKCE 
recommendation. 
 
Omitted 
Accepted the BKCE 
recommendation. 
 
Accepted 
 
 
 
Omitted 
The panel decided not to 
specify the dose. 
 
 
Omitted 
Accepted in early stage 
management. 
 
 
Accepted. 
 
 
Accepted with modification 
on the overall treatment time 
from 10-11 weeks to <14 
weeks (Rosenthal et al., 2002, 
(Langendijk et al., 2010,). 
 
Accepted. 
 
 
 
 
Accepted 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.3.6 Management of 
the neck lymph 
nodes 
a. The clinically N0 neck (levels I-III) should be treated 
prophylactically either by external beam radiotherapy or 
selective neck dissection. 
 
 
 
b. Patients with node positive disease should be treated by 
modified radical neck dissection. Elective dissection of the 
contralateral neck should be considered if the primary tumour 
is locally advanced, arises from the midline, or if there are 
multiple ipsilateral nodes involved. 
 
c. Nodal levels I-IV should be irradiated bilaterally. 
 
 
 
 
 
d. Patients with N1 disease who are receiving radiotherapy to the 
primary tumour should treated with chemoradiotherapy where 
there is clinical evidence of residual disease following 
completion of therapy.  
 
 
 
e. Patients with N2 and N3 nodal disease who are receiving 
radiotherapy to the primary tumour should be treated with 
chemoradiotherapy followed by planned neck dissection. 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
2 
 
 
 
 
 
4 
 
 
 
 
 
2 
 
 
 
 
 
2 
 
 
 
 
 
 
3 
 
2 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
1 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
1 
 
Panel 3 
Site specific 
recommendation. 
Panel 4 
What situation? 
 
 
 
 
 
 
 
Panel 3 
Unclear statement. 
 
Panel 4 
In what situation? 
 
Panel 2 
Confusing statement. 
 
Panel 4 
Decision by expert 
oncology team. 
 
Panel 4 
Decision by expert 
oncology team. 
 
 
 
 
 
 
 
 
 
 
All recommendations in this 
section were omitted 
and accepted the BKCE 
recommendations. 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.4Treatment of very advanced-stage oral cancer (M0) T4b, any N or unresectable nodal disease or unfit for surgery.  
 NA       
2.5 Treatment of  locoregional recurrence disease  
2.5.1 General 
evaluation 
a. Decisions regarding the appropriate management of a 
locoregional recurrence of head and neck cancer should be 
made on an individual basis taking into account:  
 The stage of recurrent tumour and its potential 
resectability. 
 Previous treatment 
 Likely treatment efficacy 
 Likely treatment-related morbidity and functional 
outcome and consequent effects on quality of life  
 patient‘s general health  
 patient‘s wishes.  
 
 
b. Decisions regarding the management of locoregional 
recurrence of head and neck cancer should be made by the 
multidisciplinary team in consultation with the patient 
following histological confirmation of recurrence and full 
restaging (clinical and radiological). 
 
 
c. Patients and their relatives/carers should be carefully 
counselled about the likely outcome of surgical and 
radiotherapeutic salvage, with respect to survival, risk of 
treatment-related morbidity and mortality, and likely resulting 
quality of life.  
 
 
d. Early referral to palliative care for symptom control should be 
considered. 
 
GPP 
 
 
 
 
 
 
 
 
 
 
 
 
 
GPP 
 
 
 
 
 
 
GPP 
 
 
 
 
 
 
GPP 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
4 
 
 
 
 
 
 
4 
   Accepted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accepted. 
 
 
 
 
 
Accepted. 
 
 
 
 
 
 
Accepted. 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.5.2 Resectable 
locoregional 
recurrence 
a. Salvage surgery should be considered in any patient with a 
resectable locoregional recurrence of oral cavity cancer 
following previous radiotherapy or surgery.  
 
 
b. Salvage surgery should only be performed by an experienced 
surgical team with adequate experience in reconstructive 
techniques, in centres with appropriate facilities for medical 
support and rehabilitation.  
 
Low 
 
 
 
 
GPP 
4 
 
 
 
 
4 
   Omitted. 
Accepted the NCCN 
recommendation. 
 
 
Omitted. 
Accepted the NCCN 
recommendation. 
 
2.5.3  
Unresectable 
loceregional 
recurrence 
 
a. External beam radiotherapy should be considered as 
potentially curative salvage treatment for patients with 
locoregionally recurrent disease after previous surgery,    
particularly if the recurrence is unresectable, or resection 
would result in unacceptable loss of function or cosmesis. 
 
b. Selected patients who have unresectable locally recurrent 
disease following previous radiotherapy may be considered 
for potentially curative re-irradiation.  
 
c. Patients with small accessible recurrences in a previously 
irradiated region may be considered for interstitial 
brachytherapy in centres with appropriate facilities and 
expertise. 
 
 
 
 
 
d. Re-irradiation should only be performed in centres with 
adequate expertise, and ideally only in the context of a clinical 
trial. Centres must be experienced in the recognition and 
management of acute and late radiation toxicity. 
GPP 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
 
 
 
GPP 
4 
 
 
 
 
 
4 
 
 
 
2 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
Panel 2 and 3 
The services not available 
in Malaysia 
Panel 4 
Type of therapy dependent 
on the expert decision by 
oncology team. 
 
 
Panel 4 
Type of therapy dependent 
on the expert decision by 
Oncology team 
Omitted. 
Accepted the NCCN 
recommendation. 
 
 
 
Omitted. 
Accepted the NCCN 
recommendation. 
 
Accepted: 
 
 
 
 
 
 
 
 
Omitted. 
Accepted the NCCN 
recommendation. 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.6 Treatment of metastatic or recurrent disease not eligible for curative treatment 
2.6.1 General 
recommendation 
a. The care of patients with incurable head and neck cancer 
should be managed by the palliative care services in 
conjunction with the multidisciplinary team.  
 
 
b. All modalities of therapy should be considered as options for 
the palliation of head and neck cancer. 
 
 
c. Short term toxicity and length of hospital stay should be 
balanced against likely symptomatic relief.   
 
  
d. A documented pathway of care should be discussed and 
agreed with the patient, relatives, carers and GP 
 
GPP 
 
 
 
 
GPP 
 
 
 
GPP 
 
 
 
GPP 
4 
 
 
 
 
4 
 
 
 
4 
 
 
 
4 
 
 
 
 
   Accepted. 
 
 
 
 
Accepted. 
 
 
 
Accepted. 
 
 
 
Accepted. 
 
2.6.2 Palliative 
chemotherapy 
a. Patients of adequate performance status should be considered 
for palliative chemotherapy which may reduce tumour 
volume. 
 
b. Single agent methotrexate, single agent cisplatin, or 
cisplatin/5Fu combination should be considered for palliative 
chemotherapy in patients with head and neck cancer.  
 
         
c. An excessive toxicity from intensive chemotherapeutic 
combination regimens should be avoided. 
 
 
High 
 
 
 
High 
 
 
 
 
High 
4 
 
 
 
3 
 
 
 
 
4 
 
 
 
 
1 
 
  
 
 
 
Panel 4 
Expert oncology team 
decision 
Accepted. 
 
 
 
Accepted. 
 
 
 
 
Accepted. 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
2.6.3 Palliative 
radiotherapy 
Radiotherapy may be considered for palliative treatment in patients 
with locally advanced incurable head and neck cancer. 
 
Low 4    Accepted. 
2.6.4 Palliative 
surgery 
Appropriate surgical procedures should be considered for palliation 
of particular symptoms, taking local expertise into consideration. 
 
GPP 4    Accepted. 
 
 
3) Follow-up 
Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
3.1 Clinical and 
imaging evaluation 
a. Patients should be seen frequently and regularly within the 
first three years post-treatment. 
 
 
 
b. Patients should be offered multidisciplinary follow up 
 
 
c. Patients should have access to PET scanning, if appropriate, 
when recurrence is suspected.  
 
 
d. Patients‘ weight should be monitored at follow up.  
 
 
e. Patients‘ complaints of pain should be investigated.  
 
 
f. Routine use of chest X-rays or serum markers is not 
recommended.  
 
 
g. During follow up, routine supplementation with beta carotene 
is not recommended.  
Low 
 
 
 
 
GPP 
 
 
Low 
 
 
 
Low 
 
 
Low 
 
 
High 
 
 
 
High 
4 
 
 
 
 
3 
 
 
4 
 
 
 
4 
 
 
4 
 
 
4 
 
 
 
4 
 
 
 
 
 
1 
 
  
 
 
 
 
Panel 3 
In certain centres where it‘s 
feasible to do so. 
All recommendations in this 
section were omitted and 
accepted the BKCE 
recommendation. 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(No. of panel) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
3.3 Speech and 
swallowing 
rehabilitation. 
a. Head and neck cancer patients with dysphagia should receive 
appropriate speech and language therapy to optimise residual 
swallow function and reduce aspiration risk.  
 
 
b. All patients with oral cancer should have access to 
instrumental investigation for dysphagia.  
 MBS and FEES are both valid methods for assessing 
dysphagia. 
  the SLT should consider which is the most appropriate 
for different patients in different settings.  
 
 
c. All patients undergoing chemoradiation should have access to 
a specialist speech and language therapist before, during and 
after treatment.  
 
 
 
 
d. Where communication problems are likely to occur, patients 
should be seen by a specialist head and neck speech and 
language therapist soon after diagnosis and before    treatment 
commences.  
 
 
 
 
e. Patients with communication impairment should have access 
to a speech and language therapist.  
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
 
 
 
3 
 
 
 
 
3 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
3 
 
 
 
 
 
 
3 
1 
 
 
 
 
1 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
1 
 
 
 
 
 
 
1 
 
 
 
 
 
 Panel 1 
But not widely available. 
 
 
 
Panel 3 
Selection of patients 
according to clinician‘s 
recommendation because of 
the limited availability of 
the services. 
 
 
 
Panel 3 
Selection of patients 
according to clinician‘s 
recommendation because of 
the limited availability of 
the services. 
 
Panel 3 
Selection of patients 
according to clinician‘s 
recommendation because of 
the limited availability of 
the services. 
 
Panel 3 
Selection of patients 
according to clinician‘s 
recommendation because of 
the limited availability of 
the services. 
. 
 
 
 
 
All recommendations in this 
section were omitted and 
accepted the BKCE 
recommendation. 
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Context (Scottish Intercollegiate Guideline Network, 2006). Accept 
(√) 
Comment Decision 
Recommendations LOE Yes Yes 
(M) 
No 
3.4 Nutritional 
therapy 
a. All head and neck cancer patients should be screened at 
diagnosis for nutritional status using a validated screening tool 
appropriate to the patient population. 
 
 
b. After screening, at-risk patients should receive early 
intervention for nutritional support by an experienced dietitian.  
 
 
c. The multidisciplinary team should include healthcare 
professionals skilled in gastrostomy placement. 
 
 
d. Patients should be offered information about feeding tube 
alternatives, including possible complications.  
GPP 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
GPP 
4 
 
 
 
 
3 
 
 
 
3 
 
 
 
4 
 
 
 
 
 
1 
 
 
 
1 
 
  
 
 
 
 
Panel 3 
When feasible. 
 
 
Panel 3 
Referred accordingly. 
 
 
 
 
 
All recommendations in this 
section were omitted and 
accepted the BKCE 
recommendation. 
 
3.5 Psychosocial 
counselling and 
support 
a. Head and neck cancer patients should be offered emotional 
support, which may be provided by clinical nurse specialists 
and non-clinically trained counsellors. 
 
 
b. In some situations it may be appropriate to refer patients to a 
clinical psychologist  
 
 
c. Leaflets about risk factors, prevention and early detection of 
head and neck cancer    should be available in primary care.  
 
 
d. Patients should be given information about their diagnosis and 
treatment at separate meetings. Individualised information 
should be made available. 
 
 
GPP 
 
 
 
 
GPP 
 
 
 
High 
 
 
 
GPP 
4 
 
 
 
 
4 
 
 
 
4 
 
 
 
4 
   All recommendations in this 
section were omitted and 
accepted the BKCE 
recommendation. 
 
 
 
Y(M): Accepted with modification 
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Appendix L 
The Set of Questions Used as a Guide for Focus Group Discussion 
 
1. Format of the guidelines: 
1. What is your opinion regarding the format of the guideline? 
2. Do you feel it is well organised and easy to understand? 
 
2. Section 1(Introduction) and Section 2 (Development of the guideline).           
1. Can I have your comments or opinion with regards to both sections? Is there 
anything to be added/removed? 
 
3. Section 3 (Clinical Recommendations) and the algorithm on oral cancer 
management. 
1. In your view are the wording of the recommendations are clear and precise? 
2. Do you feel any recommendations that should be added or removed? Please 
provide the evidence. 
3. Are there any recommendations that are important in practice but not included 
in the guideline? Is there any evidence related to it? 
4. Is all recommendations are acceptable? 
5. Does everyone agree that the recommendations are useful to be adapted in local 
practice? 
6. How about the interpretation of the evidence? 
7. How about the presentation of the algorithm? 
8. Can anyone suggested or proposed clinical audit indicator for quality 
improvement. 
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Appendix P 
Appraisal of the updated literature 
No Articles Critical Appraisal 
1. Almungush, et al., (2015).For early-
stage oral tongue cancer, depth of 
invasion and worst pattern of invasion 
are the strongest pathological predictors 
for locoregional recurrence and 
mortality. Virchows Archiv, 467(1), 39-
46.   
 
Study design  Cohort study (Retrospective) 
 All evaluators used scoring system of the histological risk model and were blinded to the patients‘ data and 
clinical outcome. 
 Prognostic factors measured for early-stage Oral Tongue Squamous Cell Carcinoma (OTSCC): host response 
(LHR), perineural invasion (PI), worst pattern of invasion (WPOI), depth of invasion (DOI) and others factors 
such as age, gender, stage, grade, lymphocytic. 
 Analysis proportional hazards regression model were used to analysed incidence of recurrence and mortality.  
 Seven cases were dropped out because information of DOI could not be retrieved. 
Study population  Sufficient number of cases: 476 cases from 3 countries, treated for early stage cancer (cT1-2N0) between 
1979-2012 
Outcome  This study involved large multicenter cohort that presented the predictive factors for locoregional recurrence 
(LR) and mortality for Depth of invasion (4mm or deeper) was the strong predictor for locoregional 
recurrence (LR) and mortality with a HR (1.67, 95% CI:1.07-2.60) and (2.44, 96% CI: 1.34-4.47) 
 WPOI was the strong predictors for mortality with a HR (2.34, 95% CI: 1.26-4.32) 
 Advancing age was found positively associated with oral tongue squamous cell carcinoma with HR (1.78, 
95% CI: 1.09, 2.90) and (1.29, 95% CI: 1.09, 1.53) for LR and mortality respectively. 
2. Li, Y., Bai, S., Carroll, W., Dayan, D., 
Dort, J. C., Heller, K., Jour, G., Lau, H., 
Penner, C. & Prystowsky, M. (2013). 
Validation of the risk model: high-risk 
classification and tumor pattern of 
invasion predict outcome for patients 
with low-stage oral cavity squamous 
cell carcinoma. Head and neck 
pathology, 7(3), 211-223.    
Study design  Cohort study (Retrospective) 
 WPOI was used to measure the prognostic value for low-stage OSCC  
 All evaluators reviewed reports on all consecutive head and neck resections, identified target index cases, all 
pathology slides and were blinded to the outcome. Other clinical and pathologic features and demographic 
information were collected. 
 Prognostic factors measured: LHR and WPOI. 
 Confounding factors include: smoking and alcohol intake: multivariate analysis was used 
Study population  Sufficient number of cases: 299 patients with stage I/II primary OSCC treated with en-bloc at 8 medical 
centers between 1989-2011. 
Results  This study involved large multicenter cohort that presented the WPOI as  predictive factors for locoregional 
recurrence and Disease-specific survival in low stage-OCSCC 
 17% of T1N0 and 19% of T2N0 developed LRR 
 DSS occurred in 6% of T1N0 and 10% T2N0 
 Multivariate analysis: WPOI alone was signiﬁcantly predictive for LRR adjusted for potential confounders 
with a cut-point of either WPOI-4 (p = 0.0029, HR 3.63, 95 % CI:1.56, 8.47) or WPOI-5 (p = 0.0008, 
HR2.55, 95 % CI: 1.48, 4.41) and for DSS (cut point WPOI-5, p = 0.0001, HR 6.34, 95 % CI:2.50,16.09). 
Given a WPOI5, the probability of developing locoregional recurrence is 42 %. Given a high-risk 
classiﬁcation for a combination of features other than WPOI-5, the probability of developing locoregional 
recurrence is 32 %.  
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No Articles Critical Appraisal 
3. Rosenthal, D. I., Liu, L., Lee,  
J. H., Vapiwala, N., Chalian,  
A. A., Weinstein, G. S.,  
Chilian, I., Weber, R. S. &  
Machtay, M. (2002).  
Importance of the treatment  
package time in surgery and  
postoperative radiation  
therapy for squamous  
carcinoma of the head and  
neck. Head & neck, 24(2),  
115-126.   
 
Study design  Cohort study (Retrospective) 
 Treatment time factors considered including: total time from surgery to completion of radiotherapy (package 
time), (< 100 days and > 100 day). 
 Other variable: clinical and pathological staging, margin status, RT dose, tumour site. 
 Proportion of follow-up was clearly presented: 21months for all patients and 24 month for surviving patients 
 Univariate and multivariate analysis were performed to evaluate the potential prognostic significance of 
various factors on locoregional control (LRC) 
 
Study population  Sufficient number of cases: 208, treated with radical surgery and postoperative RT for Squamous Cell 
Carcinoma of Head and Neck Cancer at University of Pennsylvania Medical Center between 1992-1997. 
 No prior cancer therapy before the surgery. 
 Patients were divided into two groups: high and intermediate risk (based on clinical and pathologic risk 
factors 
 
Outcome  The findings presented association between package time and (LRC and survival). 
 Outcome measured: locoregional control and survival. 
 The locoregional control and survival rates were 82% and 71% respectively. 
LRC 
 Based on univariate analysis:  
The package time (p=0.13), margin status (p=0.38), pathologic grouping (p=0.035) were significant 
predictor for LRC 
 Based on Multivariate Cox model:  
When risk factors and package time were incorporated: both factors were associated with LRC (HR: 
2.13, p=0.22) for package time and (HR: 2.49, p=0.17) for high-risk status. 
Overall Survival 
 Patients with shorter treatment package time had better survival (74% when < 100 days and 66% > 100 day. 
 Univariate analysis: package time significantly associated with survival (p=0.021) 
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LIST OF ABBREVIATIONS 
 
 
 
 
PGEAC The Practice Guideline Evaluation and Adaptation Cycle  
AGREE The Appraisal of Guidelines for Research and Evaluation  
OSCC Oral mucosal squamous cell carcinoma 
CT Computed Tomography 
IMR Magnetic Resonance Imaging 
PET-CT Positron Emission Tomography-Computed Tomography  
EUA Examination under anaesthesia  
HPV Human Papillomavirus 
USFNAC Ultrasound-guided fine-needle aspiration cytology  
OPG Panoramic oral radiograph 
PS Performance status 
WPOI Worst pattern of invasion 
HR Hazard ratio 
RT Radiotherapy  
CRT Chemotherapy  
RCT Randomized control trial. 
OTTRT Overall treatment time of radiation 
LRC Locoregional control 
TPP Total treatment package  
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 DIAGNOSIS PRE-TREATMENT 
ASESSMENTS 
TREATMENT      MANAGEMENT OF     
     LYMPH NODES  
POST-TREATMENT FOLLOW-UP CARE 
 
 
 
 
 
PRESENTING 
SYMPTOMS 
 
 
 
 
 
 
 
 
Investigation: 
 Clinical 
examination. 
 Biopsy 
 CT and/or MRI of 
primary. 
 FGD-PET in 
advance stage or 
nodal staging as 
clinically indicated. 
 USFNA for nodal 
staging as 
clinically indicated. 
 Others: 
chest imaging,  
endoscopy, 
pre-anaesthesia for 
identification of 
synchronous 
tumour and distant 
metastases 
 
 
 
Dental,  
nutritional,  
speech,  
swallowing  
and  
Health-related 
quality of life 
evaluation. 
 
 
 
 
Clinical Staging 
(Stage I and Stage II) 
 
 Surgery + 
reconstructive  
surgery. 
 
 Definitive 
radiotherapy. 
 
 Brachytherapy 
 
 
 
 
 
 
 
Clinical staging 
 (Stage III and IV) 
 
 Surgery+ 
Reconstructive 
surgery. 
 
 Radical external beam 
radiotherapy 
concurrent with 
chemotherapy if 
contraindication for 
surgery or patient 
refusal.  
 
 
 
 
  Clinical Staging 
  (Stage I and II) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Clinical and imaging 
evaluation. 
 Dental 
rehabilitation. 
 Speech and 
swallowing 
rehabilitation. 
 Nutritional therapy. 
 Psychosocial 
counselling and 
support. 
 Health-related 
quality of life 
assessment. 
 
 
 
 
 
 
 
 
 Locoregional 
recurrence:  
Refer to clinical 
recommendation  
(2.5, page16) 
 
 Palliative care : 
Refer to clinical 
recommendation  
(2.6, page 18) 
   
 
Clinical Staging 
(Stage I and II) 
 
 
 
 
 
   Clinical staging 
   (Stage III and IV) 
 
 
 
 
 
cN+M0  
Perform a selective 
ipsilateral/ 
contralateral neck 
dissection of at 
least level I, II, III 
and IV 
 
Other risk features *: 
Advanced T categories (T3/T4), close (< 4 mm) or positive 
resection margins, tumour thickness > 10 mm, lymph node 
involvement (> pN1) and extra-capsular rupture/soft tissue 
infiltration. It should be considered for peri-neural extension or 
lymphatic vessels infiltration. 
 
 
 
(M0) T4b, any N or unresectable nodal disease or unfit 
for surgery.  
 Standard therapy based on their PS=Performance 
Status(Eastern Cooperative Oncology Group (ECOG). 
 Downstaging of tumour: chemoradiotherapy. 
 
ii 
cN0M0, T1-T3 
Perform a selective neck 
dissection of at least 
level I, II and III, 
depending on site, size, 
grade, pattern of 
invasion, lymphatic 
infiltration and choice of 
reconstruction. 
 
Nodal 
status 
Patient 
expectation. 
Positive margin:  
Re-excision 
Extracapsular + 
positive margin 
Re-excision or 
Radiotherapy 
Extracapsular + 
positive margin 
Chemotherapy  + 
Radiotherapy 
High risk 
recurrence 
Radiotherapy 
Other risk 
features * 
Radiotherapy 
ALGORITHM FOR MANAGEMENT OF ORAL CANCER 
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SECTION 1:  
INTRODUCTION 
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1. 1 BACKGROUND. 
 
Oral cancer is defined as malignant tumours of the oral cavity. It affects the 
structures or tissues of the mouth including the tongue, gingivae, buccal 
mucosa, retromolar triangle, alveolus, hard palate, lip and floor of the mouth 
(Scottish Intercollegiate Guidelines Network, 2006, Alberta Health Services, 
2014, Ministry of Health Malaysia, 2002). The most common form of oral 
cancer reported was primary oral squamous cell carcinoma (OSCC) (>90%) 
(Brown and Langdon, 1995, Mehrotra and Yadav, 2006, Neville and Day, 
2002).  
 
Worldwide, oral and pharyngeal cancer grouped together, is the sixth most 
common cancer. The annual estimated incidence of oral cancer is around 
300,000 with two-thirds of these cases occuring in developing countries 
(Cancer Research UK, 2012, Warnakulasuriya, 2009). In Malaysia, the 
National Cancer Registry (2007-2011) reported that tongue and mouth cancer 
incidence was ranked among the 20
th 
most common cancer in the general 
population. The prevalence is found to be predominantly among the Indian 
ethnic group with 60% of the lesions are found among this communities 
(Azizah et al., 2016).  
 
Management of oral cancer is highly complex (Gotay and Muraoka, 1998, 
Bower et al., 2014). The quality of care at every stages of oral cancer 
management is crucial to achieve optimal cancer outcome and to improve 
quality of life of the cancer survivors (Moore et al., 2014). Enhancing the 
quality of care for oral cancer patients require an evidence-based framework 
outlining the current and best practises in patient management particularly 
when issues on variation of practice exist (Grimshaw et al., 1995, Shaneyfelt 
et al., 1999). Evidence has shown variation in the method of treatment used by 
the clinicians have a significant effect on patients outcomes (Robertson et al., 
2001). Practice guidelines is one of the means that helps to minimise 
inappropriate variation in clinical practice and to improve the quality of 
patients care (Field and Lohr, 1990, Green and Piehl, 2003) 
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Currently in Malaysia, only Clinical Practice Guideline (CPG) on Primary 
Prevention and Early Detection of Pre-cancerous and Oral Cancer is available 
(Ministry of Health Malaysia, 2002). Best practice guideline on oral cancer 
management involving diagnosis, treatment, and follow-up care are yet to be 
formalized for the healthcare professionals to use in a standardized manner for 
the management of oral cancer patients. Needless to say, it is timely for such a 
guideline to be developed in Malaysia to effectively manage oral cancer 
patients throughout the full continuum of care. 
1.2 OBJECTIVE. 
 
To provide best practice guideline for oral cancer management in Malaysia 
including diagnosis, treatment, and follow-up care for use by healthcare 
professionals managing oral cancer patients in our country. 
 
1.3 TARGET POPULATION. 
 
Adult patients who present with symptoms or have been diagnosed with oral 
cancer which include malignant tumours of the tongue, gingivae, buccal 
mucosa, retromolar triangle, alveolus, hard palate, lip and floor of the mouth. 
 
1.4 TARGET USERS. 
 
The guideline is applicable to all healthcare professionals managing oral 
cancer patients including Oral and Maxillofacial Surgeons, General Surgeons, 
Otorhinolaryngologist (ENT), Oral Pathologists, Clinical Oncologists, 
Radiologists, Plastic and Reconstructive Surgeons, Dentists, Nurses, Speech 
and Swallowing Therapists, Nutritionists and Psychosocial Workers. 
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SECTION 2:  
 DEVELOPMENT OF THE 
GUIDELINE 
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2.1 DEVELOPMENT OF THE GUIDELINE 
 
The concept of ―Guideline Adaptation‖ is used in the development of this 
Malaysian guideline as an alternative to a ―De Novo Development‖. It is a 
systematic approach for customizing existing guideline(s) by adopting or 
adapting the recommendations to suit the Malaysian context (Graham and 
Harrison, 2005, Graham et al., 2002). The core methodologies used were 
reviewing of high quality evidence and adaptation of recommendations from 
the existing guidelines, blended with expert judgements from a 
multidisciplinary group. The methodology was based on the Practice 
Guidelines Evaluation and Adaptation Cycle (PGEAC) by Graham et al., 
(2003). The guidelines development process consists of six steps: i) identify 
clinical areas to promote best practice, ii) literature search to identify existing 
guidelines, iii) assessment of the guidelines in terms of quality, currency, and 
content, iv) adopt or adapt guidelines for local use v) seek expert feedback and 
vi) finalize local guidelines. 
 
2.1.1 Identification of clinical areas to promote best practices. 
Clinical area of interest to promote best practice is the management of oral 
cancer, which includes diagnosis, treatment, and follow-up care.  
 
2.1.2 Literature search to identify existing guidelines. 
 
A systematic literature search for all relevant guidelines related to the clinical 
area of interest was carried out by computerized search on selected databases 
and websites including: i) clinical practice guidelines databases, ii) guideline 
developer websites, iii) specialty societies, iv) electronic databases such as 
MEDLINE, PUBMED, Cochrane Library and Centre for Reviews and 
Dissemination (CRD). In addition, a hand search was also performed on the 
reference sections of the retrieved articles. 
 
The search terms used were the combinations of oral cancer, mouth cancer, 
head and neck cancer, carcinoma, neoplasm, nodule, mass, tumour, guideline, 
practice guideline, clinical practice guidelines, best practice, recommendation, 
consensus statement, consensus, standard. Only guidelines with 
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comprehensive management of oral cancer which includes diagnosis, 
treatment, and follow-up care, published in English with year of publication 
from 2000 to 2016 are included in this study. Those guidelines focused on a 
specific stage or type of oral cancer, and articles focused entirely on a specific 
procedure, for example, PET scan or IMR, were excluded. The retrieved 
guidelines were reviewed and selected by the guideline development group 
(see Appendix 1.1 for list of the members). Fifteen potential guidelines were 
identified through the literature search. The complete search strategies are 
available upon request from the guideline development group. 
2.1.3 Assessment of the guidelines 
Following the PGEAC framework, the selection of the existing guidelines for 
adaptation was based on the assessments of the guidelines‘ quality, currency 
and content. 
2.1.3.1 Quality assessment 
The quality was assessed by two independent appraisers (see Appendix 1.2 for 
list of the appraisers) using the The Appraisal of Guidelines Research and 
Evaluation II (AGREE II) instrument. Based on the quality assessment, three 
existing guidelines which include guidelines produced by the National 
Comprehensive Cancer Network, (2015) (NCCN), Belgian Health Care 
Knowledge Centre, (2014) (BKCE) and Scottish Intercollegiate Guideline 
Network, (2006) (SIGN) were selected for adoption or adaptation in the 
guideline development. Table 3.1 shows the quality scores for each AGREE II 
domain for the three selected existing guidelines. NCCN and BKCE 
performed well in the AGREE II appraisal with scores of higher than 60% in 
all six domains. The quality scores across the six domains for the NCCN and 
BKCE guidelines ranged from 61.0% to 92.0% and 67.0% to 89% 
respectively. The quality scores for the SIGN guideline ranged from 47.0% to 
92% with four of the domains (Domain 2,3,4,5) scored higher than 80%. 
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Table 2.1 Domains‘ scores of the AGREE II appraisal 
No Guidelines’ 
developer 
DOMAINS (%) 
 
Domain 1 
 
Scope & 
purpose 
Domain 2 
 
Stakeholder 
involvement 
Domain 3 
 
Rigour of 
development 
Domain 4 
 
Clarity of 
presentation 
Domain 5 
 
Applicability 
Domain 6 
 
Editorial 
Independence 
1. NCCN 61 83 82 86 67 92 
2. BKCE 89 89 88 89 67 79 
3. SIGN 47 92 92 92 83 58 
2.1.3.2 Currency assessment 
Based on the quality assessment, the three selected existing guidelines were 
further assessed on whether they are still current and relevant for the 
adaptation process.  Methods for checking the currency of the guidelines 
include: i) review the date of publication and dates of the original studies 
cited, and ii) checking with the guideline developers, whether the guideline is 
still in use or they have plan for update. 
Based on the results of the quality and currency assessments, all three existing 
guidelines as documented in the Table 2.1 were considered appropriate by the 
guideline development group for adoption or adaptation as the Malaysian 
guideline for the management of oral cancer patients. Results of the guideline 
currency survey revealed that at the time of the guideline development, the 
latest version of the NCCN‘s guideline (1.2016) was available and is used in 
this study instead of NCCN‘s guideline (1.2016) 
2.1.3.3 Content assessment 
A total of 191 recommendations with the level of the supporting evidence 
were extracted from the three shortlisted guidelines (54 from the NCCN 
guidelines, 50 from the BKCE guidelines and 87 from the SIGN guidelines) 
and tabulated it in a table known as recommendation matrix. Various forms of 
grading system of the evidence were used by the guideline developers. The 
level of the evidence was reclassified to high level, low level and good 
practice point. The description for the level of the evidence is documented in 
Table 3.1. 
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A group of multidisciplinary expert panels comprising an Oral Maxillofacial 
Surgeon; an Oral Pathologist; an Ear, Nose and Throat Specialist; and a 
Clinical Oncologist (see Appendix 2 for list of the panel members) 
systematically assessed the clinical content of the guideline recommendations 
independently and made decisions on which recommendation to exclude or 
include into the new local guideline.  
An additional search was conducted to identify recent systematic reviews 
published since the preparation of the latest selected guidelines (2015-2016). 
This documentation is used to fill the gaps of the current evidence pertaining 
to the management of oral cancer which is not cover by the three selected 
existing guidelines (NCCN, BKCE and SIGN). The search strategy was 
focused on the databases to be higher-yield, including the TRIP database, 
Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews 
of Effectiveness (DARE) and MEDLINE. Hand search was also conducted on 
the reference list of the identified systematic review. Only systematic reviews 
published in English were included in the selection process. 
 
From these searches, nine relevant systematic reviews were identified which 
include one on the swallowing therapy, three on the chemotherapy, one on the 
targeted therapy and immunotherapy, three on the diagnostic tests and one on 
FDG-PET/CT. Of these, two systematic reviews provided evidence on the 
effectiveness of tissue biopsy and histopathological examination for diagnosis 
of oral cancer and one systematic review reported on good diagnostic 
performance showed by the FDG-PET/CT for detection of regional nodal 
metastasis in primary head and neck cancer patients. However, the 
information from the three systematic reviews were already included in the 
selected guidelines. The findings of the other six systematic reviews were 
inconclusive to support any update of the recommendations.  
2.1.4 Adaptation of the recommendation from the existing guidelines. 
A follow-up meeting was held to seek consensus among the expert panels on 
the final list of recommendations for the Malaysian guideline. Based on the 
informal group discussion during the follow-up meeting, the panels decided to 
accept 91 recommendations from the three shortlisted guidelines for 
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adaptation as the Malaysian guidelines for the management of oral cancer 
patients. Thirty three recommendations are from the BKCE guideline, 39 from 
the SIGN guideline and 19 from the NCCN guideline.  
A total of 81 recommendations were accepted by the panels without any 
modification. Six recommendations of the three guidelines were combined 
into two recommendations. Four recommendations were modified slightly 
based on the evidence of the previous literature and one recommendation was 
modified based on the expert opinion. The list of supplementary references is 
illustrated in Table 3.2. After the consensus on the final list of 
recommendations for the Malaysian guidelines was achieved, the draft 
guideline was prepared by the guideline development group.  
2.1.5 Expert feedback 
The draft was reviewed by a multidisciplinary group of healthcare 
professionals managing oral cancer patients in Malaysia comprising Oral 
Maxillofacial Surgeons; Oral Medicine and Oral Pathologists; and Dental 
Public Health Specialists (see Appendix 3 for list of the members). Focus 
group discussion technique was used to obtain feedback and consensus on the 
draft guideline.  
2.1.6 Final local guidelines. 
The final version of the best practice guideline is formatted based on the 
feedbacks received from the multidisciplinary panels.  
 
2.2 REVIEW AND UPDATE. 
 
A review of this new Malaysian guideline should be conducted at least every 
five years or earlier in order to update new emerging evidence for surgeons. 
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2.6 PROPOSED CLINICAL AUDIT INDICATORS FOR QUALITY 
MANAGEMENT. 
 
The proposed indicators are: 
a) Proportion of patients completed radiotherapy within 14 weeks after    
surgery (in the absence of postoperative medical or surgical 
complications): 
b) Proportion of patients compliance with the follow-up procedure, 
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SECTION 3: 
 CLINICAL RECOMMENDATIONS 
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3.1 CLINICAL RECOMMENDATIONS FOR THE MANAGEMENT 
OF ORAL CANCER. 
The clinical recommendations were adapted from the three selected existing 
guidelines and supplemented by additional literatures and experts‘ opinion. 
Modifications were made on some of the recommendations to suit the 
Malaysian context. The recommendations were divided into three main 
sections:1) diagnosis, 2) treatment, and 3) follow-up care. Each 
recommendation is listed with its sources and corresponding level of 
supporting evidence. The description for the levels of supporting evidence is 
illustrated in Table 3.1 and the list of the existing guidelines and references 
included in the development of the guideline recommendations is illustrated in 
Table 3.2. 
Similar to the Alberta Health Services (Alberta Health Services, 2014) and 
Cancer Care Ontario (Gilbert et al., 2009) methodology, it is beyond the scope 
of the guideline development process to make the connection between the 
recommendations and the original key evidence. However, the summary of the 
evidence used to develop the recommendations is described in the section 3.2. 
Please refer to the NCCN, BKCE and SIGN guidelines for the complete 
original key evidence of the recommendations.  
 
Table 3.1 Level of evidence. 
LEVEL OF 
EVIDENCE (LOE) 
DESCRIPTION 
 
High level 
evidence 
(High) 
 
 
 
Evidence from meta-analysis, systematic review of 
randomized control trials (RCT), high quality systematic 
reviews of case control or cohort studies, RCT and high 
quality case control or cohort studies with a very low risk of 
confounding or bias.  
Low level 
evidence 
(Low) 
 
 
Good Practice Point 
(GPP) 
Evidence from non-randomized trials, well conducted case 
controls, cohort studies, case reports, case series, expert 
opinion, clinical observation. 
 
Recommended best practice based on the clinical 
experience of the guideline development group. 
 
Adapted from (Scottish Intercollegiate Guidelines Network, 2006, Belgian Health Care 
Knowledge Centre, 2014, National Comprehensive Cancer Network, 2016). 
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Table 3.2. List of the existing guidelines and references included in the 
development of the Malaysian guideline. 
1 
1. .EXINSTING GUIDELINES 
 
1.1 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Head 
and Neck Cancer. Version 1.2016 (National Comprehensive Cancer Network, 
2016) – NCCN. 
1.2 Oral cavity cancer: diagnosis, treatment and follow-up (Belgian Health Care 
Knowledge Centre, 2014) –BKCE. 
1.3. Diagnosis and management of head and neck cancer. A national clinical 
guideline (Scottish Intercollegiate Guideline Network, 2006) – SIGN. 
 
 
2. 2. SUPPLEMENTARY REFERENCES 
 
2.1 Arya, S., Rane, P. & Deshmukh, A. 2014. Oral cavity squamous cell  
carcinoma: role of pretreatment imaging and its influence on management.  
Clinical radiology, 69, 916-930. 
 
2.2 Almangush, A., Bello, I. O., Coletta, R. D., Mäkitie, A. A., Mäkinen, L. K.,  
Kauppila, J. H., Pukkila, M., Hagström, J., Laranne, J & Soini, Y. 2015. For  
early-stage oral tongue cancer, depth of invasion and worst pattern of invasion  
are the strongest pathological predictors for locoregional recurrence and  
mortality. Virchows Archiv, 467, 39-46. 
 
2.3 Li, Y., Bai, S., Carroll, W., Dayan, D., Dort, J. C., Heller, K., Jour, G., Lau, H.,  
Penner, C. & Prystowsky, M. 2013. Validation of the risk model: high-risk  
classification and tumor pattern of invasion predict outcome for patients with  
low-stage oral cavity squamous cell carcinoma.H ead and neck pathology, 7,  
211-223. 
 
2.4 Rosenthal, D. I., Liu, L., Lee,J. H., Vapiwala, N., Chalian, A. A., Weinstein, 
G. S., Chilian, I., Weber, R. S. & Machtay, M. 2002. Importance of the 
treatment package time in surgery and postoperative radiation therapy for  
squamous carcinoma of the head and neck. Head & neck, 24, 115-126. 
 
2.5 Langendijk, J. A., Ferlito, A., TakesR. P., Rodrigo, J. P., Suárez, C.,  
Strojan, P., Haigentz jr, M. & Rinaldo, A. 2010. Postoperative strategies after  
primary surgery for squamous cell carcinoma of the head and neck. Oral  
Oncology, 46, 577-585. 
 
 
 
 
 
344 
 
No. Context Recommendations LOE 
1.1 Patient 
information and 
consultation. 
The patient must be kept fully informed about his 
condition, the treatment options and consequences. 
Information should be complete and communicated in a 
clear and unambiguous way. Patient preferences should be 
taken into account when deciding on a treatment option. 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
Low 
1.2 Clinical 
Examination 
The following investigation are recommended at diagnosis 
and staging of oral cancer: 
 Complete head and neck exam, mirror and fiberoptic 
examination as clinically indicated.  
(Source: National Comprehensive Cancer Network, 2016). 
 
Low 
1.3 Biopsy 
 
a. A biopsy should be taken from the most suspicious 
part(s) of the tumour. The pathologist should be 
provided with any clinically relevant information. If 
the result is inconclusive, or negative but the tumour 
is suspect, the biopsy should be repeated. 
 
b. When a patient with a diagnosis of oral squamous cell 
carcinoma is referred to another centre for work-up 
completion and treatment, and if no additional 
biopsies need to be performed in the reference centre, 
pathology specimens (slices and/or blocks) should be 
sent for revision to the reference laboratory for 
diagnosis confirmation upon request from the 
reference centre. Every uncommon tumour diagnosis 
beside classical squamous cell carcinoma should be 
reviewed by an expert from a reference laboratory. 
 
c. The biopsy report should include: tumour localization, 
tumour histology, tumour grade, depth of invasion (if 
assessable), lymphatic, vascular and perineural 
invasion. Some other prognostic factors, such as 
pattern of invasion (cohesive and non-cohesive) can 
be considered. 
 
(Belgian Healthcare Centre, 2014; Li et al., 2013; 
Almangush et al., 2015). 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
Low 
LOE: Level of evidence 
1) Diagnosis 
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No. Context Recommendations LOE 
1.4 Conventional 
imaging of the 
primary tumour 
The following investigation are recommended at diagnosis 
and staging of primary oral cancer: 
a. Computerized tomography (CT) with contrast and/or 
magnetic resonance imaging (MRI) with contrast of 
primary as indicated.  
 
b. May consider CT of the thorax, abdomen and pelvis 
(TAP) if there are other lesions elsewhere.  
 
(Source: National Comprehensive Cancer Network, 2016, 
Arya et al., 2014) 
 
Low 
 
1.5 
 
Imaging of locally 
advanced stage 
tumour 
 
a. In patients presenting with cervical lymph node 
metastases, where CT or MRI does not demonstrate 
an obvious primary tumour, Fluorodeoxyglucose 
positron emission tomography - computed 
tomography (FDG-PET/CT) should be performed as 
the next investigation of choice, whenever possible. 
 
b. In patients presenting with suspected recurrent head 
and neck cancer, where CT/MRI does not demonstrate 
a clear cut recurrence, FDG-PET/CT should be 
performed as the next investigation of choice, 
whenever possible. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
 
Low 
 
 
 
 
 
 
Low 
 
1.6 
 
Imaging of neck 
lumps and nodes 
 
a. CT or MRI from skull-base to sternoclavicular joints 
should be performed in all patients at the time of 
imaging the primary tumour to stage the neck for 
nodal metastatic disease. 
 
b. Where the nodal staging on CT or MRI is equivocal, 
Ultrasound guided fine needle aspiration (USFNA) 
and/or FDG-PET increase the accuracy of nodal 
staging. 
 
 (Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
 
Low 
 
 
 
 
Low 
1.7 Other staging 
interventions 
(identification of 
synchronous 
tumour and distant 
metastases) 
The following investigation are recommended at diagnosis 
and staging of oral cancer: 
 
a. Chest imaging as clinically indicated.  
b. Examination under anaesthesia (EUA) with 
endoscopy, if indicated.  
c. Pre-anaesthesia studies as clinically indicated. 
 
(Source: National Comprehensive Cancer Network, 2016). 
 
Low 
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No. Context Recommendations LOE 
1.8 Human 
Papillomavirus 
(HPV) Testing 
Due to insufficient evidence, routine HPV testing is not 
recommended in patients with oral cavity cancer. In 
patients without any of the common risk factors (e.g. 
smoking, alcohol abuse) for oral cavity cancer, HPV 
testing is recommended although there is no evidence at 
present that it alters treatment decisions in these patients. 
(Source: Belgian Health Care Knowledge Centre, 2014; 
expert‘s opinion) 
 
Low 
1.9 Histopathology. 
 
1.9.1 Resection 
margin 
 
a. To avoid a positive resection margin (which is 
associated with a poorer prognosis), frozen sections 
taken intraoperatively may be useful.  
 
b. A distance of at least 10 mm from the palpable 
tumour margin, whenever technically or anatomically 
possible, should be taken as a guide for resection to 
allow a minimal distance of 3-5 mm from the margin 
of the resected tissue to the primary tumour in the 
formalin-fixed specimen. 
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
Low 
 
Low 
1. 9.2 Primary site 
reporting. 
For discussion with the clinician, the histopathological 
findings must describe the exact tumour margin. The 
anatomical topography must be clearly indicated when 
sending the tumour specimen to the pathologist. This may 
be done with suture markers or colour-coding.  
The histopathological result must include:  
 tumour localization,  
 macroscopic tumour size,  
 histological tumour type,  
 histological tumour grade,  
 depth of invasion,  
 pattern of invasion, 
 lymphatic,  
 vascular and perineural invasion,  
 locally infiltrated structures,  
 pT classification,  
 details of affected areas and infiltrated structures,  
 
(Belgian Healthcare Centre, 2014; Li et al., 2013; 
Almangush et al., 2015). 
 
 
 
 
 
Low 
LOE: Level of evidence 
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No. Context Recommendations LOE 
 
1.9.3 
 
Neck and 
metastatic 
disease 
reporting. 
 
The histopathological findings from a neck dissection 
specimen must describe: 
 the anatomical topography, 
 the side of the neck,  
 type of neck dissection,  
 eliminated levels,  
 total number of lymph nodes plus number of 
lymph nodes affected,  
 number of lymph nodes per level,  
 level of the affected lymph nodes,  
 diameter of the largest tumour deposit,  
 additionally removed structures, 
 extracapsular spread (if present). 
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
Low 
 
        2)Treatment 
No. Context Recommendations LOE 
2.1 Multidisciplinary involvement 
 
 
2.1 Multidisciplinary 
involvement 
 
a. Treatment plans should be formulated by a 
multidisciplinary team (core members and non-core 
member) in consultation with the patients and family 
member or caregiver. 
The core members comprise the specialist 
disciplines of: 
 Oral and Maxillofacial Surgery,  
 Otorhinolaryngology,  
 Pathology, 
 Clinical Oncology,  
 Radiology, 
 Plastic and Reconstructive Surgery. 
 Clinical Psychology. 
 
The non-core members comprise of: 
 General Practitioner, 
 Dentist, 
 Nursing Care, 
 Speech and Swallowing Therapist, 
 Nutritional Therapist, 
 Psychosocial Worker, 
 Maxillofacial Technologist. 
 
b. Individual patient characteristics, local expertise and 
patient preference should guide management of oral 
cancer. 
(Source: National Comprehensive Cancer Network, 
2016; Belgian Health Care Knowledge Centre, 2014;                    
Scottish Intercollegiate Guideline Network, 2006). 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GPP 
LOE: Level of evidence 
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No. Context Recommendations LOE 
2.2 Pre-treatment assessments 
 
2.2.1 Dental evaluation Patients with head and neck cancer, especially those 
planned for resection of oral cancers or whose teeth are 
to be included in a radiotherapy field, should have the 
opportunity for a dental or prosthodontics evaluation by 
an appropriately experienced dental practitioner. The 
evaluation should include panoramic oral radiograph 
(OPG), risk assessment of caries and periodontal status. 
The dental practitioner should give preventive advice and 
perform necessary restorative or prosthodontic work. 
(Source: National Comprehensive Cancer Network, 
2016; Belgian Health Care Knowledge Centre, 2014;                   
Scottish Intercollegiate Guideline Network, 2006). 
 
Low 
2.2.2 Nutritional, 
speech and 
swallowing 
evaluation. 
Nutrition, speech, and swallowing evaluation/therapy 
before and after treatment as indicated and should 
involve a registered dietitian and a speech-
language/swallowing therapist. 
 
(Source: National Comprehensive Cancer Network, 
2016). 
 
 
Low 
2.3 Treatment of primary non-metastatic oral cancer 
 
2.3.1 General 
recommendations 
 
Factors to be considered in treatment plan: 
 
 Management of early oral cavity tumours should be 
individualised for each patient.  
 
 Decisions regarding the choice of primary treatment 
modality should be made in consultation with the 
patient and the family, and should take into account 
the anatomical location of the tumour and 
availability of local expertise. 
 
 In those patients where surgical resection is possible, 
the likelihood of obtaining adequate surgical 
margins with acceptable morbidity, functional 
outcome and quality of life must be considered.  
 
 The likely short and long term morbidity resulting 
from radiotherapy must be considered. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
 
 
 
 
 
 
 
 
 
 
GPP 
 
 
 
GPP 
 
 
 
 
GPP 
 
 
 
 
GPP 
LOE: Level of evidence 
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No. Context Recommendations LOE 
 
2.3.2 
 
 
Clinical staging 
(Stage I and II) 
 
 
 
 
a. Provided the patient's general condition permits it 
and the oral cavity carcinoma can be curatively 
resected, surgical resection of the tumour should be 
performed and followed by immediate 
reconstruction, when required. 
 
b. In case of a microscopically residual tumour (R1 
resection), targeted follow-up resection should ensue 
with the aim of improving the patient's prognosis, 
whenever possible.    
 
c. Continuity of the mandible should be preserved on 
tumour resection or restored post-resection, provided 
no radiological or intraoperative evidence has been 
found of tumour invasion of the bone. 
 
d. Reconstructive measures should from the onset be 
integrated in the surgical approach. When planning 
reconstruction, consideration must be given to the 
entire oncological scenario. The anticipated 
functional or cosmetic improvement must justify the 
efforts involved in reconstruction. 
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
e. Definitive radiotherapy (RT) may be offered to early 
stage patients (T1-2, N0) who are medically 
inoperable or refuse surgery. Patients who go on to 
develop residual disease after definitive RT should 
be considered for surgery.  
 
(Source: National Comprehensive Cancer Network 
2016). 
 
f. Interstitial brachytherapy may be offered to early 
stage patients. The treatment should be performed 
by experienced teams in centres with adequate 
radiation protection facilities. 
 
g. Re-excision should be considered to achieve clear 
histological margins if the initial resection has 
positive surgical margins.  
 
h. If re-excision is not possible, postoperative 
radiotherapy should be considered. 
 
i. Administration of chemotherapy (CRT) concurrently 
with postoperative radiotherapy should be 
considered, particularly in patients with 
extracapsular spread and/or    positive surgical 
margins. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
GPP 
 
 
High 
LOE: Level of evidence 
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No. Context Recommendations LOE 
 
2.3.3 
 
Clinical staging 
(Stage III and IV) 
 
 
a. Patients with resectable disease who are fit for 
surgery should have surgical resection with 
reconstruction, whenever possible. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
b. The decision to perform surgery must be made on 
the basis of the ability to achieve tumour-free 
resection margins and postoperative quality of life. 
For locally advanced tumours, the postoperative 
functional consequences need to be prospectively 
and carefully assessed. For instance, when a total 
glossectomy (+/- total laryngectomy) is the only 
oncologically suitable surgical option, non-surgical 
organ preservation protocols must be seriously 
considered.   
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
c. Radical external beam radiotherapy with concurrent 
chemotherapy should be considered when:  
 the tumour cannot be adequately resected.  
 the patient‘s general condition precludes 
surgery. 
 the patient does not wish to undergo surgical 
resection. 
 
d. Postoperative radiotherapy should be considered for 
patients with clinical and pathological features that 
indicate a high risk of recurrence. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
e. Postoperative radiotherapy should be performed for 
advanced T categories (T3/T4), close (< 4 mm) or 
positive resection margins, tumour thickness > 10 
mm, lymph node involvement (> pN1) and extra-
capsular rupture/soft tissue infiltration. It should be 
considered for peri-neural extension or lymphatic 
vessels infiltration. For high-risk patients (e.g. close 
or positive resection margins, extracapsular spread) 
administration of chemotherapy concurrently with 
postoperative radiotherapy can be considered. 
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
f. Interrupting and prolonging a course of radical 
radiotherapy should be avoided. 
 
g. Overall estimated treatment time from surgery to 
completion of radiotherapy should not exceed 14 
weeks in the absence of postoperative medical or 
surgical complications. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006; Rosenthal et al., 2002; Langendijk et al., 2010). 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
High 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
High 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
Low 
LOE: Level of evidence 
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No. Context Recommendations LOE 
 
2.3.3 
 
Clinical staging 
(Stage III and IV) 
Continue. 
 
h. Concurrent chemoradiotherapy should only be 
administered where there are appropriate facilities 
for monitoring toxicity, with rapid access to 
appropriate outpatient and inpatient support for the 
treatment of acute radiotherapy and chemotherapy 
toxicity. 
 
i. The routine use of neo-adjuvant chemotherapy in 
oral cavity cancer is not recommended. 
(Source: (Scottish Intercollegiate Guidelines Network, 
2006). 
 
High 
 
 
 
High 
 
2.3.4 
 
Management of 
the neck lymph 
nodes. 
 
 
a. Management of the neck lymph nodes should follow 
the same treatment principles as those applied for 
the primary tumour (e.g. if the primary tumour is 
surgically treated, a neck dissection should be 
performed). 
  
b. Perform a selective neck dissection of at least level 
I, II and III in all patients with a cN0M0 oral cavity 
SCC that is treated surgically, depending on site, 
size, grade, pattern of invasion, lymphatic 
infiltration and choice of reconstruction. 
 
c. A neck dissection can be omitted exceptionally in 
some patients with a cT1N0M0 oral cavity SCC, 
depending on the localisation and thickness of the 
tumour.  
 
d. Perform a selective ipsilateral neck dissection of at 
least level I, II, III and IV with – if oncologically 
feasible – preservation of the sternocleidomastoid 
muscle, jugular vein and spinal accessory nerve in 
all patients with a cN+M0 oral cavity SCC that is 
treated surgically. 
 
e. Consider a contralateral neck dissection in patients 
with a non-metastatic oral cavity SCC that is at or 
crossing the midline or not clearly localized 
laterally.   
 
f. Consider performing a diagnostic evaluation of the 
neck with conventional imaging techniques (CT or 
MRI) or PET/CT three to six months after 
completion of primary (chemo) radiotherapy.  
 
g. In patients with oral cavity cancer (N1-3) and 
complete response to chemoradiotherapy (assessed 
by FDGPET/CT, CT or MRI), there is no data to 
support an additional lymph node dissection. 
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
Low 
 
LOE: Level of evidence 
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No. Context Recommendations LOE 
2.4 Treatment of very advanced-stage oral cancer (M0) T4b, any N or unresectable nodal 
disease or unfit for surgery. 
  a. Participation in clinical trials is preferred for all 
patients with very advanced cancers. 
 
b. Patients should undergo standard therapy based on 
their PS = Performance Status (Eastern Cooperative 
Oncology Group [ECOG]).  
 
c. For patients with a PS of 0 or 1, the standard treatment 
is concurrent chemotherapy and radiotherapy. Other 
options are induction chemotherapy followed by RT 
or chemotherapy/RT. 
 
d. PS 0-2: Definitive RT with or without concurrent 
chemotherapy.  
 
e. PS 0-3: Palliative RT or single-agent chemotherapy or 
best supportive care. 
 
f. Perform neck dissection following the above 
treatment (if feasible) in the instance of residual neck 
disease and primary site are controlled. 
 
(Source: National Comprehensive Cancer Network, 2016). 
 
g. Chemoradiotherapy can be considered for tumour  
downstaging in order to enable resection. 
Low 
 
 
Low 
 
 
 
Low 
 
 
 
 
Low 
 
 
Low 
 
 
Low 
 
 
 
 
 
GPP 
2.5 Treatment of locoregional recurrence disease. 
2.5.1 General 
evaluation. 
a. Decisions regarding the appropriate management of a 
locoregional recurrence of head and neck cancer 
should be made on an individual basis taking into 
account:  
 The stage of recurrent tumour and its potential 
resectability. 
 Previous treatment 
 Likely treatment efficacy 
 Likely treatment-related morbidity and functional 
outcome and consequent effects on quality of life  
 patient‘s general health  
 patient‘s wishes.  
 
b. Decisions regarding the management of locoregional 
recurrence of head and neck cancer should be made by 
the multidisciplinary team in consultation with the 
patient following histological confirmation of 
recurrence and full restaging (clinical and 
radiological). 
 
c. Patients and their relatives/carers should be carefully 
counselled about the likely outcome of surgical and 
radiotherapeutic salvage, with respect to survival, risk 
of treatment-related morbidity and mortality, and 
likely resulting quality of life.  
 
d. Early referral to palliative care for symptom control 
should be considered. 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
GPP 
 
 
 
 
 
 
 
 
 
 
 
 
GPP 
 
 
 
 
 
 
GPP 
 
 
 
 
 
GPP 
LOE: Level of evidence 
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No Context 
Recommendations  
LOE 
2.5.2 Resectable 
locoregional 
recurrence 
 
a. Surgery is recommended for resectable recurrent or 
persistent locoregional disease. 
 
b. For patients with resected oral cavity cancers, who 
have adverse features of extracapsular nodal spread 
and/or positive margin and the patients did not have 
prior RT, postoperative chemotherapy/RT is 
recommended. 
 
c. For patients with resected oral cavity cancers, who 
have other risk features such as pT3 or pT4 primary, 
N2 or N3 nodal disease, nodal disease in levels IV or 
V, perineural invasion, or vascular tumor embolism 
and the patients did not have prior RT, the options 
include RT or consider chemotherapy/RT. 
 
d. For patients with resected oral cavity cancers with 
prior RT, the options include surgery with or without 
postoperative reirradiation or chemotherapy/RT. 
 
e. Enrolment in a clinical trial can be considered. 
 
(Source: National Comprehensive Cancer Network, 2016). 
 
 
Low 
 
 
High 
 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
 
 
 
Low 
2.5.3 
 
Unresectable 
loceregional 
recurrence 
 
 
a. If the recurrence is unresectable and the patients did 
not have prior RT, then RT with concurrent 
chemotherapy is recommended, depending on the PS 
(Performance Status). 
 
b. If the recurrence is unresectable and the patients have 
prior RT, the treatment option include reirradiation 
with or without chemotherapy, or chemotherapy 
alone. 
 
(Source: National Comprehensive Cancer Network, 2016). 
 
c. Patients with small accessible recurrences in a 
previously irradiated region may be considered for 
interstitial brachytherapy in centres with appropriate 
facilities and expertise. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
Low 
 
 
 
 
 
 
Low 
LOE: Level of evidence 
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No. Context Recommendations LOE 
2.6 Treatment of metastatic or recurrent disease not eligible for curative treatment. 
 
2.6.1 
 
General 
recommendation 
 
a. The care of patients with incurable head and neck 
cancer should be managed by the palliative care 
services in conjunction with the multidisciplinary 
team.  
 
b. All modalities of therapy should be considered as 
options for the palliation of head and neck cancer. 
  
c. Short term toxicity and length of hospital stay should 
be balanced against likely symptomatic relief.  
  
d. A documented pathway of care should be discussed 
and agreed with the patient, relatives, carers and 
general practitioner. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
 
GPP 
 
 
 
 
GPP 
 
 
GPP 
 
 
GPP 
 
2.6.2 
 
Palliative 
chemotherapy 
 
a. Patients of adequate performance status should be 
considered for palliative chemotherapy which may 
reduce tumour volume. 
 
b. Single agent methotrexate, single agent cisplatin, or 
cisplatin/5Fu combination should be considered for 
palliative chemotherapy in patients with head and 
neck cancer.  
         
c. Excessive toxicity from intensive chemotherapeutic 
combination regimens should be avoided. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
 
High 
 
 
 
High 
 
 
 
 
High 
2.6.3 
 
Palliative 
radiotherapy 
 
Radiotherapy may be considered for palliative treatment in 
patients with locally advanced incurable head and neck 
cancer. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
 
Low 
2.6.4 
 
Palliative surgery 
 
Appropriate surgical procedures should be considered for 
palliation of particular symptoms, taking local expertise 
into consideration. 
 
(Source: Scottish Intercollegiate Guideline Network, 
2006). 
 
 
GPP 
 
 
 
 
LOE: Level of evidence 
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No. Context Recommendations LOE 
3.1 Clinical and 
imaging 
evaluation 
 
An individually structured follow-up schedule should be 
devised for each patient. The quality of life, side effects 
of treatment, nutritional status, speech, dental status, 
thyroid function, smoking and alcohol consumption, etc. 
should be surveyed periodically. There is no evidence to 
support routine use of imaging techniques for the 
detection of locoregional or metastatic recurrence during 
follow-up. Follow-up frequency, even in symptom-free 
individuals, should be at least every month in the first 
and second year, every 3 months in the third to fifth year, 
and annually henceforth. 
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
 
Low 
 
 
 
 
3.2 Dental 
rehabilitation 
 
a. In patients having undergone surgery and/or 
irradiation for carcinoma of the oral cavity, the 
masticatory function should be restored with the 
help of functional masticatory rehabilitation, using 
conventional prosthetics and/or implants. Surgical 
interventions (e.g. extractions) should be performed 
by professionals with experience in treating patients 
with head and neck cancer. The patients should 
undergo routine dental check-ups at a frequency 
depending on the individual patient case (usually 
every 4-6 months). 
 
b. Osteoradionecrosis of the jaw is a serious treatment 
complication that should be managed in specialised 
centres. 
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
Low 
3.3 Speech and 
swallowing 
rehabilitation.  
a. Patients with chewing, speaking and swallowing 
problems should be timely provided with 
appropriate functional therapy. The patients should 
be introduced to suitably qualified therapists prior to 
commencing treatment if the scheduled surgical or 
conservative procedures (e.g. radiotherapy) are 
likely to cause problems with chewing, swallowing 
and/or speech. 
 
b. Patients with dysphagia should undergo appropriate 
diagnostic procedures, e.g. clinical exam by the 
speech therapist, videofluoroscopy or fiber-optic 
endoscopy. 
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
LOE: Level of evidence 
Follow-up care 
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No. Context Recommendations LOE 
3.3 Speech and 
swallowing 
rehabilitation. 
Continue. 
 
a. Patients having eating and speaking problems due to 
carcinoma of the oral cavity and/or its management 
should have access to speech therapists and 
nutritional therapists with experience of such 
pathologies before, during and after treatment. 
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
Low 
3.4 Nutritional 
therapy. 
Patients should be regularly screened for malnutrition 
due to oral cavity cancer or its treatment. Patients at risk 
for malnutrition should receive timely and on-going 
professional dietary counselling and nutritional therapy. 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
Low 
3.5 Psychosocial 
counselling and 
support. 
 
Patients with oral cavity cancer (and their family, carers) 
should be offered dedicated psychosocial support on a 
continuous basis within the context of a multidisciplinary 
team.  
 
(Source: Belgian Health Care Knowledge Centre, 2014). 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOE: Level of evidence 
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3.2 SUMMARY OF THE EVIDENCE USED TO DEVELOP THE 
RECOMMENDATIONS. 
The summary of the evidence is extracted from the source guidelines (NCCN, 
BKCE and SIGN) and the supplementary references. 
 
3.2.1 Diagnosis. 
 
 
3.2.1.1 Clinical and histopathology assessments. 
 
Diagnosis for patients with head and neck malignancy consists of a complete 
head and neck examination, biopsy and other appropriate test. The precise 
clinical prescription and histopathology classification may serve a number of 
objectives in managing cancer patients including selection of primary, 
adjuvant therapy and estimation of disease prognosis (National 
Comprehensive Cancer Network, 2016).  
 
To avoid the need for repeating the biopsy, it should be representative of the 
most suspicious part(s) of the tumour. The biopsy report should contain 
minimal information about prognostic factors (Belgian Health Care 
Knowledge Centre, 2014). Beside reporting of the tumour localization, tumour 
histology, tumour grade, depth of invasion, lymphatic, vascular and perineural 
invasion (Belgian Health Care Knowledge Centre, 2014), analyzing and 
reporting the pattern of invasion (cohesive or non-cohesive) in prognostication 
and treatment planning of early-stage oral squamous cell carcinoma is 
recommended by the expert panels based on the current literatures (Li et al., 
2013, Almangush et al., 2015).  
 
A retrospective cohort study by Almangush et al., 2015 evaluated the worst 
pattern of invasion (WPOI) of 479 patients with early-stage oral tongue cancer 
(cT1-T2N0). The study found that worst pattern of invasion (WPOI) is the 
strong pathological predictors for mortality, with the hazard ratio (HR) of 
2.34, 95 % CI 1.26–4.32) respectively. Another cohort study by Li et al., 
(2013) on 299 patients with stage I/II oral squamous cell carcinoma reported a 
similar finding in which the WPOI would signiﬁcantly predict the 
locoregional recurrence with HR of 3.63 (95 % CI: 1.56,8.47) for WPOI-4 and 
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2.55 (95% CI: 1.48, 4.41) WPOI-4. WPOI also significantly predictive for 
disease specific mortality with HR of 6.34 (95% CI: 2.50, 16.09). 
 
3.2.1.2 Imaging of the tumour. 
 
Imaging of the head and neck areas using Computerized Tomography (CT) 
with contrast and/or Magnetic Resonance Imaging (MRI) with contrast is done 
to evaluate the extent of the primary tumour, regional lymph nodes status or 
metastases to the neck (National Comprehensive Cancer Network, 2016). CT 
is used to rule out pulmonary metastases in higher T stage cancers, 
particularly with nodes involvement. CT of the abdomen is indicated when 
clinical index of hepatic metastases is high (Arya et al., 2014). Based on this 
literature, the expert panels decided to include CT of thorax, abdomen and 
pelvis as well if undergoing CT for primary oral cancer. 
 
For patients who appear to have advance stage disease, Fluorodeoxyglucose 
positron emission tomography-computed tomography (FDG-PET) is more 
accurate than CT and MRI in staging of distant disease, identifying occult 
primary tumours and identification of recurrent head and neck cancer 
(sensitivity 100%, specificity 61-71%). The accuracy is greatest when imaging 
is performed at least three months after completion of therapy (Bongers et al., 
2002, Lonneux et al., 2000). FDG-PET detecting 24-26% more primaries, and 
alters the treatment plan in 20% of cases (Jungehulsing et al., 2000, Johansen 
et al., 2002, Regelink et al., 2002).  
 
 
3.2.1.3 Imaging of neck lumps and nodes. 
 
Assessment using CT and MRI are similarly accurate in detecting neck node 
metastases, and are superior to physical examination (Van den Brekel et al., 
1993). However, CT scanning cannot be expected to achieve 100% accuracy. 
Woolgar et al. (1994), in their study reported that, detailed histopathological 
assessment showed the incidence of 27% false negative for the clinically 
negative neck (based on clinical examination and CT imaging). Extranodal 
spread of metastatic carcinoma was present in 16% of clinically negative 
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necks. CT is marginally more accurate in detecting infrahyoid node 
metastasis. However, MRI is more accurate than CT in detecting perivisceral 
nodal involvement (Wilson, 1998).  
 
 In the clinically node negative neck and where CT or MRI show marginally 
enlarged nodes (short axis diameter 5 mm or more), ultrasound guided fine 
needle aspiration (USFNA) has a higher specificity for diagnosing lymph node 
metastases (Takes et al., 1998). FDG-PET has been found to increase the 
accuracy of diagnosing lymph node metastases as compared to CT or MRI 
(Stokkel et al., 2000, Adams et al., 1998).  
 
3.2.1.4 Other staging interventions (identification of synchronous tumour and 
distant metastases). 
 
In individual cases, endoscopic examination under anaesthesia can be used for 
a more thorough examination (identification of any synchronous tumour and 
distant metastases). Pre-anaesthetic studies should precede any invasive 
procedures requiring general anaesthesia to discover or identify a disease or 
disorder that may affect perioperative management of the tumour (National 
Comprehensive Cancer Network, 2016). 
 
3.2.1.5 HPV testing. 
 
 
Both subtypes Human papillomavirus HPV are associated with oropharyngeal 
and oral cancer (Dayyani et al., 2010, Termine et al., 2008). Globally, HPV-
related tumours (HPV 16 positive) are mainly seen in the oropharyngeal 
region as compared to oral cancer (Kreimer et al., 2005). To date, there is no 
evidence from randomized control trials (RCT) that HPV status of a head and 
neck tumour can play a role in treatment decisions. RCTs investigating 
downscaling treatment strategies are ongoing. Hence, routine tests for HPV 
status as prognostic indicators are currently not recommended in patients with 
oral cavity cancer (Belgian Health Care Knowledge Centre, 2014).  
 
 
 
 
360 
 
3.2.2 Treatment. 
 
3.2.2.1 Oral and dental evaluation 
 
There is evidence that patients with head and neck cancer are at risk of oral 
and dental complications after radiotherapy which include radiation induced 
dental caries, tooth loss and periodontal loss attachment (Epstein et al., 2001, 
Denis et al., 2003). In addition, RT to the dental hard tissues is also associated 
with bone demineralization and trismus of the masticatory muscles. Dental or 
oral management can help decrease dental caries and associated problems 
such as dentoalveolar infection and osteoradionecrosis (Chang et al., 2007, 
Epstein et al., 2012). 
 
3.2.2.2 Nutritional, speech and swallowing evaluation. 
 
 
Patients with head and neck cancer are at risk for weight loss as a result of 
treatment-related toxicity. All patients should receive nutritional evaluation 
before and after treatment to assess the need for interventions (eg, enteral 
support via feeding tubes) particularly those with significant weight loss of 
more than 10% of body weight (Langius et al., 2013). Treatment and/or the 
progression of their disease may cause deterioration in the patients‘ ability to 
speak and/or swallow (Wilson et al., 2011, Tschiesner, 2012). Evaluation by a 
speech-language/swallowing therapist is valuable before and after treatment, 
because it can help mitigate potential problems (Cnossen et al., 2012, Roe et 
al., 2012) 
3.2.2.3 Surgery 
Histologically involved soft tissue margins are predictive of local recurrence 
and survival following surgery. Evidence from case series suggested that the 
presence of positive margin leads to locoregional recurrence (Shikama et al., 
2003, Sieczka et al., 2001, Hicks et al., 1998). Re-excision of involved 
surgical margins to achieve histologically clear margins results in good local 
control (Bailey et al., 2001). 
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For optimum tumour control, it must be considered that a distance of less than 
1 mm between the histologically demonstrated tumour margin and the 
resection line counts as a positive margin of resection. Hence a distance of 1 to 
3 mm between tumour and resection line is viewed as a narrow margin and 5 
mm or more as a safe margin (Wolff K-D et al., 2012) 
 
3.2.2.4 Radiotherapy 
 
Radiotherapy may be used alone for curative intent (radical radiotherapy) or as 
adjuvant therapy following surgery or concurrently with chemotherapy in 
order to improve local control and survival outcomes. Radiotherapy is also 
used as palliative therapy to provide symptomatic relief for the patients 
(Scottish Intercollegiate Guidelines Network, 2006). 
 
Postoperative radiotherapy (conventional fractionation) with doses of 60Gy or 
more in daily dose results in good local control in patients with close or 
positive margins (92%), although this is less effective in oral tongue 
primaries. Radiotherapy delivered postoperatively to selected patients at high 
risk of locoregional recurrence may improve locoregional control (Vikram et 
al., 1984) and survival (Huang et al., 1992, Lundahl et al., 1998).  
 
Interrupting and prolonging a course of radical radiotherapy should be avoided 
because the importance of the overall treatment time to the patients‘ outcomes 
has been presented in the literatures. A review by Langendijk et al., (2010) 
reported that 5-year loco-regional tumour control rate 61% among patients 
treated within a total treatment package (TPP) of 11-13 weeks. A retrospective 
review on 208 consecutive patients treated with surgery and postoperative 
radiotherapy (>55 Gy) for Squamous Cell Carcinoma of Head and Neck 
Cancer showed that shorter treatment package time of 100 days or less was a 
strong predictor of better 2-year survival (p=0.021) and locoregional control 
(p=0.13) (Rosenthal et al., 2002). Based on these finding and resources 
available locally, the expert panels recommended the overall estimated 
treatment time from surgery to completion of radiotherapy should not exceed 
14 weeks in the absence of postoperative medical or surgical complications. 
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Recurrence rates following radical radiotherapy alone in locally advanced oral 
cavity cancer may be higher than in other head and neck sites (Levendag et al., 
1996). Patients with advanced floor of mouth tumours may be best treated by 
a combination of surgery and radiotherapy rather than radiotherapy or surgery 
alone (Rodgers et al., 1993) 
       
The effectiveness of palliative radiotherapy in advanced head and neck cancer 
has not been identified in any clinical trials. A case series of 505 patients 
revealed that 55% of the patients had durable system relief after a short course 
palliative radiotherapy (20Gy) in five fraction over five days (Mohanti et al., 
2004). 
.  
Brachytherapy as a single modality is more effective than in combination with 
external beam radiotherapy for local control of the primary tumour. Evidence 
showed that treatment of patients with early cancers (T1 and T2) of the oral 
tongue and floor of mouth with an interstitial brachytherapy implant results in 
local control rates at five years (Mazeron et al., 1990). 
  
3.2.2.5 Chemotherapy 
 
Data from two meta-analysis, showed that addition of concurrent 
chemotherapy to radical radiotherapy for treatment of patients with locally 
advanced oral cavity cancer results in 17% reduction in the risk of death 
(Pignon et al., 2000, Bourhis et al., 2004). A combined analysis of two 
randomized trials indicated that the administration of cisplatin chemotherapy 
(100mg/m
2
 every 3 weeks for 3 doses) concurrently with standard 
postoperative radiotherapy results in significantly better locoregional control 
and disease- free survival in patients with extracapsular spread and/or positive 
surgical margins. For those with multiple involved regional nodes without 
extracapsular spread, there was no survival advantage (Cooper et al., 2012, 
Bernier et al., 2005). Survival advantage was also demonstrated in patients 
with other adverse effect such as multiple positive nodes (without 
extracapsular nodal spread), vascular/lymphatic/perineural invasion, pT3 or 
pT4 primary, positive level 4 or 5 nodes receiving cisplastin concurrent with 
postoperative RT compared to RT alone (Bernier et al., 2004). 
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A trial of high dose cytarabine in combination with cisplatin and 5FU reported 
a response rate of 57% (Jelić et al., 2002). Patients with good performance 
status have a better response rate to chemotherapy (Jacobs et al., 1992). 
Palliative chemotherapy treatment with single agent cisplatin may result in 
longer survival than single agent methotrexate, but is more toxic (Cne, 1990). 
The response rate to palliative chemotherapy may be improved by the 
combination of chemotherapeutic agents. However, there is no evidence that 
combination chemotherapy improves survival compared to treatment with 
single agents (Jacobs et al., 1992, Jelic et al., 2002). 
Patients with advanced carcinoma (any T, N2–3) who undergo nonsurgical 
treatment, such as concurrent chemotherapy and RT, need very close follow-
up to evaluate for local recurrence and to assess for ipsilateral or contralateral 
neck recurrence (Adelstein et al., 2003). 
3.2.2.6 Management of the neck lymph nodes. 
 
 
Although evidence is limited, there are indications that elective lymph node 
dissection of the neck may result in improved disease-free survival (Bessell et 
al., 2011). However, small tumours (e.g. T1 tumours of the oral tongue with a 
thickness of less than 4 mm) may be acceptable exceptions as the risk of 
occult lymph node metastases is very low for these tumours. In that case, good 
follow-up of the neck is needed (Ebrahimi et al., 2012).  
 
The extent of the neck dissection depends on the risk of spread to the different 
levels of the neck, mainly determined by the thickness of the tumour, T-stage 
and localisation of the primary tumour. For all tumours of the oral cavity, at 
least unilateral dissection of level I, II and III should be performed. In some 
cases (e.g. anterior floor of mouth), inclusion of level IV may be beneficial. In 
general, it is advisable to avoid multimodality treatment in order to limit 
treatment-related toxicity as much as possible. If surgery is the preferred 
treatment for the primary tumour, also the neck should then be approached 
surgically (Flach et al., 2013, Ebrahimi et al., 2012). 
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Available data show no oncological benefit for (modified) radical 
lymphadenectomy compared to selective lymph node dissection (Shepard et 
al., 2010, Park et al., 2013, Yanai et al., 2012). In case of clinically N0, 
dissection of lymph nodes of the contra-lateral neck is only indicated for those 
tumours that are located on or near the midline (i.e. not located at the lateral 
site of the neck). If only one lymph node in level I or II contains metastatic 
disease and there is no capsular rupture, dissection of level IV can be omitted 
(Lim et al., 2006, González-García et al., 2008). 
 
3.2.3 Follow-up care. 
 
3.2.3.1 Clinical and imaging evaluation. 
In patients with head and neck cancer, 76% of recurrences occur within the 
first two years and an additional of 11% during the third years of the post-
treatment (Boysen et al., 1992). Several treatments can be associated with 
long-term adverse events. No evidence is available to support a specific 
frequency of follow-up (Belgian Health Care Knowledge Centre, 2014). 
3.2.3.2 Oral rehabilitation. 
 
Many head and neck cancer patients have dental diseases such as dental caries 
and periodontal disease at presentation (Toljanic et al., 2002). The treatments 
for oral cavity cancer (surgery and radiotherapy) often results in acute and 
chronic disruptions to dental status. Osteoradionecrosis is a very serious 
complication after radiotherapy or chemotherapy, and requires specialist 
treatment (Tong et al., 1999). However, the evidence on hyperbaric oxygen 
therapy is too weak to justify a separate mentioning in the recommendation 
(Belgian Health Care Knowledge Centre, 2014).  
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3.2.3.3 Speech and swallowing rehabilitation. 
 
Patients with dysphagia and the inability to take adequate nutrition and 
hydration by mouth are considered at high nutritional risk and often have 
multiple risk factors for aspiration pneumonia (Sullivan and Guilford, 1999). 
The risk of aspiration prior to the onset of treatment is 14% for oral cancer 
patients (Kreuzer et al., 2000). High-frequency contrast-enhanced fluoroscopy 
and fiber-optic endoscopy, in addition to clinical exam by a speech therapist, 
are valid methods for assessing dysphagia (Aviv, 2000, Eisbruch et al., 2002). 
 
3.2.3.4 Nutritional therapy. 
All patients with head and neck cancer should be screened at diagnosis for 
nutritional status using a validated screening tool. Early nutritional 
intervention and ongoing nutritional support in at-risk patients has an impact 
on treatment outcome and quality of life (Belgian Health Care Knowledge 
Centre, 2014). 
  
3.2.3.5 Psychosocial support 
There are evidence that patients with head and neck cancer suffer from 
anxiety, depression, disturbance of body image and difficulty in maintaining 
quality of life (Chawla et al., 1999, Gritz et al., 1999). Patients with oral 
cancer require professional support including physical, psychological, social, 
spiritual, health information, and interpersonal communication in coping with 
the treatment consequences. However there is no evidence on the clinical 
benefit of psychological support or who should provide the support (Belgian 
Health Care Knowledge Centre, 2014). 
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